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 Pancreatic ductal adenocarcinoma (PDAC) is the most lethal common 
cancer in the United States: in 2017 there will be around 54,000 new cases and 
43,000 patient deaths. (SEER, 2017) The high mortality of PDAC is related to 
late disease presentation and aggressiveness; nearly 52% of patients present 
with metastatic disease at the time of diagnosis. (SEER, 2017) Current 
treatments have marginal improvements on survival, with the most efficacious 
treatment, gemcitabine and nab-paclitaxel, having a median survival of 12.2 
months. (Wu 2018) Failure of current PDAC treatments is attributed to the 
inefficacy of systemic chemotherapeutics and the development of resistance. 
(Rahib, 2014) The Dual Endothelin1/Signal PeptideVEGF receptor (DEspR), 
represents a promising therapeutic target for the treatment of PDAC: it is a highly 
expressed, specific tumor antigen, which is involved in tumor vasculogenesis and 
cancer stem cell (CSC) survival. DEspR is a developmentally crucial receptor, 
responsible for early angiogenesis and neural crest migration, with minimal 
 
 vii 
expression in normal adult tissue. In vitro and in vivo studies of anti-DEspR 
therapy in PDAC have shown efficacy in decreasing CSC survival, tumor 
angiogenesis, and improving overall survival in xenograft models of PDAC, with 
anti-DEspR therapy being a promising candidate for clinical use. Furthermore, 
anti-DEspR therapy seems to augment chemotherapeutic therapy in vitro and in 
vivo, suggesting that a DEspR-targeted antibody drug conjugate (ADC) would be 
highly effective. ADCs are a re-emerging drug class with significant promise. 
Initial failures of ADCs in clinic were related to poor antigen specificity and 
failures in drug conjugation chemistry to minimally impact the antibody. To 
develop our ADC, I have developed a novel method of site-specific conjugation 
that relies on a novel method of supramolecular assembly. My system employs 
two specific protein sequences that do not self-interact, and tightly assemble 
through coulombic and hydrophobic interactions, allowing site-specific, 
stoichiometric self-assembly. To facilitate stable drug delivery, I have synthesized 
a novel enzymatically cleavable tyrosine-clickable linker, which prevents drug 
release prior to tumor delivery. Both further investigation into the efficacy of anti-
DEspR therapy, and the development of a stoichiometric, site-specific, stable 
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CHAPTER ONE: Advancements in Therapy for Pancreatic Adenocarcinoma 
Section One: Clinical Snapshot of Pancreatic Adenocarcinoma 
Pancreatic cancer is the most lethal common tumor in America; it is 
expected to affect approximately 55,000 Americans and cause almost 44,000 
cancer-related deaths in 2018. (SEER, 2018) Incidence and mortality have been 
rising since 2000, with an age-adjusted increase in incidence of 2.85/100,000 
person years (2000 to 2014) and an increased mortality of 3/100,000 person 
years over the same range. (Wu, 2018) All age groups show increased incidence 
of pancreatic cancer, with the highest increases in ages 20-29 (annual percent 
increase of 1.6%) and > 80 (annual percent increase of 3.4%). (Wu. 2018) The 
rising incidence, unabated mortality, and disproportional improvements in other 
common tumors results in pancreatic cancer being the third leading cause of 
cancer related death, with a projection as the second cause by 2030. (Rahib, 
2014) 
Pancreatic ductal adenocarcinoma (PDAC) represents the majority of 
pancreatic cancer: accounting for 85% of total pancreatic cancer incidence, it is 
the major clinical challenge in treating this disease. (Ryan, 2014) Increased 
incidence of PDAC is linked with several behavioral factors: smoking (relative risk 
(RR): 2-3), nonhereditary or chronic pancreatitis (RR: 2-6), chronic diabetes 
mellitus (RR: 2), obesity and/or sedentary lifestyle (RR: 2), non-type O blood 




2011) The majority of patients with PDAC exhibit de novo disease; hereditary or 
genetic factors are only responsible for 5-10% of cases. (Siegel, 2011)   
A few genetic associations are linked with higher PDAC lifetime risk. Individuals 
with Hereditary Pancreatitis, associated with Trypsin-1 (PRSS1) or serine 
protease inhibitor Kazal-type 1 (SPINK1) mutations, possess a lifetime PDAC 
risk of 50%, while patients with Peutz-Jegher syndrome, associated with 
mutations of serine/threonine kinase 11/ liver kinase B1 (STK11 [LKB1]), and 
Familial Atypical Multiple Mole and Melanoma Syndrome (FAMMM), associated 
with p16 mutations, carry lifetime risks of 30-40% and 10-20% respectively. 
(Amundadottir, 2016) Other syndromes, such as Lynch Syndrome, associated 
with MLH1, MSH2, and MSH6 mutations; hereditary breast and ovarian cancer 
syndromes, caused by inherited BRCA1/2 or PALB2 mutations; Ataxia-
telangiectasia, caused by mutations in the ATM; and Li-Fraumeni Syndrome, 
caused by germline p53 mutations, are associated with pancreatic cancer risk. 
(Amundadottir, 2016) Lifetime risk is increased with family history in first degree 
relatives: individuals with a first degree relative (FDR) who have PDAC have 1.76 
times the odds of developing PDAC (1.82 if FDR was greater than or equal to 60 
at time of diagnosis, 1.54 if he/she was less than 60), and 4.26 times the odds if 
he or she has two or more first degree relatives with PDAC.(Jacobs, 2010) 
Currently, clinical assessment and improvements in PDAC outcome are 
hampered by inadequate diagnostic measures, and lack of consensus for 




Section Two: Diagnosis of Pancreatic Cancer 
Treatment improvements in several common tumors, breast, colon, 
cervical, and prostate are a consequence of advances in diagnosis and resulting 
staging (e.g., earlier detection, reliable markers, monitoring, effective screening 
regimes and clinical measures for early detection); unfortunately, this same 
advancement has not been achieved in PDAC. Typically, PDAC patients remain 
asymptomatic, or with non-specific symptoms, which delay diagnosis until 
advanced stage disease where tumor invasion into other organs produces more 
specific symptoms. The majority of tumors (60-70%) will originate at the head of 
the pancreas, while 20-25% present on the body and tail, and a small percent will 
originate in the pancreatic duct, islets of Langerhans, or are listed as “unknown”. 
(Mondolell, 1999) (Artinyan, 2008) Presentation of disease depends on location, 
but common symptoms include painless jaundice (as tumor at the head spreads 
to bile duct), abdominal pain, asthenia, anorexia, and unintentional weight 
loss.(Deshwar, 2018) A comparative case-control analysis of PDAC patients (n= 
120) to control patients (n = 180) revealed that bile obstruction (odds ratio (OR): 
20), pale stool (OR: 31), anorexia (OR: 41), abdominal pain (30), and unusual 
bloating/ belching (OR: 20 and 17) are the most common general pancreatic 
cancer symptoms. (Holly, 2004) The non-specificity of symptoms prevents an 
effective screening method for patients at risk for PDAC. 
Attempts to develop accurate diagnostic tests are limited by the dearth of 




Lewis blood group antigen, and carcinoembryonic antigen (CEA), are used as 
circulating biomarkers of pancreatic cancer. CA 19-9, while present in PDAC 
patients, is also highly expressed in other pancreatic diseases, pancreatitis and 
pancreatic pseudocyst, as well as choledocholithiasis and cirrhosis. 
(Loewenstein, 1978) Thus, the sensitivity of CA 19-9 ranges from 79-81% and 
specificity ranges from 82-90%, limiting use of CA 19-9 alone. (Loewenstein, 
1978) Furthermore, CA 19-9 lacks sensitivity as a biomarker for early detection, 
and is only used reliably to monitor the course of patient disease. (Yue, 2011) 
Although CEA is used to monitor gastrointestinal (GI) malignancies, it suffers 
from similar limitations as CA 19-9. CEA is expressed at elevated levels in 
alcoholic cirrhosis, hepatitis, and biliary disease, and thus, its utility in screening 
is limited. (Lee, 2013) 
Efforts to identify clinically relevant biomarkers, based on patient samples 
and preclinical models, are ongoing, and a number of potential novel targets are 
reported. For example, specific changes in the methylation states of leukocyte 
DNA have been observed in patients with PDAC. Potential markers unique in 
PDAC patients include:  IL-10_P348, LCN2_P86, ZAP70_P220, AIM2_P624, 
TAL1_P817, TNFRSCF10C, ACIN1, Line-1, and ALU repeats. (Pedersen, 2011) 
(Dauksa, 2012) Similarly, specific epigenetic changes in circulating tumor DNA 
(ctDNA), present at the early stages of tumorigenesis, can be detected in patient 
blood samples. Bauden et al. report that specific nucleosome targets, 5MC, 




relevant for detection of early disease. (Bauden, 2015) Similarly, mutations in 
KRAS, one of the most commonly mutated genes in PDAC, can be detected in 
ctDNA. KRAS mutations are implicated as early genetic drivers in PDAC 
formation, with mutations detected in precursor lesions of ductal 
adenocarcinomas: pancreatic intraepithelial neoplasms. (Ryan, 2014) Tumor 
specific KRAS mutations are well conserved between ctDNA and the tumor 
tissue, suggesting that ctDNA tests for specific mutants are a viable approach in 
conjunction with other screening methods. (Jones, 2008) (Kinugasa, 2015) 
Finally, microRNAs have been studied as potential biomarkers for PDAC. The 
microRNA miR-223 is significantly elevated in both human PDAC tissue and in 
the circulation of PDAC patients compared to normal, healthy volunteers. 
(Komatsu. 2015) 
 
Section Three: Conventional Therapy of Pancreatic Cancer 
 The poor 5-year survival, lowest amongst all common cancers, is 
reflective of the limited treatment options available. Surgical resection remains 
the only current curative intent therapy for pancreatic cancer; however, it is 
limited to 15-20% of patients. (Strobel, 2019) Even patients eligible for surgery 
are often found to have microscopically positive margins at surgery - evidence of 
more locally invasive disease. (Oberstein, 2013) Surgical removal typically 
requires a pancreaticoduodenectomy (Whipple procedure) to remove tumors 
localized to the head/neck pancreas and bile structures. (Strobel, 2019) 




2011) More distal tumors in the body or tail require a distal pancreatectomy, often 
with concomitant splenectomy to remove invasive tumor. (Siegel, 2011) In order 
to improve surgical outcomes, guidelines and recommendations have been put 
forth, including: 1) favoring resection of PDAC tumors in high PDAC volume 
hospitals, (Lidsky, 2017) (Krautz, 2018)  as technical performance, awareness of 
post-surgical complications are improved in surgical teams more acquainted with 
these procedures; (Birkmeyer, 2002) (Finks, 2011) 2) reservation of preoperative 
biliary drainage for patients with elevated bilirubin, associated coagulation 
disorders, or with intended neoadjuvant therapy; (van der Gaag, 2010) (ACR, 
2017) 3) consultation with interventional radiology to manage perioperative 
mortality (Neoptolemos, 2018), early angiography, and intervention following a 
sentinel bleeding episode; (Khalsa, 2015) 4) interventional drainage for fluid 
collection from a pancreatic fistula; (Hartwig, 2013) (Dong, 2016) 5) modified 
pancreatico-duodenectomy surgical procedures, such as the “uncinate process 
first”,  or hanging maneuver to detect tumor infiltration into superior mesenteric 
artery; (Martin, 2009) (Pędziwiatr, 2017) and, 6)  total pancreatectomy in 
advanced stage disease. Other attempts at optimizing surgical outcome show 
equivocal results, for example, extended lymphadenectomy to treat nodal 
disease in patients with surgically amenable tumors shows no improvement in 
survival outcome, while increasing the risk of delayed gastric emptying post-




use, perioperative somatostatin in resectable patients does not improve survival 
outcomes, and should be avoided as standard practice.  
 Adjuvant, neo-adjuvant, and palliative treatment of locally advanced to 
metastatic PDAC relies on non-specific chemotherapeutics. Current treatment 
options for advanced/ metastatic PDAC are summarized in the table below: 
 
Table I. Current Treatments in PDAC 
 































































mFOLFIRINOX Phase II 10.2 vs. 
6.1 mo 
n = 37  Chung, 
2018 
 
First line chemotherapy in advanced/ metastatic PDAC typically entails 
combination therapy with gemcitabine and a nanoparticle formulation of 
paclitaxel, Abraxane, or combination therapy of 5-fluorouracil, leucovorin, 




considered for patients not-amenable to more aggressive combination therapy; 
single agent gemcitabine has improved survival outcomes compared to other 
single agent therapies, with overall patient survival of 6-7 months in advanced 
disease. (Hajatdoost, 2018) Available treatment outcomes show marginal 
improvement in overall survival at best, with overall survival falling short of one 
year in most trials. Lack of target specificity, dose-limiting toxicity, and poor drug 
penetrance underlie major limitations in PDAC therapy efficacy, and highlight the 
discrepancy in care between PDAC and other solid tumors. Regardless, current 
treatment modalities in advanced/ metastatic PDAC are limited to non-specific 
chemotherapy, which underscores poor survival outcome in this disease.  
  
Section Four: Targeted Therapy in Pancreatic Cancer 
 The lack of targeted therapy in PDAC is responsible in part for poor 
treatment outcomes in PDAC. Targeted therapies, such as anti-VEGF therapy 
(Bevacizumab), anti-EGFR/ FGR therapy, and checkpoint inhibitors, have failed 
to extend overall survival compared to chemotherapy alone. (Table II). At best 
addition of biologic or targeted therapies affords identical or marginal 
improvements (< 2 months) in overall and progression free survival compared to 
standard chemotherapy alone. However, several targeted therapies yield worse 
outcomes than standard chemotherapy alone. Combination therapy of the 
MEK1/2 and AKT inhibitors Selumetinib and MK-2206 decreased overall survival 




of these therapies is attributed to driver mutations in PDAC that facilitate 
receptor-independent mitogenesis (Hajatdoost, 2018), unique challenges in 
tumor microvasculature and angiogenesis compared to other GI tumors, 
(Oberstein, 2013) heterogeneity in oncogenic and tumor suppression genes 
(Grivennikov, 2010) (Waters, 2018), and tumor desmoplasia, facilitating high 




































Table II. Previous Targeted Therapy Trials in PDAC 
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Subsection 4.1: RAS and SMAD4- Drivers of PDAC Oncogenesis 
 Ras mutations are commonly observed in most PDAC tumors, with Ras 
mutants (at glycine-12, glycine-13, or glutamine-61 residues) (Zeitouni, 2016) 
implicated in high mitogenic activity of cancer cells. While Ras targeting has 
eluded success in clinical trials, efforts are ongoing to target members of the 
Ras/Raf signaling pathways. The common mutation, Kirsten rat sarcoma (KRAS) 
is frequently encountered in PDAC tumors, 
with 95% harboring a mutation of 
chromosome 12. (Zeitouni, 2016) This pro-
oncogenic stimulus is associated with loss 
of function and loss of heterogeneity (LOH) 
from somatic mutations as well as 
epigenetic suppression of tumor 
suppressors cyclin-dependent kinase 
inhibitor 2A (CDKN2A), which regulates 
p16/Ink4a and p14/Arf, which in turn 
regulates cyclin dependent kinase 4/6 
(CDK4/6) and mouse double minute 2 
homolog (MDM2) which negatively 
regulates p53. Dysregulation of this axis 
inactivates Rb tumor suppression, leading 
to tumor progression and dysregulated cell 
 
Figure 1| Ras signaling.  
Activation of Receptor Tyrosine 
Kinases (RTK) leads to 
serine/threonine phosphorylation and 
recruitment of adaptor proteins, such 
as Shc and Grb2. Recruitment of SOS 
leads to Ras activation via accelerated 
dissociation from GDP to GTP. GTP 
bound Ras phosphorylates Raf, which 















growth. A summary of RAS mediated signaling is detailed in Figure 1. Ras 
mediated signaling relies on protein-protein interactions, which, to date, cannot 
be effectively, or selectively, inhibited in human trials. Attempts to target parts of 
Ras signaling are summarized in Table II, and explained in detail in the following 
section.  
The SMAD (mothers against decapentaplegic) axis is also commonly 
dysregulated in PDAC. 
SMADs are a diverse set of 
proteins involved in signal 
transduction of the TGF-β 
signaling pathway; these 
proteins, including receptor-
regulated Smads (R-Smads), 
Smad1, Smad2, Smad3, 
Smad5, and Smad8), 
common mediator Smad (co-
Smad), Smad 4, and inhibitor 
Smads (I-Smads), Smad6/7. 
(Ahmed, 2017) A summary of 
TGF-β signaling is given in 
Figure 2. Proper regulation of 
R-Smads and I-Smads is 
 
 
Figure 2| TGF-β signaling.  
Activation of TGF-β Receptors leads to dimerization, 
and subsequent phosphorylation of Smads2 and 3. 
Smads2/3 with partner with the common signal 
transducer, Smad4, and translocate to the nucleus, 
activating a host of transcriptional factors, such as AP-
1, bZIP, and Fox. Inhibitor Smads 6 and 7 provide a 
















essential for controlling normal cell cycle; therefore, inactivation of Smad4 
removes control on cell cycle checkpoints. Loss of this crucial tumor suppressive 
pathway is present in 60-90% of PDAC patients via loss of Smad4; this occurs 
from Smad4 inactivation (20%), deletion (30%), or loss of the 18q2 region, where 
Smad4 is found (90%).(Ahmed, 2017)  Direct clinical targeting of Smad4 is 
limited, and has not been met with success. Reactivation of Smad4 is 
challenging, with attempts showing some promise in preclinical models; however, 
no current drugs or therapies directly target Smad4 activation. (Duda, 2003) 
Attempts to target TGF-β signaling upstream of Smad4 are showing some 
success. A Phase II study comparing dual therapy of galunisertib, a small 
molecule inhibitor of TGF-β receptor Type I and gemcitabine to gemcitabine 
alone in 156 patients for first-line therapy in unresectable PDAC showed an 
improvement in overall survival (8.9 mo vs 7.1 mo, hazard ratio: 0.8 [0.6-1.09]. 
(Duda, 2003) This result suggests targeting the TGF-β pathway is a viable 
approach in combination PDAC therapy. 
 
Subsection 4.2: Targets Upstream of Ras 
Unfortunately, inhibition of mitogenic signaling pathways associated with 
tyrosine kinase receptors, especially members of the ErbB family, EGFR, HER2, 
ErB3, and ErbB4, shows limited PDAC treatment efficacy. Members of the ErbB 




activating down-stream RAS and phosphatidyl inositol 3 kinase (PI3k)/ AKT 
signaling pathways. Overexpression of EGFR is a common characteristic in 
pancreatic cancer, and anti-EGFR therapy has been evaluated in clinic. Direct 
inhibition of EGFR via the chimeric monoclonal antibody, cetuximab, shows no 
clear clinical benefit in phase III randomized trials, despite pre-clinical success. 
(Philip, 2010) Attempts to target overlapping ErbB receptors, via combination 
therapy of cetuximab (EGFR) and trastuzumab (HER2), in the Phase I/II Therapy 
trial also fail to show treatment benefit. (Assenat, 2015) Targeting the 
downstream activation of ErbB receptors, via tyrosine kinase inhibitors (TKIs), is 
an alternative approach but has also met setbacks. A randomized phase III 
clinical trial of the National Cancer Institute of Canada Clinical Trials Group 
investigating erlotinib (a TKI of EGFR) with gemcitabine vs. gemcitabine in 569 
patients with advanced disease alone failed to meet study criteria in overall 
survival (6.24 vs. 5.91 months, p =0.038). (Moore, 2007) However, a recent study 
shows that treatment of 88 metastatic pancreatic cancer patients possessing 
EGFR mutations gemcitabine with erlotinib improves median overall survival 
compared to gemcitabine alone (7.2 vs 4.4 months, p<0.001). This finding 
suggests that targeting EGFR in EGFR mutant patients is effective, even in the 
presence of KRAS mutants, and provides motivation for additional clinical 
evaluation.  
Another mitogenic transmembrane receptor, the insulin-like growth factor-




PDAC, as high levels of IGF-1 are correlated with a worse prognosis in PDAC. 
(Valsecchi, 2012) Co-expression with EGFR is associated with poor prognosis, 
with cross-talk between receptors implicated in advanced disease. (Guo, 2009) 
(Kopantzev, 2017) In a Phase Ib trial, treatment with gemcitabine and erlotinib 
with and without cixutumumab, a monoclonal antibody targeting IGFR, fails to 
show significant improvement in median overall survival (7.0 vs. 6.7 months) or in 
progression free survival (3.6 vs. 3.6 months). (Philip, 2014) Anti-IGFR therapy 
was attempted again using a novel bispecific anti-IGF-1R/HER3 antibody, MM-
141. A Phase II trial comparing nab-paclitaxel and gemcitabine, with or without 
MM-141, also failed to show any improvement in overall survival. (Ko, 2016) 
Another approach involves the non-specific target of receptor tyrosine 
kinases via a promiscuous tyrosine kinase inhibitor, TKI. Two such TKIs, 
Sunitinib and Sorafenib, are being evaluated for the treatment of metastatic 
PDAC. In a phase II study by the Central European Society for Anticancer Drug 
Research, treatment with gemcitabine in the presence or absence of sunitinib in 
106 patients with advanced pancreatic cancer shows no survival benefit with 
gemcitabine and sunitinib compared to gemcitabine alone (30.4 weeks vs. 36.7 
weeks, p = 0.78), with increased neutropenia noticed in the combination arm. 
(Bergmann, 2015) A slightly better outcome is seen in a phase II study of 
sorafenib, oxaliplatin, and high dose capecitabine in the 24 patients; the median 
overall survival increases to 8.1 months without a control arm. (Gonçalves, 2012) 




the result of the low prevalence of wild type KRAS in PDAC patients; the majority 
(~95% of PDAC patients) carry mutations in KRAS that cause Ras to function 
independent of upstream mitogenic signals; therefore, inhibition of EGFR or 
IGFR is ineffective in the majority of patients.  
 
Subsection 4.3: Direct Ras Inhibition 
Consequently, direct inhibition of KRAS then, would seem to be a highly 
effective target in PDAC. However, drugs targeting KRAS have failed to show 
clinical efficacy. Direct targeting of Ras and members of Ras activation is difficult; 
the activation and signaling of Ras with its co-proteins requires a series of protein 
modification steps. The first attempts to target Ras involved inhibitors of 
farnesylate transferase. Activation of Ras requires the farnesylation of a cysteine 
located in the C-terminus of the peptide (in the CAAX box), mediated by the 
enzyme farnesyl transferase. (Zeitouni, 2016) This modification allows the 
cleavage of the terminal AAX amino acids on Ras by Ras-converting enzyme I, 
which then allows anchoring of Ras to the cell membrane. (Zeitouni, 2016) 
Inhibition of farnesyl transferase prevents the step-wise anchoring of Ras to the 
plasma membrane and disrupts Ras function in vitro. (Zeitouni, 2016) 
Unfortunately, a Phase III clinical trial comparing the farnesylate transferase 
inhibitor tipifarnib plus gemcitabine vs. gemcitabine plus placebo in patients with 




with tipifarnib treatment (193 vs. 182 days, p=0.75, n =680 patients). (Van 
Cutsem, 2004) Alternative approaches to preventing Ras protein anchoring are 
also being investigated including the use of a farnesyl-cysteine mimetic, farnesyl 
thiosalicylic acid or salirasib. This mimetic dislodges Ras from the cell 
membrane, allowing degradation (Haklai, 1998); the approach shows limited in 
vivo efficacy in targeting Ras signaling in patient derived xenografts of pancreatic 
cancer, decreasing growth in 2/14 patient derived xenograft models studied. 
(Laheru, 2012) In this same integrated preclinical/ Phase I study, Salirasib plus 
gemcitabine is tolerated in 19 patients with metastatic pancreatic cancer, 
showing a median overall survival of 6.2 months. (Laheru, 2012) Current studies 
in Salirasib are ongoing, with another Phase I study showing the same tolerability 
with gemcitabine combination in patients with relapsed or refractory solid tumors. 
(Furuse, 2018) Finally, attempts to disrupt KRAS trafficking and translocation 
with the membrane via inhibition of the enzyme prenyl-binding protein 
phosphodiesterase 6 delta (PDEδ) are being explored. The small molecule 
inhibitors of PDEδ, Deltarasin, exhibits in vitro efficacy in RAS membrane 
delocalization in Panc1 and Panc-Tu-I cells, decreases proliferation, and shows 
dose-dependent tumor inhibition in in vivo Panc-Tu-I subcutaneous xenografts. 
(Zimmermann, 2013) Currently, there are no clinical studies investigating 





Subsection 4.4: Targeting Downstream of Ras 
 Given the limitations in targeting TKIs in Ras/KRAS signaling in PDAC, 
and current failures to disrupt KRAS signaling in humans, opportunities for 
treatment are potentially found downstream. Activation of Ras via GTP binding 
activates downstream MEK-ERK signaling as well as PI3K signaling cascades. 
Both downstream ERK1/2 signaling and PTEN/Akt/mTORC1 signaling are thus 
potential targets in PDAC therapy. Attempts to inhibit upstream proteins in these 
cascades, notably BRAF mutations, have not proven successful in PDAC. 
Monotherapy of individual targets in either cascade also fails to show clinical 
benefits. (Bodoky, 2012) (Infante, 2014) Selective inhibition of MEK (selutetinib) 
and AKT (MK-2206) does not show any improvement in therapy versus 
mFOLFOX in patients having progressed on gemcitabine therapy. (Chung, 2017) 
Toxicities from these inhibitors prevent continuous dosing, which further limits 
treatment efficacy. (Chung, 2017) Attempts at dual targeted therapy in a phase II 
trial, with an erlotinib and selumetinib, also failed as no significant improvement is 
observed. (Ko, 2016) The exact reason for these failures is not well understood, 
but may highlight the diverse functions of Ras signaling, which cannot be limited 
to any specific downstream path. 
 Setbacks in the development of targeted therapy for PDAC underscores 
the need to explore novel targets as well as new treatment paradigms. 
Advancements in tumor-omics, biomaterial drug formulations, in combination with 




management of PDAC. In the following section, I review several new approaches 
under development in the preclinical setting and their potential impact for 
treatment of PDAC. 
 
Section Five: Novel Pre-clinical Developments in PDAC 
 Poor survival outcome in PDAC necessitates novel, innovated approaches 
towards disease management. Effective treatment of pancreatic cancer, requires 
the following improvements: 1) better visualization of tumor margins during 
surgery, improving complete resection rate; 2) better targets for biologic therapy 
and small molecule inhibitors; and, 3) improvements in drug delivery to overcome 
biophysical limitations in PDAC treatment. Here, I discuss recent improvements 
in these areas, offering insight into recent successes and future clinical 
applications.  
 
Subsection 5.1: Surgical Visual Aids 
Identification of gross and microscopic tumor margins, as well as the 
presence and extent of distal disease is essential for optimizing surgical 
outcomes. (Donahue, 2015) Advances in optical imaging probes are enhancing 
surgical procedures via maximizing tumor volume reduction, reducing the risk of 
recurrent disease, and alleviating the need for more aggressive chemotherapy, 
limiting the progression into uncurable disease. Use of fluorescent probes in the 




available for fluorescence guided surgery.(Buchs, 2012) (Sherwinter, 2012) 
(Tummers, 2015) Clinical trials are ongoing for fluorescent imaging probes in 
several cancer subtypes, including colon cancer (LUM015, RAPIDO-TRACT, and 
Fluorescent lectin), lung cancer (EC17, and ICG), and breast cancer (BLZ-100, 
LYM015, AVP-620, EC17); preclinical studies are demonstrating new methods of 
fluorescent agent delivery, better tumor specificity of fluorescent agents, and 
improved resolution to currently available methods. These new methods and 
applications provide the opportunity for better tissue resolution as well as safer 
delivery compared to currently available agents or those currently in clinical trials. 
Development of surgical aids specifically for pancreatic cancer are limited; 
however, promising developments in the field of biomaterial agents for cancer 
could be readily applied to pancreatic cancer surgery. 
Guided imaging of cancer can either rely on non-specific bulk delivery of 
dye relying on properties of tumor microvasculature, microenvironment, or 
metabolism, or rely on specific targeting of tumor cells by antibody, for example, 
directed tumor visualization. (Tringale, 2018) Non-specific imaging guiding 
techniques, through the use of labeled and modified nanostructures, provide the 
benefit of improved tumor field visualization without dependence on tumor 
specific epitopes, providing greater generalization across tumor subtypes and 
avoiding receptor heterogeneity. The use of nanoparticle dye carriers shows 
promise as a means of localized dye delivery as a function of tumor metabolic 




nanoparticles covalently linked with rhodamine methyl methacrylate (HRF-eNP) 
were able to localize to peritoneal tumors in a xenograft model of Panc1 in RNU 
rats. (Colby, 2017) Targeting and retention of the HFR-eNPs in peritoneal tumor 
sites are highly effective, with specificity, sensitivity, and accuracy of 0.99, 0.92, 
and 0.95 in the 202 normal samples and 253 histologically confirmed samples 
surveyed. Use of HRF-eNPs allowed sub-millimeter tumor detection, a currently 
unmet need in image resolution, providing an alternative imaging technique for 
improving surgical resection. Ghosh et al. report the use of a modified M13 
bacteriophage to stabilize single-walled carbon nanotubes (SWNTs) for targeted 
imaging of ovarian tumors. (Ghosh, 2014) SWNTs offer the potential for high 
target to noise ratios, with near-IR emission, decreasing optical scattering and 
allowing deeper tissue penetration compared to imagining techniques in the 
visible light range, along with greater resistance to photobleaching. The M13 
bacteriophage stabilized SWNTs target prostate tumors (Yi, 2012) (Ghosh, 2012) 
and ovarian tumors (van Dam, 2011) effectively in in vivo murine cancer models, 
and improve surgical outcomes. Application of this technology in pancreatic 
cancer may provide better precision in the detection of surgical margins. 
Functionalized nanosheets for improved visualization are being 
investigated for applications in photoacoustic, computed tomography (CT), and 
magnetic resonance imaging. For example, Se-BiOCl nanosheets, functionalized 
with Prussian blue analogues, by Chen et al, provide improvement in tumor field 




affected region. (Chen, 2019) Use of these functionalized Se-BioOCl nanosheets 
also improves contrast in T1- and T2-weighted imaging, comparable to 
commercial contrast agents, and with greater resolution than other nanoparticle 
formulations. Additionally, these nanosheets function as a specific CT contrast 
agent, providing better resolution enhancement than similar bismuth agents 
(84.16 HU mL/mg vs. 35.7 Hu mL/mg for Bi2Se3) or clinical agents (15 Hu mL/mg 
iopromide and 19.7 HU mL/mg iodine). Palladium nanosheets are an effective 
photoacoustic contrast agent for head and neck tumors, with greater resiliency 
than gold-based nanoparticles, which are known to degrade in response to laser 
irradiation. Work by Nie et. al showed that palladium nanosheets are 
photothermally stable compared to gold nanoparticles, with excellent selectivity 
for tumor tissue photoacoustic signaling, producing better signal resolution and 
signal depth than vector control. (Nie, 2014) Use of modified nanosheets for 
multimodal imaging may provide a significant improvement in tumor boundary 
detection in image-guided surgery or post-surgical evaluation.  
Another approach to guiding surgical imaging is via fluorescent marking of 
the tumor margins. A comparison of bright light surgery (BLS) to fluorescence-
guided surgery (FGS) by Metilidi et al. showed that in orthotopic mouse models 
of BxPC-3 pancreatic cancer, fluorescent marking of the tumor improves surgical 
outcomes (BLS had evidence of disease in 63.2% of mice, with no complete 
resection vs. 20% complete resection with GFS and 75% with only minimal 




with red fluorescent protein (RFP), limiting direct application clinically; however, if 
an appropriate target were selected, FGS fluorescence guided antibody imaging 
could prove useful. Building upon this result, the same group applied this 
approach to a fluorophore conjugate of an antibody targeting the 
carcinoembryonic antigen (CEA), a marker employed in monitoring several GI 
malignancies, including PDAC. (Metildi, 2014) Significant improvements in 
surgical outcome are seen using the BxPC-3 orthotopic cancer model (92% FGS 
complete resection vs. 45.5% in BLS, with 40% cure rate in FGS and 4.5% in 
BLS). Similar results are described by Bouvet and Hoffman, using anti-CEA and 
CA 19-9 antibodies emitting in the visible and near-infrared range, using PDX 
models. (Bouvet, 2015) Fluorescence is detected for up to two weeks, and use of 
these fluorescent antibodies provides visual representation of the tumor field. In 
addition to fluorescent targeting of cancer cells via CA 19-9, enhancement of 
positron emission tomography with near-infrared fluorescent (NIRF)-guided 
delineation of the surgical margins is accomplished using a modified CA 19-9 
antibody conjugated with either desferrioxamine (DFO) and/or a NIRF dye (FL). 
Using a subcutaneous and orthotopic xenograft model of either CA19.9 positive 
(BxPC-3) or negative (MIAPaCa-2), the antibody conjugate specifically 
internalizes in receptor positive cells to provide an improvement in PET/CT 
signaling. (Houghton, 2015) In a tandem PET/CT-NIRF imaging experiment with 




nodal migration is delineated, demonstrating this approach is advantageous both 
in surgical resection, staging, and monitoring. 
Development of modified nanoparticles functionalized with tumor specific 
antibodies provides an avenue for greater signal resolution with higher dye 
loading than antibodies alone, while improving specificity of nanoparticle delivery. 
Work by Qiu et al, in the development of theranostic nanoparticles based on gold 
nanocages, show that nanoparticle functionalization with anti-glypican-1 antibody 
and oridonin provide tumor specific signal in NIRF over 24 hrs, with maximal 
signal detection around 12 hrs post injection, as well as improvement in magnetic 
resonance imaging (MRI) signal detection, showing high signal retention in tumor 
tissue, as well as liver and kidneys in BxPC-3 orthotopic xenograft models. (Qiu, 
2018) Similarly, use of a mixed Fe3O4-SiO2 nanoprobe modified with anti-
mesothelin (MSLN) antibody shows promise as a contrast agent for MRI imaging. 
(Liu, 2016) Lysine conjugated Fe3O4-anti-MSLN nanoparticles, tested in 
subcutaneous xenograft models, attenuate the transverse relaxation time, T2, in 
MRI images. The functionalized nanoparticles accumulate in high local 
concentration in the tumor tissue, lung, and liver, without significant toxicity in 
non-cancerous tissue.  
Improvements in dye specificity to target tumor tissue are being made by 
incorporation of protease cleavable sites within dye-biomaterial conjugates, 
resulting in protease-activatable probes. Protease specificity to the tumor 




dye accumulation in metabolically active, non-cancerous tissue. (Sekar, 2003) 
(Lee, 2008) (Elias, 2008) (Lee, 2010). Matrix metalloproteinases (Egeblad, 
2002), cathepsins (Pham, 2004), or caspases (Pham, 2003) are employed as 
enzymes for directed cleavage of target sequences. For example, Nakamura et 
al describe a γ-glutamyl hydroxymethyl rhodamine green activatable probe 
(gGlu-HMRG), which produces a fluorescent signal following γ-
glutamyltranspeptidase exposure. (Nakamura, 2016) Use of gGlu-HMRG 
provides rapid (approximately 10 minutes) fluorescent detection of cancer foci, 
with maximal signal detected around 30 minutes. The fluorescent detection is 
cancer specific (here ovarian peritoneal carcinomatosis using the SHIN3 cell line 
was detected) in the peritoneum, with minimal fluorescence of surrounding 
structures. The enzyme γ-glutamyltranspeptidase is produced in pancreatic 
cancer cells, and the same method could be applied to peritoneal metastasis of 
PDAC.   
Another method of protease specific fluorophore release relies on a dual 
antibodies system that uses a fluorescent dye, Alexa Fluor 700, and a quencher 
system IRDye QC-1, which prevents fluorescence until proteolytic cleavage. 
(Girgis, 2017) The system repurposes two antibodies, cetuximab and 
trastuzumab, which target receptors expressed on PDAC, but have not shown 
clinical efficacy. Both proteolytically activated immunoconjugates provide 
improved signal resolution of AsPC-1 orthotopic xenografts, as well as enhance 




dual imaging improves signal resolution, maximizing signal in cancer cells which 
have higher receptor expression of both targets. This particular system takes 
advantage of two antibodies which have not shown therapeutic efficacy, but can 
be used to visualize tumor fields.  
 
Subsection 5.2: Novel Targets and Biologic Therapy 
 
Identification of novel targets in pancreatic cancer is essential to improving 
treatment outcomes. Current treatment paradigms rely solely on non-specific 
chemotherapeutics, which limited improvement in advanced and metastatic 
disease (vide supra). Biologic therapies offer greater target specificity by blocking 
tumor-dependent signals or tumor-enhanced signals required for maintaining 
aberrant growth and metastatic potential not seen in normal tissue. Recent 
advancements in preclinical targets offer potential hope in advancing pancreatic 












Table III. Summary of Selected Targets for Antibody Therapy in PDAC 
Targets Function Downstream 
Signaling 
Preclinical Data 





































































Mucin 1:  
MUC1, a glycosylated transmembrane phosphoprotein of the mucin family, is 
expressed on normal epithelial cells, and protects and lubricates the lumen. High 
expression of mucins, particularly MUC1, are associated with multiple cancer 
subtypes (Kufe, 2009) (Kaur, 2013) (Kufe, 2009); PDAC tumors in particular 
show a strong correlation between MUC1 expression and drug resistance, tumor 
progression, and metastasis (Moniaux, 2004). Expression levels are significantly 
higher on PDAC cells compared to normal luminal surfaces and pancreatic 
epithelial cells, suggestive that MUC1 expression plays a pivotal role in PDAC 
progression and survival. A correlation exists between MUC1 and EGFR 
expression across multiple tumor types, with targeting of MUC1 attenuating 
EGFR signaling and EGFR mediated growth in PDAC cell lines and xenograft 
models. (Bruns, 2000) (Tobita, 2003) (Merlin, 2011) Work by Wu et al. showed 
that anti-hMUC1 demonstrated specificity across several cell lines with 
internalization and retention in MUC-1 positive cell lines (Capan-1, Capan-2, 
CFPAC-1), but no internalization in MUC-1 negative cells (Panc1). (Wu, 2018) 
Inhibition of MUC1 did not decrease cell viability or proliferation in vitro; however, 
anti-MUC1 therapy did attenuate EGFR mediated ERK1/2 and cyclin D1 
signaling in MUC1 positive, but not MUC1 negative cells. MUC1-fluorochrome 
conjugates localized to tumor sites in Capan-2 subcutaneous xenograft models, 
with MUC1 treatment showing a moderate decrease in tumor volume by 11 




MUC1 in PDAC cell lines- 91.9% of the PDAC samples survey (n = 33) showed 
MUC1 expression with 60.6% of cells demonstrating expression in at least 11% 
of cells. Combination therapy with MUC1 and other targets may provide 
improved treatment outcomes or provide synergistic antagonism of downstream 
MEK/ERK signaling, and are worthy of further investigation. However, potential 
limitations of anti-MUC1 treatment include targeting normal gastrointestinal (GI) 
parenchyma, leading to undesirable GI toxicities, and disrupting the protective 
mucin barrier of normal luminal cells. Patient populations at risk of worsening 
luminal disease, such as patients with peptic ulcer disease (PUD), may not 
receive benefit from anti-MUC1 treatment.  
PARP1 and DR5:  
Poly (ADP-ribose) polymerases (PARPs) are a class of proteins involved in DNA 
repair, genomic stability, and regulating cell death. PARP-1, a member of the 
PARP family, is involved in death receptor activated extrinsic apoptosis 
(Gonclaves, 2011) (Gibson, 2012); expression of PARP-1 is limited the nucleus 
in normal pancreatic tissue, but is expressed within the cytoplasm of cancer cells. 
(Melisi, 2009) (Fogelman, 2011). Inhibition of PARP1 results in an acceleration of 
irreparable DNA damage, leading to induction of apoptosis. (Melisi, 2009) 
(Gibson, 2012) In work by Xu et al, elevation of cytoplasmic PARP-1 was 
associated with acquired resistance to tumor necrosis factor-related apoptosis-
inducing ligand (TRAIL) induced apoptosis via death receptor 5 (DR5). (Xu, 




MIA PaCa-2; however, when cytoplasmic PARP-1 was elevated in both cell lines, 
induction of apoptosis by TRA-8 was significantly reduced. Elevation of nuclear 
PARP-1, was not shown to impact sensitivity of TRA-8 in either cell line, 
suggesting that cytoplasmic PARP-1, which represents a different isoform, is 
crucial for resistance to TRAIL induced cell death via DR5. (Xu, 2019) 
Recombinant TRAIL or anti-human DR4/5 agonists have seen limited success in 
clinical trials, with the agonist TRAIL-R antibody Conatumumab, and gemcitabine 
failing to show improvement in overall survival to monotherapy of gemcitabine. 
Similar clinical results were observed with TRA-8 suggesting that despite pre-
clinical success, resistance to TRAIL therapy prevents application in humans. 
Association of cytoplasmic PARP-1 with TRAIL agonism suggests that 
combination therapy targeting both DR5 and PARP-1 may improve response 
rates to treatment. However, a major challenge of PARP-1 antagonists will be 
effective local drug delivery, since pancreatic tumors are poorly vascular and 
highly desmoplastic.   
 
GPR87 
GPR87 is a novel, recently identified G-coupled protein receptor related to the 
lysophosphatidic acid (LPA) receptor, which is highly expressed in several 
cancer subtypes, including squamous cell lung (Gugger, 2008), non-small cell 
lung (Nii, 2014), bladder (Yan, 2013), cervical (Zhang, 2009), liver (Yan, 2013), 




expression is significantly elevated in The Cancer Genome Atlas (TCGA) 
samples (n = 178, p < 0.01), with high expression correlating with worse overall 
survival (n = 115, p < 0.027). (Wang, 2017) In commercial pancreatic cancer cell 
lines, GPR87 was significantly elevated in AsPC-1, Capan-1, BxPC-3, MIA 
PaCa2, Capan-2, and PANC1, while poorly expressed in normal human 
pancreatic ductal epithelial cells. Overexpression of GPR87 resulted in increased 
anchorage independent colonies, cell proliferation, and angiogenesis in response 
to cancer cell conditioned media, as well as greater protection from apoptosis by 
gemcitabine treatment in Panc1 and AsPC-1 cell lines. Silencing of GPR87 
produced the opposite result, dramatically decreasing tumor cell viability and 
angiogenic response. In vivo subcutaneous modeling of GPR87 overexpressing 
and silenced cells showed that inhibition of GPR87 greatly reduces tumor cell 
viability and overall growth compared to vector treated cells. This preliminary 
data suggests that targeting GPR87 may significantly improve survival outcomes 
in PDAC patients. However, the exact function of GPR87 in normal parenchyma 
is not well characterized. (Gugger, 2008) (Nii, 2014) Analysis of GPR87 mRNA 
expression shows that normal GI parenchymal cells express this receptor, along 
with normal endothelial cells. (Nii, 2014) The implication of GPR87 in LPA-like 
signaling in normal endothelial functions may limit the therapeutic window of this 
receptor. Further understanding of GPR87 signaling in normal cells is of 






The transmembrane four L6 family member 5 (TM4SF5) is a member of the 
tetraspanin family, implicated in cell development, growth, and motility. (Yanez-
Mo, 2009) (Sala-Valdes, 2012) (Detchokul, 2014) Expression of TM4SF5 is 
elevated in several GI cancer subtypes, including pancreatic, liver, colon, and 
esophageal tumors. (Lee, 2008) (Choi, 2009) (Wu, 2013) Overexpression of 
TM4SF5 drives tumor growth and metastasis, as well as EMT and angiogenesis 
in GI tumors. Ahn et al developed a novel chimeric monoclonal antibody targeting 
the EC2 domain of TM4SF5. (Ahn, 2017) When evaluated in colon cancer cell 
lines, the antibody is recognized and internalized by cancer cells, modestly 
reduced proliferation of SNU449T7 and SNU449Tp cell lines, and decreased 
invasion and migration of HCT-116 and Colo205 cancer cell lines in Matrigel 
assays. Treatment with anti-TM4SF5 antibodies significantly reduced tumor 
volume of SNU449T7 subcutaneous xenografts, suggesting inhibition of TM4SF5 
is an effective clinical target in colon cancer. As TM4SF5 is highly expressed in 
pancreatic cancer, this target and antibody are worthy of future work. 
 
DEspR 
The dual-endothelin-1/VEGF-signal peptide receptor (DEspR) is a novel single 
transmembrane receptor, identified as an embryonic-lethal null mutation 
phenotype characterized by dysregulated vasculogenesis and angiogenesis, and 




signaling is associated with VEGFR signaling in vasculogenesis, which seems 
concerted, as part of the propeptide of VEGF is a ligand for DEspR. Work by 
Herrera et al demonstrated that DEspR is associated with CSC anoikis 
resistance in Panc1 non-adherent in vitro models, showing that inhibition of 
DEspR by an anti-DEspR antibody decreased viability compared to PBS control. 
(Herrera, 2016) Furthermore, inhibition of DEspR decreased HUVEC 
angiogenesis, via tube assays, and cancer cells invasiveness. Treatment of 
subcutaneous xenograft RNU rat models of Panc1 with an anti-DEspR antibody 
showed a decrease in tumor volume compared to normal control, which is not 
seen in gemcitabine treatment, suggesting that DEspR may be an effective target 
in clinical studies.  
 
CD109 
CD109 is a glycosylphosphatidylinositol linked surface antigen expressed on 
cells of T-lymphocyte derivation, endothelial cells, and platelets. Importantly, 
CD109 is highly expressed on certain cancer cell lines, with expression elevated 
in BxPC-3, Capan-2, MIA PaCa-2, Panc-1, CFPAC-1, and FA-6. (Arias-Pinilla, 
2018) Treatment of BxPC-3, AsPC-1, and CFPAC-1 cells with two murine 
antibodies, KU42.33C and KU43.13A directed towards CD109, did not decrease 
growth or invasion of the cancer cells, suggesting that CD109 does not directly 
affect tumor cell growth. Evaluation of CD109 expression in human samples did 




staining observed in normal pancreas, small intestine, ovary, and no expression 
in other normal tissues. While no direct in vitro effect of CD109 is observed, the 
high specificity of this receptor may be used for future immunoconjugate 
development. However, potential immune complications of this therapy, such as 
inhibition or non-desired targeting of T-lymphocytes and platelets, as well as 
damage to non-tumor blood vessels, could impact the application of CD109 
immunoconjugates. The exact role of CD109 expression in pancreatic cancer is 
not well known, and it remains to be shown if CD109 may influence tumor 
induced angiogenesis or immunomodulatory effects.  
 
Subsection 5.3: Small Molecule Inhibitors 
Small molecule inhibitors have not shown success in recent trials in pancreatic 
cancer; relevant agents in the RAS signaling cascade were discussed previously, 
and despite preclinical efficacy, issues in tumor cell heterogeneity, signaling 
redundancy, or poor target specificity lead to failure in clinical trials. Rather than 
focusing on reapplication of these agents to subtypes of pancreatic cancer, I will 
focus on new targets and novel small molecule inhibitors currently under 
investigation in the preclinical setting. These agents provide alternative routes to 
treating pancreatic cancer, focusing on proteins that are highly expressed and 






Tubulin βIII/ βIV inhibitor (VERU-111) 
Tubulins play an essential role in regulating cellular trafficking, DNA segregation, 
and cell division; given the high metabolic activity of cancer cells compared to 
normal cells, it is not surprising that several isoforms are upregulated in different 
tumor subtypes. (Katsetos, 2012) (Parker, 2017) Tubulin isoforms βIII/ βIV are 
highly expressed in PDAC tumors, with a causal link to cancer cell progression, 
invasion, and drug resistance. (McCarroll, 2015) (Sharbeen, 2016) For example, 
VERU-111, a pan-β tubulin inhibitor, exhibited high specificity for tubulin βIII/ βIV, 
and treatment of PDAC cell lines decreased cell viability and metastasis, 
associated with cell cycle arrest in the G2/M phase and induction of cell cycle 
and apoptosis associated regulatory genes. (Kashyap, 2018) These in vitro data 
corroborate with greater inhibition of subcutaneous xenografts compared to 
vector control, with excised tumors showing similar cell cycle arrest to in vitro 
cells.  
 
β-catenin and MDM2 
Wnt/ β-catenin signaling is implicated as a major driver of cancer cell initiation, 
progression, and metastasis, directing “stemness” properties in tumors, and 
supporting dysregulated growth outside the bounds of normal cell cycle 
regulation. (Blagodatski, 2014) β-catenin plays a diverse role in cancer cell 
progression, with cellular localization affecting cellular signaling; membrane 




β -catenin regulates several transcription factors, such as T cell factor, CREB 
binding protein, and B cell lymphoma 9, mediating pro-oncogenic genes. 
(Damalas, 1999) (Cha, 2016) Work by Qin et al with β-carboline derivatives, 
revealed effective inhibition of MDM2 and a decrease in protein levels of β-
catenin, leading to decreased cell viability in Panc-1 p53 mutant and AsPC-1 p53 
null cell types. (Qin, 2018) Panc-1 and AsPC-1 orthotopic tumors showed 
decreased expression of β-catenin, c-Myc, and cyclin D1 following treatment with 
the lead agent, SP141, although survival outcomes were not assessed. As the 
Wnt/ Β-catenin pathway has been a focus of several unsuccessful targeted 
therapies in the past, the initial success of this targeted agent may provide 
another route for clinical treatment. 
 
SIRT2 
The sirtuin family are nicotinamide adenine dinucleotide (NAD+) dependent 
deacetylases, involved in cellular metabolism, stress, and gene regulation. SIRT2 
functions as a deacetylase for several transcriptional factors, metabolic enzymes, 
checkpoint kinases, tubulin, and histones. (North, 2003) (Vaquero, 2006) The 
diverse targets of SIRT2 underlie its complicated role in cellular metabolism and 
autophagy. SIRT2 offers promise as a target in pancreatic cancer, as SIRT2 
knockdown significantly impacts viability in certain PDAC cell lines. (Zhao, 2013) 
Inhibition of SIRT2 with a specific small molecule inhibitor, NPD110333, by Kudo 




dose dependent manner equivalent for increasing eIF5A acetylation, the 
physiological substrate of SIRT2. (Kudo, 2018) While the IC50 of this compound 
is relatively high, selectivity and safety of the SIRT2 antagonist is promising, and 
represents another potential target that may work synergistically in clinic. 
 
SUMO inhibitors 
Small ubiquitin-like modifier (SUMO) proteins, are responsible for post-
translational modification of lysines, with four major SUMO paralogues, SUMOs 
1-4, expressed in normal eukaryotic cells. SUMOylation of lysines, within 
recognized consensus sequences, facilitates cell cycle regulation, DNA repair, 
and transcriptional processes within cells; dysregulation of this cancer process is 
thought to play a major role in several cancer subtypes. (Cheng, 2007) (Li, 2013) 
In pancreatic cancers, a particular SUMO protease, sentrin-specific protease 1, 
SENP1, is upregulated, and implicated in supporting tumor growth, metastasis, 
and regulating hypoxic response within the tumor. (Ma, 2007) Several derivations 
of SENP1 inhibitors exhibited efficacy in prostate or breast cancer cell lines; 
however, none of these have yet been tested in pancreatic cancer. Knockdown 
of SENP1 decreased proliferation, migration, and tumor colony formation in 
Panc-1 and SW1990. Furthermore, silencing SENP1 was correlated with 
decreased MMP-9 expression, which is well associated in PDAC cell growth and 




given in vitro efficacy in other cell lines, and the correlation of SENP1 in PDAC 
cell growth and invasion.  Thus, a clear opportunity exists for additional studies. 
 
Creatinine transporter SLC6a8 
Increased production of phosphocreatine via creatine kinase-B is observed in 
several tumor subtypes, such as colon and pancreatic cancer, as a means of 
meeting the high energy demand of growing tumors. Importing of 
phosphocreatine by the creatine transporter SLC6a8 allows cells in the 
metastatic niche to harness this phosphate storage to generate ATP; depletion of 
SLC6a8 in colon and pancreatic cancer showed that loss of this energy pathway 
reduced the ability of cancer cells to colonize the liver in murine xenografts. 
(Sullivan, 2015) Kurth et al tested the orally available small molecule RGX-202, 
an inhibitor of SLC6a8, in KRAS wild-type and KRAS mutant cell lines, as well as 
human PDX models. (Kurth, 2018) Tumor cell expression of SLC6a8 correlated 
with dependency of phosphocreatine, and treatment of these cells with RGX-202 
significantly decreased cell proliferation and survival. In vivo murine models 
showed excellent synergy between RGX-202 and gemcitabine in a KPC 
syngeneic mouse model pancreatic cancer. While further studies in PDAC are 
necessary, success of this treatment in colon cell lines, the association of 
SLC6a8 in both colon and PDAC cancers, and synergy between the SLC6a8 
inhibitor and gemcitabine in KPC models suggest small molecule inhibition of this 





Subsection 5.4: Nanoparticles 
 As an alternative to immunotherapies and small molecule inhibitors, 
nanoparticles rely on bulk delivery of cytotoxic agents. Drug delivery typically 
relies on the greater metabolic activity and leakier vasculature of tumors 
compared to normal tissue, termed the enhanced permeability and retention 
effect (EPR). (Brigger, 2002) (Petros, 2010) While the differences in 
biomechanical properties between normal and cancerous tissue can be useful in 
aiding drug delivery, the EPR effect is often exaggerated in many preclinical 
models, where tumor proliferation rates drastically exceed those of human 
tumors. (Brigger, 2002) This higher proliferation rate produces less developed, 
leakier blood vessels, which are not reflective of most human tumor vessels. 
Therefore, modifications to nanoparticle materials to improve tumor specificity, 
such as including tumor specific proteins in the polymeric structure, may be 
necessary. (Petros, 2010) 
Resistance to cancer therapies can be viewed as both molecular and biophysical 
in nature. Molecular resistance is influenced by many factors, including the 
redundancy of pro-oncogenic pathways, modification or alteration of tumor 
specific proteins and receptors, and survival of target negative cells. The failure 
of targeted therapies in pancreatic cancer is reflected by this tumor 
heterogeneity. Biophysical mechanisms of resistance relate to environmental 




(Lammers, 2011) The composition of the tumor extracellular matrix, a dense 
collagen and elastic network, interspersed with glycosaminoglycans and 
proteoglycans, produces a hydrophilic gel, increasing local hydrostatic pressure. 
In pancreatic cancer, the low blood vessel density and thick desmoplastic matrix 
inhibits drug penetrance. (Nie, 2007) (Ding, 2013) To compound these 
challenges in drug delivery, the tumor microenvironment tends to be more acidic, 
contains numerous proteases, and is a nidus of reactive oxygen species, which 
can de-activate the drug, degrade protein therapies, and alter drug kinetics. (Nie, 
2007) Nanoparticle based drug delivery vehicles are designed to overcome the 
above challenges with local accumulation of drug payload. Various nanoparticle 
formulations are investigated, ranging from polymeric, protein, or lipid assembly, 
and used to deliver conventional chemotherapeutics, nucleic acids, or 
immunomodulatory agents. Here I will discuss recent preclinical advances in 
nanoparticles for the treatment of pancreatic cancer. 
 
Polymeric nanoparticles 
Biocompatible polymers, such as poly lactic acid, PLA, and copolymer 
derivatives, such as poly lactic-co-glycolic acid (PLGA) are commonly employed 
in nanoparticle development. For example, Wu et. al. report PLGA nanoparticles 
with an anti-MUC1 antibody, TAB004, for delivery of paclitaxel to PDAC cell 
lines. (Wu, 2018) TAB004 is conjugated to the nanoparticle via amide linkages 




Internalization of the nanoparticle was specific to MUC1 positive cells, with 
MUC1 positive cells exhibiting decreased viability when treated with the 
nanoparticle vs. paclitaxel alone. In vivo imaging studies of isocyanine green 
encapsulated TAB004 conjugated nanoparticles showed localization to target 
tissue in KCM orthotopic tumors, through single IP administration of a 50 mg/kg 
of the nanoparticle, suggesting that this targeted nanoparticle could be useful for 
targeted bulk delivery to tumors. In another study, Verma et al achieved delivery 
of a sonic hedgehog inhibitor, α-mangostin, by encapsulation in PLGA 
nanoparticles. (Verma, 2018) α-Mangostin-encapsulated nanoparticles reduced 
growth in CSC-like cells in vitro as well as prevent EMT by upregulating E-
cadherin and inhibiting N-cadherin and Slug, Nanog, c-Myc, and Oct4. In the 
genetically engineered KPC mouse model, this nanoparticle formulation 
prevented progression of pancreatic intraneoplasia to adenocarcinoma and liver 
metastasis. As with in vitro studies, the in vivo efficacy of this nanoparticle stems 
from inhibition of pluripotency factors, Gli targets, and the Shh pathway, 
preventing crucial steps in tumor progression. A responsive polymeric 
nanoparticle is reported by Herrera et. al for delivery of paclitaxel in a rat model 
of metastatic PDAC. (Herrera, 2016) The expansile nanoparticle swelled in the 
acidic environment of the tumor, while maintaining tight encapsulation of 
paclitaxel prior to reaching the tumor. Rhodamine-labeled nanoparticles 
accumulated in the tumor following intraperitoneal injection. Treatment with the 




paclitaxel; however, substantially fewer side-effects were observed, suggesting 
that nanoparticle delivery under this method may reduce dose-limiting toxicities 
and enable completion of dosing regimens.  
Polymeric nanoparticles can also be used to improve the solubility of 
immunomodulatory or tumor suppressive agents that cannot otherwise be 
delivered intravenously. Curcumin has been studied as a suppressor of 
carcinogenesis in several cancer subtypes: breast, colon, pancreatic, prostate, 
and ovarian. (Arya, 2018) Curcumin acts through several pathways, regulating 
cell cycle arrest through upregulation of p16, p53, and p14ARF, induction of 
apoptosis through Bax, Bad, and Bcl proteins, and modulating NFkB signaling. 
(Arya, 2018) The anti-oxidant properties of curcumin offer numerous health 
benefits in cancer prevention; however, there is also work in the application of 
curcumin in inhibiting cancer growth and metastasis. Administration of curcumin 
inhibited metastasis and angiogenesis in numerous xenograft cancer models, 
particularly in orthotopic xenograft models of PDAC, suggesting that its benefits 
extend beyond cancer prevention. However, delivery of curcumin at sufficient 
levels to observe anti-metastatic effects is hindered by its poor aqueous solubility 
and stability. Thus, encapsulation offers a potentially viable method for delivery. 
Curcumin delivered using PLGA-chitosan nanoparticles showed greater 
internalization and retention than native curcumin in Panc1 and MIA PaCa2 cells, 
with greater in vitro potency, and a significant improvement in reducing tumor 




soluble carrier system could allow curcumin-based therapies to be used in 
cancer treatment protocols; however, in vivo studies need to be undertaken to 
confirm their benefit.  
In order to improve the local delivery and penetrance of nanoparticles, 
which typically rely on EPR and bulk diffusion, modifications to the polymer 
backbone can be made. By changing the specific characteristics of the polymer 
(e.g. charge, hydrophilicity, lipophilicity) or through the addition of aptamers, 
peptides, or even antibodies which improve selective internalization, better 
pharmacokinetic profiles can be achieved. He et al report a sequentially triggered 
nanoparticle composed of an aptamer conjugated to a cell-penetrating peptide-
campothecin prodrug (Apt/CPP-CPTD) and amphiphilic PEG copolymer 
nanoparticle. The nanoparticle utilized a GBI-10 aptamer “camouflage”, relying 
on GBI-10’s negative charge and tenascin-C’s targeting ability to reduce non-
specific uptake of a cell-penetrating peptide nanoparticle. (He, 2018) The 
nanoparticle polymer backbone contains on a reductively cleaved disulfide 
linkage, taking advantage of the greater glutathione concentration within the 
tumor environment, to release camptothecin following internalization of the 
nanoparticle. Release of the modified camptothecin agent occurred only in a 
reductive environment; in vitro cleavage of the nanoparticle was dependent on 
dithiothreitol concentration, with a low reductive environment (10 μM 
dithiothreitol) showing no release, but a high reductive environment (10 mM 




release favored drug delivery after internalization compared to extracellular 
camptothecin loss. Cytotoxicity of the nanoparticle had comparable cytotoxicity in 
MIA PaCa2 cells to free campothecin, and improved penetration as measured by 
spheroid penetrance. Furthermore, this nanoparticle variant demonstrated 
improved in vivo efficacy to free campothecin. First, the modified nanoparticle, 
after intravenous (IV) administration of equivalent 10 mg/kg of the drug, localized 
primarily in the target tissue of a subcutaneous xenograft MIA PaCa2 mouse. 
This suggests that the overall nanoparticle design achieved the desired outcome 
of tumor specific delivery. In mice with subcutaneous tumors, the nanoparticle 
treatment group showed a significant decrease in tumor volumes compared to 
free camptothecin alone, or saline control, demonstrating this nanoparticle 
formulation allows better drug delivery to the tumor tissue. Through modification 
of polymeric nanoparticles, greater tumor selectivity can be achieved, avoiding 
off-target delivery to normal tumor tissues.  
Protein based nanoparticles offer another biocompatible alternative to 
drug delivery, offering alternative functionalization, potentially greater 
biocompatibility, and stability to engineering polymeric nanoparticles. (Jain, 2018) 
This approach was employed in the development of an albumin-based 
nanoparticle carrying paclitaxel, Abraxane®, which is currently used in clinic. 
More recently, a plasmid based bovine serum albumin (BSA) nanoparticle was 
developed which carried hMDA-7, a tumor suppressor gene. This system was 




tumor suppressor gene, in order to arrest further tumor growth. Successful gene 
delivery occurred in Panc1 and BxPC-3 cancer cells, with a marked reduction in 
cell proliferation observed. (Zhu, 2017) hMDA-7 delivery to cancer cells was 
marked by increased apoptosis, associated with elevation of vascular endothelial 
growth factor (VEGF) expression. Treatment of subcutaneous BxPC-3 and Panc-
1 xenografts with the formulation significantly decreases tumor volume relative to 
nanoparticle controls. Similar to polymer-based nanoparticles, albumin derived 
nanoparticles improved delivery of effective, but poorly water-soluble, anti-tumor 
agents. Encapsulation of Parviflorin D, an anti-proliferative agent derived from 
the Plectranthus genus, in an albumin-based nanoparticle significantly improved 
drug delivery by increasing drug solubility in vitro, and demonstrated improved 
potency in BxPc-3 and Panc-1 PDAC cell lines. (Santos-Rebelo, 2018) 
A separate approach was made to improve the specificity of albumin-
based nanoparticles by conjugation with arginine-glycine-aspartic acid (RGD) 
peptide.  Ji et al demonstrated that RGD modified BSA nanoparticles showed 
greater internalization and retention in BxPC-3 cells compared to BSA 
nanoparticles alone, and that these nanoparticles were safe and tolerable in vitro 
and in vivo without cytotoxic payload. (Ji, 2012) The greater specificity of these 
RGD-albumin nanoparticles improved internalization beyond relying on the EPR 
effect. Encapsulation of the nanoparticles with gemcitabine significantly improved 




formulation may improve overall success of BSA derived nanoparticles and an 
advancement over the Abraxane® formulation. 
 Repurposing cell derived exosomes from the pancreatic cancer cell line, 
SOJ, Ristorcelli et al investigated whether these tumor derived nanoparticles 
could repress tumor cell growth. (Ristorcelli, 2008) Protein characterization of 
SOJ-derived nanoparticles revealed a diverse packaging of proteins, including 
glucose-6-phosphate isomerase, Hsp90, and BSDL. Interestingly, treatment of 
SOJ-derived nanoparticles effectively reduced SOJ cell (the host cell) 
proliferation in a dose dependent response, with similar, but variable response in 
other cell lines. Human umbilical vein endothelial cells (HUVECs), selected as a 
normal control, are not affected by the SOJ nanoparticles. Nanoparticle efficacy 
outcomes include a decrease in overall PI3K/Akt/GSK-3β activity, an increase in 
phosphatase and tensin homolog protein (PTEN) dephosphorylation, an 
elevation of Bax, and a decrease of Bcl-2 expression. Bioapplication of cell 
derived exosomes as protein-based nanoparticles is a new and exciting 
bioengineering alternative to polymer-based approaches.  
Nanoparticle formulations offer an alternative to immunoconjugates and 
peptide-based approaches, with greater potential drug delivery at the expense of 
target specificity. Approaches to increase selectively of nanoparticle delivery are 
an ongoing subject of research, and offer the potential to greatly improve the 
success of nanoparticle therapies in clinic. With the success of Abraxane® as an 




research in nanoparticles provides the potential for new clinical options to expand 
treatment regimens in the clinic.  
 
Subsection 5.5: Nucleic Acids Therapies  
Direct genetic modification, rather than the reliance on small molecule 
agents that alter a step in a protein pathway, represents a potentially ideal 
therapy for pancreatic cancer. Known genetic mutations have been discussed, 
and represent key targets for drug developers. For example, the loss of crucial 
tumor suppressive genes can result in acquired drug resistance in cancer cells, 
limiting the efficacy of many therapies. (Nayerossadat, 2012) Gene delivery, 
considered a holy grail in cancer therapy, is advancing in the clinic – although the 
path is arduous with few successes and many of those are in non-cancer 
indications. Successful preclinical studies often fail to show efficacy in clinical 
trials further complicating the translational path. (Touchefeu, 2010) (Liu, 2014) 
Next, I describe several recent nucleic acid treatments in PDAC.  
 Delivery of silencing RNAs (siRNAs) targeting oncogenes offers a 
therapeutic potential to abrogate tumor progression. Direct delivery of siRNAs is 
not feasible, as this extraneous RNA will be rapidly degraded before it reaches 
the tumor tissue. Therefore, a protective carrier is needed, which can allow 
selective delivery of the siRNA to the tumor. Several different approaches to 
siRNA delivery have been taken. Rahman et al proposed the use of 




Inclusion of a nucleolin targeting aptamer improved DNP targeting, and DNP 
delivery successfully reduces tumor volume in DMS53 subcutaneous xenografts. 
(Rahman, 2018) An alternative approach was taken by Strand et al, using a 
peptide-based nanoparticle, to deliver siRNA. This peptide-based nanoparticle 
was successful in delivering Ras inhibiting siRNA was successfully delivered to 
KP1 and KPCC tumors in mice. (Strand, 2017) The siRNA inhibiting KRAS 
managed to successfully decrease KP1 cell line viability. The former approach 
offers a more targeted method of siRNA delivery compared to the peptide 
nanoparticle; with the delivery of siRNA, greater tumor selectivity is necessary to 
ensure therapeutic benefit.  
A different approach was taken in the modified reprograming of 
mesenchymal stroma/stem cells (AD-MSC) to release trimeric and multimeric 
sTRAIL. (Spano, 2019) Rather than relying on delivery of siRNA through a 
nanoparticle carrier, AD-MSC could be induced to produce of sTRAIL via 
lentiviral transduction. These modified AD-MSCs produced stable multimeric, 
soluble sTRAIL structures, capable of inducing apoptosis in BxPC-3, MIA PaCa-
2, and primary PDAC cell lines. These sTRAIL structures produced greater 
toxicity in pancreatic cancer cell lines than rhTrail, and demonstrated improved 
stability. Modified AD-MSCs could be transplanted into tumor bearing BxPC-3 
mice. These AD-MSCs produced sufficient levels of sTRAIL to decrease tumor 
volumes in BxPC-3 subcutaneous models. The benefit of this system is that 




microenvironment; systemic treatment would not be required and ideally locally 
delivery to the tumor would be improved. However, this technique would be 
technically challenging and expensive compared to nanoparticle delivery, and 
may not be amenable for metastatic disease treatment.  
MicroRNA delivery provides an alternative to direct gene modification, 
relying on pan-suppressive effects. Uz et al described a pentablock copolymer of 
poly (ethylene glycol) diacrylate (PEG-DA) and miR-345 coblock polymer, which 
encapsulated gemcitabine. (Uz, 2019) Dual delivery of both miR-345 and 
gemcitabine significantly reduced Capan-1 cell viability in vitro and reduced in 
tumor burden in subcutaneous xenograft models. Ding et al undertook a different 
approach, employing human derived exosomes from human umbilical cord 
mesenchymal stromal cells (HucMSC) to deliver miR-145-5p. (Ding, 2019) 
Exosomes isolated from HucMSCs were loaded with miR-145-5p mimics, 
utilizing the surface proteins of HucMSC exosomes to improve miRNA delivery. 
Derived exosomes were rapidly internalized in human Panc-1 cell lines, 
associated with an increase in apoptosis and cell cycle arrest. Overexpression of 
miR-145-5p significantly reduced tumor volume in a subcutaneous murine 
xenograft model of Panc1. Cell derived exosomes offer better potential 
biocompatibility than polymeric nanoparticles; however, variability and potential 
immunogenicity issues are a concern. The reproducibility of these exosomes 




characterized, and even functional modifications to the polymeric backbone can 
be readily compared to native polymer to better gauge pharmacodynamics.  
 
Aptamer based approaches 
An alternative approach to nucleic acid therapy is the use of aptamers- single 
stranded oligonucleotides for targeted delivery in a means analogous to 
antibodies. (Bruno, 2013) (Kruspe, 2017) The ease of chemical synthesis, 
chemical modification, and high stability makes aptamers a practical alternative 
to antibodies (Zhu, 2015) (Parashar, 2016) (Zhou, 2016) (Arab, 2017) (Poolsup, 
2017); however, limited success in aptamer targeted therapies have has been 
seen in cancer. (Morita, 2018) Park et al reported a novel aptamer-drug 
conjugate (ApDC) utilizing AS1411, which bound selectively to the nucleolin, a 
cellular protein highly expressed in several PDAC subtypes. (Park, 2018) 
Conjugation of AS1411 with gemcitabine produced a stable ApDC, which was 
internalized and retained in Capan-1, MIA PaCa2, and AsPC-1 cancer cell lines, 
but not normal H6c7 cell lines. An AS1411-gemcitabine conjugate showed a 
slight decrease in potency, but greater target specificity than gemcitabine alone, 
and demonstrated excellent reduction in tumor volumes using a subcutaneous 
xenograft model of Capan-1 in mice. An alternative approach was reported by 
Yoon et al utilizing a pancreatic cancer specific aptamer, 2’-Fluoropyrimidine 
RNA aptamers (2’F-RNAs) conjugate designed to deliver a small activating RNA 




Downregulation of C/EBPα occurs from loss of KDM6B, leading to increased 
metastasis in pancreatic cancer. C/EBPα downregulation appears to be an early 
change in tumor progression; previous work in models of hepatocellular 
carcinoma showed promise in restoration of C/EBPα. C/EBPα-based aptamers 
were highly specific to cancer cell lines, demonstrating good internalization and 
retention in Panc1, AsPC-1, MIA PaCa2, and Capan-1 cell lines, and lead to 
restoration of C/EBPα in Panc-1 cell lines, correlated with decrease in cell 
proliferation. Treatment of subcutaneous models of Panc1 with C/EBPα-aptamer 
afforded a modest decrease in tumor size, without significant toxicity, confirming 
target specificity and relevance of C/EBPα in PDAC progression. Expanding on 
this concept, researchers are investigating more potent chemotherapeutics, such 
as auristatins, drugs typically reserved for ADCs, for aptamer drug conjugates. 
Kratscher and Levy described an aptamer-auristatin constructs for targeting 
EGFR. It selectively and effectively targeted pancreatic cancer cell lines, showing 
less potency but greater selectivity in Panc1, MIA PaCa2, and BxPC-3 cell lines 
compared to free drug alone. (Kratschmer, 2018) 
 Identification of more selective aptamers along with target validation is an 
active area of research. Kim et al discovered several aptamers generated by 
Cell-SELEX screening of human pancreatic cancer (HPAC)-derived sphere cells 
to target potential cancer stem cell (CSC)-initiating or CSC-related genes. (Kim, 
2017) Seven of the aptamers exhibited high affinity binding, and were associated 




Excitingly, these aptamers bound to circulating tumor cells derived from patients. 
Further validation of these targets is necessary, but may provide and additional 
method for aptameric drug delivery. Variations of nucleic acid delivery offer 
another method of targeted drug delivery, in the application of aptamer 
conjugates, as well as direct targeting of aberrant oncogenes and repressed 
tumor suppressors.  
 
 
Section Six: Conclusions 
 
Outcomes in PDAC are limited by the dearth of available, successful 
treatment options. Nonspecific early symptoms and late stage aggressiveness 
result in dismal treatment outcomes that significantly lag behind other cancers. 
For those patients amenable to surgery, there is hope for curative intent 
treatment, but this is still limited by available diagnostic and imaging modalities. 
In addition to improving the quality of surgical care, the adaptation of new 
imaging modalities offers the prospect to improve outcomes in the 15-20% of 
surgical candidates. FDA approval of surgical cameras with NIR detection affords 
potential for better detection of tumor margins and more complete surgeries. 
Coupled with new developments in systemic tumor detection, visual contrast 
agents, and combined theranostic materials provide not only the potential for 
better treatment outcomes, but the prospect of better early detection of disease. 
Current treatment modalities in PDAC are dismal; there have been no 




chemotherapy, and conventional chemotherapy causes unacceptable toxicity. 
Current research into 1) novel targets, 2) new drug delivery modality, and 3) 
optimization of current drug delivery platforms offers new potential to circumvent 
known limitations in treatment. Tumor heterogeneity, biophysical limitations in the 
tumor microenvironment, and redundancy of pro-oncogenic pathways complicate 
PDAC treatment; however, the advances and approaches listed here offer new 
avenues in targeting, and hopefully eliminating, escape of cancer cells from drug 
treatment. Several discussed agents offer the potential to augment conventional 
chemotherapeutics, inhibiting pathways that confer resistance. Novel methods of 
drug delivery offer the potential for both safer and targeted delivery of 
conventional chemotherapeutics, hopefully increasing the therapeutic window of 
these agents, or providing targeted delivery to the tumor, eschewing systemic 
toxicity responsible for limiting doses in clinic. In concert with other treatment 
modalities, improved and multimodal targeting will prevent drug evasion and 
tumor progression characteristic of late-stage PDAC. Continuing advancements 
in tumor -omics, as well as development of novel delivery and imaging systems 
will translate to better patient outcomes in the coming decade. With the 
successes in significantly reducing cancer related death in breast, prostate, 
colon, and lung, it is ever more apparent how dismal the outcomes are in PDAC.   
Failures in PDAC therapy and disparities in outcomes relative to other cancers 
outline a unique clinical challenge, one which will require a multidisciplinary 




CHAPTER TWO: Antibody Drug Conjugates in Pancreatic Cancer 
Section One: Antibody Drug Conjugates as a Reemerging Drug Class 
 
 Antibody Drug Conjugates (ADCs) are a multimodal drug class, combining 
the specificity of biologic therapies with the potency of chemotherapeutics to 
provide targeted combination chemotherapy.  ADC development dates back to 
the work of Paul Ehrlich, who in 1913, proposed the concept of a “magic bullet” to 
target cancer, highly specific targeted therapy based on specific recognition of 
tumor cells. (Ehrlich, 1900) (Ehrlich, 1908) Practical application of Dr. Ehrlich’s 
theory began in 1958, with conjugation of methotrexate to anti-leukemia antigen 
1210 antigen via a diazo linkage. (Mathe, 1958) Early ADCs relied on polyclonal 
antibodies, with relatively simple and unreliable linkage strategies. (Ghose, 1967) 
(Ghose, 1972) (Rowland, 1975) These early ADCs provided the foundational 
understanding of future ADC development, that: 1) the specificity of purity of the 
antibody was essential for proper targeting; 2) a stable linkage was essential for 
effective delivery; and 3) chemotherapeutic potency directly correlated with ADC 
success. Unsurprisingly, the variability in polyclonal antibodies, and poorly 
defined chemical conjugate, along with relatively low potent chemotherapeutics 
failed to produce clinical success. (Ford, 1983) (Ford, 1987) 
 First generation ADCs relied primarily on conventional chemotherapeutics, 
as these agents had shown efficacy in treating cancer cells, and were well 
studied. (Ghose, 1978) (Manabe, 1984) (Ford, 1987) Additionally in these first-




significant toxicities via immunogenic response which further limited success 
(Ghose, 1972) (Oon, 1974). Work by Moolten and Sigband in 1970 showed that 
efficacy could be achieved, albeit in vitro, through antibody immunoconjugates 
via the conjugation of diphtheria toxin to anti-mumps antibody. (Moolten, 1970) 
Improvements in ADC development were led primarily by advancements in 
antibody production, first by the development of monoclonal antibodies by Kohler 
and Milstein in 1975, (Kohler, 1975) the development of chimeric antibodies by 
Morrison et al in 1984, (Moorison, 1984) and complete humanization of antibody 
by Jones et. al in 1986. (Jones, 1986) Methods to produce pure, less 
immunogenic antibodies significantly decreased host response to ADC therapy, 
reducing toxicities from direct immune response and from ADC sequestration or 
early degradation prior to payload delivery. Along with the development of better 
antibodies came an improved understanding of the biologic process guiding 
antibody pharmacokinetics and pharmacodynamics. The understanding of 
endocytosis, endosomal/ lysosomal processing, drug recognition by target cells 
began to take shape in the late 70s and early 80s, providing a more complete 
understanding of how ADCs release their payload; these improvements lead to 
significant improvements in ADC development (Gallegeo, 1984) (Blattler, 1985) 
(Billman, 1988), and the first FDA approved ADC, Muromonab-CD3, used as an 
immunosuppressive in renal transplant patients. (OMTSG, 1985)  
Development of improved targeted ADCs coincided with the discovery of 




ozogamicin, targeting CD33, was FDA approved in 2000 (withdrawn in 2010 and 
reintroduced in 2017) to treat relapsed acute myeloid leukemia. (Bross, 2001) Its 
target, CD33, was discovered about 20 years earlier. (Andrews, 1983) 
Brentuximab vedotin, FDA approved in 2011 for relapsed or refractory Hodgkin’s 
lymphoma (Younes, 2012) and relapsed or refractory systemic anaplastic large 
cell lymphoma (Pro, 2012), targets CD30 (first identified as Ki-1 by Stein and 
Lennert in 1985). (Stein, 1985) Trastuzumab emtansine, the only ADC approved 
for a solid tumor, received approval in 2013 for HER-2 positive breast cancer in 
patients having failed prior trastuzumab treatment, (Amiri-Kordestani, 2014) with 
HER-2 first identified as an oncogene in 1984. (Schechter, 1984) Finally, 
inotuzumab ozogamicin, an ADC targeting CD22, first identified by Dörken et. al 
in 1986, (Dörken, 1986) was FDA approved for the treatment of relapsed or 
refractory B-cell precursor acute lymphoblastic leukemia in 2017. (Lamb, 2017) 
The field of ADC development is rapidly expanding and coincides with the 
successful FDA approval of four ADCs. Currently, there are more than 60 ADCs 
in clinical trials, and hundreds in preclinical development. (Beck, 2017) 
Significant focus is being paid to each of the core ADC components including 
the: 1) tumor target; 2) core antibody; 3) drug payload; 4) linker composition; and, 
5) conjugation method. Improvements in tumor-omics are affording a plethora of 
potential targets, with ADC development mirroring advances in biologic therapy. 
(Beck, 2017) (Drake, 2017) As better targets are identified, the need for more 




becomes more evident. Here, I describe current chemical conjugation methods 
and drug linkages, followed by new developments as we enter the stage of fourth 
generation ADCs, and finally focus on ADC development in PDAC, as a means 
of providing more effective drug delivery.  
 
Section Two: Methods of Drug Linkage 
 Effective delivery of the ADC payload to the desired target requires a 
stable linkage that is resistant to plasma proteases, eludes reactions with 
circulating proteins, such as retro-Michael addition to albumin, avoids hydrolysis, 
and allows specific release in the target cell. The method for conjugation must 
also not disrupt antibody binding and stability, nor produce aggregation, acting as 
functionally specific as possible to allow drug delivery. Lower drug loading, as 
ADC drug loading is optimal in the range of 2-4 drugs per antibody (Hamblett, 
2004) (Lyon, 2015), compared to other delivery vectors, such as nanoparticles, 
necessitates the use of more potent agents than employed in conventional 
therapy. While new agents are being discovered, the range of effective payloads 









Table IV. Employed Drug Payloads in ADC Development 
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 Chemical conjugation of the above toxic payloads requires a highly stable 
linkage to minimize early release, off-target effect, and undesired toxicity. To 
accomplish this goal, both cleavable, the introduction of sensitive motifs, and 
non-cleavable linkages are being employed. Employed cleavable linkers include 
disulfide, hydrazone, dipeptide, and β-glucuronide linkers. Noncleavable linkers 
possess short chemical spacers between the drug and antibody, typically 
bifunctional maleimide or succinimide linkers, relying on degradation of the ADC 
to release the payload. Cleavable linkers, as the most commonly employed in 
new generation ADCs, are discussed first, followed by a brief review of the 




Disulfide/ Reducible Linkage 
 Disulfide or reducible linkages rely on the difference in reductive 
environment between plasma and the extracellular space, and cytosolic 
conditions within tumor cells. Higher cytoplasmic concentration free thiols, such 
as reduced glutathione (GSH), which can undergo thiol-thiol exchange (Mills, 
1996) (Wu, 2004), and enzymes, such as disulfide isomerase (Russo, 1986), 
which catalyze thiol-thiol exchange and reduce disulfide linkages. The greater 
intracellular reducing environment favors cleavage of these linkers following 
internalization; design of these linker structure takes advantage of disulfide 
linkages that are sterically hindered, requiring higher free thiol concentrations to 
release drug payloads. Disulfide linkages are not inert in circulation; extracellular 
protein disulfide isomerases (Fang, 2016), GSH, and cysteine (Mills, 1996) can 
reduce disulfide linkages. Increased steric hindrance of the disulfide residue can 
be employed to reduce the rate of cleavage. (Thorpe, 1987) (Thorpe 1988) While 
this improves plasma stability, increasingly bulky aliphatic groups slow the rate of 
intracellular reduction, increasing circulation of the ADC and reducing drug 
efficacy. (Erickson, 2010) Proper design of disulfide linkers requires a balance 
between these opposing forces, so as not to mitigate the efficacy of the ADC. 
Disulfide linkers are used in diverse ADCs application, including an anti-CanAg 
ADC, C242-DM1 (Erickson, 2008), an anti-C19 antibody, SAR3419 





Acid Cleavable Linkage 
 Acid labile linkages, the first employed ADC linkers, relied on the 
difference in pH between the endosomal-lysosomal system (pH 4.5-6.5) and 
plasma (pH 7.3-7.5) (Van der Velden, 2001) to release their payload. Diverse 
linker compositions are known; however, the most commonly employed is the 
hydrazone linkage, a functional group with the structure R1R2C=NNH2. Hydrolysis 
of hydrazones depends on the functionality of the non-carbonyl nitrogen, with 
greater negative induction further stabilizing the species and slowing hydrolysis. 
(Kalia, 2008) Hydrazone linkers were commonly employed in early ADCs; 
however, the plasma instability of the linker, as a result of imine protonation and 
subsequent hydrolysis, decreased their in vivo efficacy. (Braslawksy, 1990) 
(Greenfield, 1990) (Trail, 1992) This susceptibility of hydrazone linkers to 
hydrolysis is responsible for their clinical failure in the treatment of solid tumors 
(Senter, 2009) however, successful employment has been seen in two ADCs, 
gemtuzumab ozogamicin and inotuzumab ozogamicin, for the treatment of 
leukemia. While successful because these ADCs still reach the target cancer 
cells, significant off-target toxicity is still observed for both drugs. Premature 
hydrolysis of the linker in circulation is a major issue, potentially limiting maximal 
efficacy of these ADCs. (Bross, 2001) (Younes, 2007) (Pro, 2012) Even with 
observable plasma release, both drugs received FDA approval, suggesting that 




development is examining similar targets with more stable linkers, which could 
minimize the off-target toxicity observed by these ADCs. (Lamb, 2017)  
 
Peptide and β-Glucuronide Cleavable Linkers 
 An alternative to reducible or acid-labile linkers, peptide cleavable linkers 
rely on sequence specific recognition of the linker by cellular or lysosomal 
enzymes. Synthetic peptide linkers exhibit improved plasma stability over 
reducible or acid-labile linkers, as they are less prone to reduction or hydrolysis. 
The stability of the linkage depends therefore on the presence of plasma 
enzymes that recognize the linker sequence. (Koblinski, 2000) (Ciechanover, 
2005) (Sanderson, 2005) Adaptation of peptide linkers has been simplified from 
longer peptide sequences towards dipeptide sequences, such as valine-citrulline 
or phenylalanine-lysine, which provide improved plasma stability compared to 
previously mentioned linker subtypes, but possess more rapid lysosomal 
hydrolysis compared to larger sequences. (Trouet, 1982) (Kroger, 1992) 
(Kirsche, 1995) (Otto, 1997) Direct conjugation of the drug to the dipeptide 
linkage results in charged intermediates following lysosomal cleavage; 
depending on the enzyme sequence, various parts of the linker will remain 
covalently linked to the drug, producing intermediates of various potency. 
(Francisco, 2003) (Doronina, 2008) To circumvent this issue, “self-immolative” 
spacers, groups which undergo elimination reactions following enzymatic 




benefits: elimination of intermediates and production of free drug, which can 
improve ADC efficacy via bystander killing (the elimination of receptor negative 
cells via short diffusion of the drug payload). (Dubowchik, 1998) (Toki, 2002) The 
most commonly employed spacer, a para-amino-benzyl carbonyl group, 
undergoes a specific 1,6 elimination following enzymatic cleavage, and is 
employed in the FDA approved drug, brentuximab vedotin. Similar variations of 
dipeptide linkers are employed in renal, breast, and prostate cancer, as well as 
lymphoma. (Naumovski, 2010) (Thompson, 2011) (Keir, 2012) Today, peptide 
cleavable linkers provide the best combination of plasma stability and tunable 
release in tumor cells. 
 An alternative approach to peptide linkage, relying on application of 
biomimetic bonds, β-glucuronide linkers utilize glycoside linkages that are 
susceptible to lysosomal degradation. The high lysosomal specificity of β-
glucuronidase provides an alternative to traditional dipeptide approaches 
(Dubowchik, 1999) (Jeffery, 2006) (Ma, 2007), showing similar stability to 
dipeptide linkers. (Albin, 1993) (Jeffrey, 2007) Currently, no FDA approved ADCs 
employ this method of conjugation; however, there are several ADCs currently in 









 Eschewing a specific recognition sequence, noncleavable linkers rely on 
complete degradation of the ADC within the lysosome to release the cytotoxic 
payload. Typically, noncleavable linkers employ short, simple bifunctional linkers, 
producing thioester bonds, via reaction of cysteine thiols with maleimides, or 
amide bonds, via interaction of lysine amines with activated esters. The inherent 
advantage of noncleavable linkers is the greater plasma stability, as chemical 
linkages exhibit greater resistant to hydrolysis and reduction compared to those 
previously mentioned. (Nolting, 2013) Furthermore, intermediates of the cleaved 
payload tend to be more hydrophilic than other linkers, reducing off-target 
toxicity. (Erickson, 2006) (Lewis Phillips, 2008) The greater plasma stability, as 
well as reduced off-target effect significantly improves ADC safety when highly 
expressed tumor targets are employed. (Lewis Phillips, 2008) However, because 
charged intermediates are produced from cleavage, these ADCs cannot rely on 
bystander killing, limiting application in heterogenous tumor types, and depend 
on drug linkers that produce active intermediates. (Erickson, 2006) (Lewis 
Phillips, 2008) The production of less potent drug intermediates can significantly 
reduce ADC efficacy, and limits applicability of this linker type. (Erickson, 2006) 
Successful application of a noncleavable linker is employed in the succinimidyl-4-
(N-maleimidomethyl) cyclohexane linkage of emtansine trastuzumab, and 
additional noncleavable linkers have been employed in ADCs targeting 




 Current development of ADCs significantly favors use of dipeptide linkers 
with self-immolative spacers. Following the success of emtansine trastuzumab 
and greater application of ADCs toward solid tumors, dipeptide linkers provided 
the best combination of high plasma stability and tunable targeted release. With 
stability approaching noncleavable linkage in vivo and the ability to capitalize on 
bystander killing, it is not surprising that most ADCs in clinical trials and in 
preclinical development utilize this linkage. (Lambert, 2017) Direct improvement 
on chemical linkage depends on the method of conjugation; in the next section 
the recent advances in biochemical conjugation are discussed.  
 
 
Section Three: Methods of Chemical Conjugation 
Conjugation methods employed in early generation ADCs relied on non-
specific coupling to lysine or cysteine residues. These amino acids are readily 
coupled with activated esters, producing amide bonds, or maleimides, producing 
thioesters, providing simple, reproducible chemical coupling. In exchange for 
simplicity, these conjugation methods suffer from labeling heterogeneity, 
(Stephan, 2011) decreased antibody stability in disulfide reduction, (Junutula, 
2008) increased off-target effect through conjugation in the antigen binding 
region, (Zhou, 2017) and decreased stability of linkers compared to specific 
conjugation. (Wakankar, 2010) Limitations in non-specific conjugation explain the 
failure of numerous ADCs in clinical trials (Stephan, 2011) (Wakankar, 2010), as 




both related to the drug and emergent toxicities from nonspecific binding. 
(Wakankar, 2010) Adaptation of more specific conjugation methods to FDA 
approved ADCs in the clinical setting significantly improves linker stability. 
(Wakankar, 2010) The dramatic improvements in therapeutic window from non-
specific to specific conjugation underscore a major challenge in ADC 
development, which has the potential to revolutionize the field. Current 
advancements in ADC conjugation are summarized below, detailing successes 
and limitations of each method. 
 
Modified Cysteine Residues 
 To avoid the destabilizing effect of non-specific reduction, specific, 
engineered cysteine residues have been introduced into monoclonal antibodies. 
The first site-specific conjugation, THIOMABs, introduce specific sequences into 
the heavy or light chains. Generated THIOMABs require partial reduction, an 
unfavorable condition that does impact stability, but produced ADCs that with 
more uniform conjugation of moles of drug to moles of antibody (antibody drug 
ratio or ADR) than native cysteine conjugation. (Beck, 2013) (Patterson, 2014) 
(Kline, 2015) Despite have fewer moles drug per moles of ADC than native 
cysteine conjugation (2 vs 3), these THIOMABs showed equivalent efficacy at 
the same antibody dose, and improved therapeutic range in rats and cynomolgus 
monkeys, suggesting that controlled conjugation was more important than drug 




While modified cysteine ADCs were a significant improvement over non-
specific variants, the engineered residues were more accessible to competing 
thiols, resulting in a higher rate of retro-Michael addition of thioester linkages. 
(Shen, 2012) To minimize retro-Michael addition, thiol bridge methods were 
employed, which covalently links a single linker to two reduced cysteines. 
Modification via thiol bridge conjugation produced ADCs with an ADR around 4, 
improving ADC stability and efficacy compared to nonspecific conjugation. 
(Behrens, 2015) (Bryant, 2015) While this conjugation afforded significant stability 
over native cysteine conjugation, the need to reduce disulfide bridges in the 
antibody significantly impacts circulation stability, and limits the potential clinical 
application of this technique.  
An alternative to this approach was the development of more reactive 
cysteine residues within the antibody. A modified phenylalanine-cysteine-proline-
phenylalanine sequence was introduced into the trastuzumab heavy chain, which 
demonstrated high selectivity to perfluoroaromatic linkers. To test whether 
modification of trastuzumab affected antibody selectivity, the cytotoxicity of this 
engineered ADC, carrying the auristatin MMAE, was compared in the HER2 
positive cell line BT474, and the HER2 negative cell line CHO. The engineered 
ADC was effective in killing HER2 positive BT474 cells, while being nontoxic to 
CHO cells. This method produced a stable linkage that: 1) did not require 
extensive reduction and oxidation; 2) was site specific; and, 3) produced 




The use of more specific cysteine linkers was applied in the development of 
carbonylacrylic linkers, which produced thioether linkages instead, avoiding 
Retro-Michael addition, and proving more selective for light chain modification. 
(Bernardim, 2016) 
Despite improvements in cysteine conjugation, there continue to be 
significant challenges with antibody stability and uniform loading of ADCs 
prepared by this method. Reduction of the disulfide bridges destabilizes the 
antibody structure, and can have negative impacts on the binding specificity of 
the resultant ADC. (McAuley, 2008) (Liu, 2010) Several ADCs using modified 
cysteine residues are currently under investigation in clinical trials; based on 
preclinical success, it is possible that modified cysteine ADCs will show 
significant improvement compared to other conjugation methods. (Herrera, 2017) 
However, even with the best method, complete conversion of the antibody to a 
fully functionalized ADC is not possible, and specific site modification is difficult. 
Additionally, the use of chemical solvents can impact the overall stability of the 
native antibody, increasing toxicity.  
 
Modified Lysine and Serine 
Incorporation of other modifiable amino acid sequences can improve the 
reactivity of specific amino acids, allowing selective linker conjugation. To provide 
specific lysine conjugation, a modified ADC dual-variable-domain of trastuzumab 




conjugation. (Nanna, 2017) The higher nucleophilic character of this pocket 
allows selective conjugation to 1,3-diketone and β-lactams, and has been used 
previously for site specific conjugation. (Rader, 2014) Utilizing a β-lactam-MMAF 
linker, a site-specific ADC was generated with ADR approximately equal to 2, 
with significant improvement in in vivo efficacy compared to emtansine 
trastuzumab. An alternative approach to amino acid specific conjugation, the 
introduction of an N-terminal serine residue, was used to produce an ADC of 
anti-EphA2 with MMAE using oxime coupling. (Thompson, 2015) Oxidation of the 
N-terminal serine followed by oxime formation produced a site-specific linkage. 
Both conjugation methods offer an alternative to cysteine specific conjugation, 
with the caveat that conjugation occurs close to the antigen binding region. Close 
proximity to the antigen binding region and the dependence on long chemical 
reaction times may have a deleterious effect on overall stability, though more 
research in necessary to elucidate if this particular method of conjugation 
adversely affects antibody binding. Furthermore, while better than non-specific 
lysine conjugation alone, the introduction of the h38C2 pocket requires significant 
modification of the antibody, limiting the feasibility of large-scale production. It 
may also deleteriously affect the immunogenicity of the antibody, and may affect 
the antibody production. N-terminal serine modification requires less changes to 






Unnatural amino acids 
To circumvent the problems of lysine or cysteine conjugation, the 
incorporation of unnatural amino acids into antibodies via specifically engineered 
tRNA/ aminoacyl-tRNA synthetases can be employed. Unnatural amino acids 
afford novel biorthogonal reactions that are site selective to the engineered 
sequence. Initial application of unnatural amino acid incorporation relied on 
expression of specific tRNA/ aminoacyl-tRNA synthetase pairs in E. coli. (Liu, 
2010) Two-step selection of E. coli was readily applied to allow the generation of 
modified antibodies. (Liu, 2010) Initial ADCs using this method relied on the 
expression of p-acetylphenylalanine amino acids to produce trastuzumab-
auristatin conjugates using oxime conjugation. (Wang, 2003) (Axup, 2012) Oxime 
conjugation is slow, similar to the methods employed in serine conjugation, but 
under controlled conjugation, the yield was stoichiometrically favorable. 
(Zimmerman, 2014) Using a cell-free approach, which uses clarified E. Coli 
lysate for expression of unnatural amino acids, a trastuzumab auristatin 
conjugate was prepared via azide-alkyne click chemistry. (Zimmerman, 2014) 
This ADC derivative used para-azidomethyl-I-phenylalanine to produce a stable 
linkage, with a significant improvement in efficacy compared to emtansine 
trastuzumab in in vitro assays. Furthermore, a significant improvement in in vivo 
efficacy was seen, with greater reduction of subcutaneous xenografts in the 




The use of E. coli antibody production or derivates was non-ideal for large 
scale production, as the glycosylation is significantly different than mammalian 
cells traditionally used for large scale antibody production. (Liu, 2010) 
Incorporation of unnatural amino acids into eukaryotic cells requires evolution in 
prokaryotic cells, followed by shuttling to eukaryotic cells. (Liu, 2010) Modified 
ADCs in CHO and human embryonic kidney (HEK) cells have been produced, 
which provide site-selective conjugation under more optimal glycosylation than E. 
coli produced antibodies. (Axup, 2012) (Boswell, 2011) However, production of 
modified antibodies in eukaryotic cells is significantly less than under normal 
conditions, posing a challenge for upscaling. (Xiao, 2013) Despite limitations, the 
use of unnatural amino acids for conjugation provides the most versatile 
approach for ADC development. The diversity of potential amino acids allows 
greater functionality in chemical linker synthesis, and allows the introduction of 
different conjugation methods. 
The incorporation of selenocysteine offers a compromise in the adaptation 
of unnatural amino acids. Selenocysteine is a naturally occurring amino acid in 
eukaryotes, but requires Sec insertion machinery and a Sec insertion sequence 
element. (Hatfield, 2002) Methods have been developed for selenocysteine 
modification of the C-terminus of antibodies, allowing for specific diseleno 
conjugation between selenocysteines (Li, 2015) or iodoacetamine conjugation. 
(Guimaraes, 2013) These ADCs function similarly to THIOMABs abs, but provide 




Unnatural amino acids offer a versatile approach, with over 40 potential 
amino acids allowing a variety of different drug linker approaches. (Liu, 2010) 
However, limitations in upscaling, combined with the need for organic solvents, 
long, or incomplete reactions produce variability in drug loading and have the 
potential to negatively impact the antibody. Furthermore, expression in a 
eukaryotic cell is challenging, requiring specific optimization and expertise 
beyond more traditional approaches. Despite this, the sheer volume of 
biorthogonal reactions offers more potential in this approach.  
 
Enzymatic Conjugation 
 A number of enzymatic approaches have recently been employed for site 
specific conjugation, repurposing naturally occurring enzymes to modify specific 
peptide sequences. The Staphylococcus aureus transpeptidase, Sortase A, has 
been employed in a number of peptide modification applications. (Mazmanian, 
2001) (Guimares, 2013) (Witte, 2013) The native enzyme recognizes the LPXTG 
motif on the host peptide, and ligates a recognized N-terminal polyglycine 
sequence to the C-terminus. (Mazmanian, 2001) (Popp, 2011) Applications in 
ADCs produce site-specific conjugation, with better cytotoxicity and stability than 
nonspecific conjugation (Beerli, 2015), however, the conjugation rate to heavy 
chain vs light chain is highly species dependent. (Beerli, 2015) (Chen, 2016) 
Native Sortase A has a low conversion rate with around 26% conversion in the 




mutants have been identified with higher conversion efficiency and improved 
reaction rates, as well as better specificity, which can improve the yield of 
conversion. 
 The enzyme formylglycine-generating enzyme is used to selectively 
modify cysteine to formylglycine. Formylglycine-generating enzyme recognizes 
the sequence CXPXR, and converts the included cysteine residue into 
formylglycine. (Carrico, 2007) Formylglycine has an N-terminal aldehyde, which 
forms a stable azacarboline for drug delivery. ADCs generated by this method 
minimally impact antigen binding, and demonstrate effective inhibition of 
subcutaneous tumor growth. (Wu, 2009) (Rabuka, 2012) 
 Conjugation to glutamine can be achieved through transglutaminase. The 
specificity of transglutaminases depends on their cell of origin, with different 
recognition sites and affinity per species. (Jeger, 2010) (Albers, 2014) (Drake, 
2014) Bacterial transglutaminase showed different selectivity to glycosylated and 
non-glycosylated antibodies, which impact drug loading. (Josten, 2000) (Mindt, 
2008) Isoform specificity of IgG conjugation was observed, which significantly 
impacted ADR, limiting applicability of this technique. (Josten, 2000) (Mindt, 
2008) Application of microbial transglutaminase showed more tunable results, 
with specific affinity for the Gln295 residue of the aglycosylated heavy chain of 
IgG1. (Strop, 2013) Conjugation via azide-alkyne cycloaddition produced near 
uniform drug loading with an ADR of 2, while more variable loading in thioester 




 Variations in isoform recognition, as well as the need for deglycosylated of 
the antibody, limit the applicability of this technique. Under certain conditions, 
uniform drug loading can be achieved, but there is a significant limitation in the 
linkers that are employed, and the antibody’s immunogenicity is compromised for 
this technique to work.  In this final section, the development of ADCs for PDAC 
will be discussed, with an integration of the above concepts. 
 
Section Four: ADCs in PDAC 
 As mentioned at the start of this work, pancreatic cancer is a major health 
concern, which has numerous clinical challenges.  ADCs provide both targeted 
and combination chemotherapy; the promise of more effective specific therapy 
has led to the development of hundreds of potential candidates for cancer 
treatment. (Drake, 2017) Several ADCs are currently under investigation in 
Phase I or Phase II clinical trials, and will be discussed first, followed by those 


















Table V. Summary of ADCs in PDAC  
 




MMAE Dipeptide Phase II 
Anetumab 
Ravtansine 
Mesothelin Mertansine Disulfide Phase II 
DMUC5754A MUC16 MMAE Dipeptide Phase II 
ABFN-107 TAA AG7 Unknown Unknown Phase I 
BA3011 AXL MMAE Dipeptide Phase I/II 
EGFR-MMAE EGFR MMAE Dipeptide Preclinical 
SAS1B-Duo SAS1B Duocarmycin Acid Labile Preclinical 
TEM8-MMAE TEM8 MMAE Dipeptide Preclinical 
RON-MMAE RON MMAE Dipeptide Preclinical 
 
 An anti-guanyl cyclase C (GCC) ADC utilizing the dipeptide-PABC-MMAE 
linker is currently under investigation for the treatment of advanced GI cancers, 
including pancreatic cancer. GCC is a cell surface receptor that regulates 
intestinal transport, but is upregulated in several GI malignancies. (John, 1998) 
GCC is expressed in roughly 50% of pancreatic tumors, with minimal expression 
on most normal tissue. Intestinal cells do express GCC; however, expression is 
significantly lower than in cancer cell lines. (Kloeters, 2008) The anti-GCC ADC 
demonstrates selectivity for only receptor positive cells, and affords, upon IV 
administration, a significant reduction in subcutaneous tumor models. 
(Almhanna, 2016) The dipeptide linker, identical to the linker employed in 
brentuximab vedotin, allows bystander killing of receptor negative cells, 
improving ADC efficacy despite variability in GCC tumor expression. (Almhanna, 
2016) Initial Phase I trials were successful for safety endpoints, and Phase II 




 An anti-mesothelin ADC is currently under investigation in Phase II trials 
for metastatic PDAC. Mesothelin is a glycoprotein with putative regulation of cell 
proliferation, migration, and adhesion in several tumor subtypes. (Hassan, 2004) 
(Hassan, 2008) Mesothelin is highly expressed in several GI adenocarcinomas, 
including pancreatic cancer, but typically has low expression in normal pancreatic 
epithelium. (Bharadwaj, 2011) Combination therapy of an anti-mesothelin agent 
with taxanes exhibits some benefit (Orth, 2012), and the ADC anetumab 
ravtansine, shows potential promise in solid tumors. This ADC uses a disulfide 
linkage to delivery mertasine to cancer cells, demonstrating preclinical success. 
(Gallery, 2018) A Phase I study was completed of the final drug formulation, 
MLN0264, which met preliminary safety goals to progress to Phase II trials. 
(Golfier, 2014)  
 A MUC16 targeting ADC also employs the dipeptide-PABC-MMAE linker 
for treating unresectable PDAC. MUC16 is a cell surface glycoprotein, which acts 
as a lubricating barrier on epithelial surfaces. (Haglund, 1986) MUC16 is 
upregulated in moderately to well-differentiation PDAC tumors, and has been 
shown to be an effective target of certain pancreatic tumors. (Macdonald, 1988) 
(Chen, 2013) The anti-MUC16 ADC, DMUC575A, demonstrates preclinical 
success in inhibiting PDAC cell lines in vitro and in in vivo subcutaneous models, 
and has met safety goals for Phase I study in platinum resistant ovarian cancer 




 Two recently developed ADCs are currently being investigated in clinical 
trials, AbGenomics’ AbGn107 and BioAtla’s BA3011. AbGn-107 targets tumor 
antigen, which expresses on approximately 50% of cancer cells. The exact 
mechanism of release and payload is proprietary, but does appear to be 
dependent on linker cleavage and release of free drug. (AbGenomics, 2019) 
BA3011 targets the AXL receptor, a tyrosine kinase which regulates cell 
proliferation and survival. (Neubauer, 1997) AXL is overexpressed in several 
PDAC tumors, with AXL signaling implicated in PDAC proliferation, invasion, and 
metastasis; loss of AXL signaling induces apoptosis and significantly affects 
PDAC metastatic potential. (Ludwig & Brekken, 2015) BA3011 employs the 
dipeptide-PABC-MMAE linker system, with a modification to the antibody that 
minimizes binding to normal tissue. (Sharp, 2018) BA3011 is currently under 
investigation in Phase 1/2 trials for several advanced solid tumors, including 
PDAC, following successful preclinical inhibition of GI malignancies. (Rodon 
Ahnert, 2018) (Sharp, 2018)  
Several ADCs are currently in preclinical development for the treatment of 
metastatic PDAC, and will be discussed below. An EGFR targeting humanized 
ADC was prepared via non-specific thiol conjugation with a maleimide capped 
valine-citrulline-PABC-MMAE spacer, identical to brentuximab vedotin, and a 
disulfide rebridging pyridazinedione capped valine-citrulline-PABC-MMAE 
spacer. (Li, 2019) This ADC exhibits relative specificity for PDAC cancer cells; 




observed in EGFR overexpressing Panc1 cell lines. Overall, both ADCs show 
minimal impact on antibody binding and stability, although stability was only 
assessed for seven days, which may not completely account for changes from 
reduction of cysteines to allow conjugation. Both ADCs significantly inhibit growth 
of subcutaneous BxPC-3 tumors in a mouse model; however, the 
pyridazinedione capped linker exhibits better overall stability.  
An ADC targeting the cancer oocyte antigen ASTL/SAS1B, carrying 
duocarmycin, prepared with an acid-labile, non-specific linker, demonstrated 
excellent specificity for pancreatic cancer cells. Despite ASTL/SAS1B being 
designed a cancer oocyte antigen, ASTL/SAS1B is highly expressed on 
pancreatic tumors. The majority of normal pancreatic ductal cells are SAS1B 
negative, while 68% of pancreatic cancers express the tumor antigen. (Walters, 
2013) In vitro efficacy was observed in several cancer cell lines, correlating to the 
surface expression of the SAS1B receptor, and correlates with 
immunohistochemistry (IHC) and microscopy data on SAS1B expression. 
(Knapp, 2018) The specificity of SAS1B offers another potential avenue for ADC 
development. 
Another novel target, tumor endothelial marker 8 (TEM8), is employed in a 
dipeptide-PABC-MMAE ADC. TEM8 is a transmembrane glycoprotein expressed 
on the surface of endothelial cells, that helps regulate cellular adhesion and 
cytoskeleton organization. (St Croix, 2000) (Yang, 2011) (Chaudhary, 2012) 




components, and was selected as a target to decrease tumor supportive cells. 
(Szot, 2018) Treatment with TEM8-based ADC significantly decreased tumor 
volume in subcutaneous PDAC model compared to the antibody or drug alone, 
and significantly improved survival in orthotopic models compared to vehicle 
control. (Wang, 2006) This success of this ADC highlights other potential routes 
to treating PDAC besides direct tumor killing, with excellent regression and 
survival outcomes seen by targeting of supporting vasculature and 
microenvironment. 
Finally, an anti-RON ADC, employing the dipeptide-PABC-MMAE linker 
and the SMCC-DM1 linker has been tested in pancreatic cancer cell lines. The 
RON receptor is a tyrosine kinase receptor related to c-MET, implicated in 
invasion and cell migration. (Yao, 2018) Two variations of an anti-RON ADC 
were prepared, mimicking brentuximab vedotin and ado-trastuzumab emtansine. 
The dipeptide-PABC-MMAE linker showed significant improvement versus the 
noncleavable linker, consistent with previous data, and demonstrates efficacy in 
BxPc-3, FG, and L3.6pI, but not Panc1 cells. (Hanahan, 2011) In a subcutaneous 
model of BxPC-3, a significant reduction in tumor volume is observed, suggesting 
this therapy could be effective in certain PDAC subtypes. 
 
Section Five: Conclusions and Future Directions 
 The application, and early success of ADCs in PDAC treatment is 
promising in a disease where survival outcomes are dismal. With five ADCs 




process of application, the potential for more effective, targeted therapy seems a 
realistic goal. Furthermore, several labs are actively pursuing ADC development 
in PDAC, with the majority employing novel receptors that can work in 
conjugation with established treatments.  
A major limitation in current PDAC ADC development is the reliance on 
rather antiquated conjugation methods, with the majority employing the same 
linker/ conjugation method employed by brentuximab vedotin. Newer methods of 
site-specific conjugation have consistently demonstrated that controlled, specific 
conjugation in the C-terminus of the antibody produces more effective, safer, and 
more stable ADCs than non-specific conjugation. (Strop, 2013) The disconnect 
between newer conjugation advances and current production of PDAC ADCs 
highlights the need for better integration of biochemical and chemical conjugation 
with novel antibody targets. Clinical failures have been correlated with 
inadequate methods of conjugation (vide supra), spawning separate 
development of improved conjugation methods. 
The development of more effective therapies in solid tumors, particularly 
PDAC, necessitates a merging between novel targets, identified here in several 
ADCs in both clinical and preclinical development, and new methods of 
conjugation, particularly the incorporation of unnatural amino acids, or methods 
of enzymatic ligation, which have shown superior drug loading and minimal 
effects on antibody stability. As more research is focused on new treatment 



























CHAPTER THREE: DEspR As a Target for PDAC 
Section One: Metastatic PDAC as an Unmet Need 
Metastasis, the spread of cancer cells into adjacent stroma and 
parenchyma, then distal tissues, is the cancer hallmark unique to malignant 
tumors. (Hanahan & Weinberg, 2011) An almost inevitable outcome of invasive 
cancers (Hanahan & Weinberg, 2011), metastasis underlies greater than 90% of 
all cancer deaths regardless of tissue type. (Wirtz, 2011) Despite major gains in 
high-throughput genetic and -omics tumor analyses, advancements in targeted 
biologic therapy, and advances in drug delivery, curative intent therapy eludes 
most metastatic cancers. (Riggi, 2018) Pancreatic cancer exemplifies the 
challenge and human burden of metastatic cancer: with a 45:55 ratio of deaths to 
cases per year, and rising incidence, PDAC has the worst prognosis of any 
common tumor (Ryan, 2014) (SEER, 2017) (Wu, 2018) Pancreatic cancer is 
complicated by late disease diagnosis, high desmoplastic response, low 
intratumoral vasculature, and rapid resistance to conventional 
chemotherapeutics. (Oberstein, 2013) Metastasis to vital organs, particularly the 
brain, lung, and liver, complicate treatment outcomes, and underly a significant 
challenge in managing drug delivery in a rapidly progressing, multifocal disease. 
(Ryan, 2014) (Oberstein, 2013) 
 A subset of metastatic gastrointestinal disease, and PDAC in particular, 
peritoneal carcinoma, represents a unique treatment challenge. Patients who 




stages of metastatic seeding, carry a worse prognosis than patients with cell-
negative fluid. (Juhl, 1994) These patients do not see a significant survival benefit 
from removal of their primary tumor and post-operative chemotherapy, having 
worse overall survival than negative cytology fluid (OS; HR 3.18, P = 0.0001) 
(Cao, 2017), and equivalent survival to stage IV patients. (Ferrone, 2006) 
Pancreatic peritoneal metastases carry a worse prognosis than liver, lung or 
brain metastases; this higher mortality is a result of greater metastatic potential of 
peritoneal metastases compared to hematogenous metastases. (Morizane, 
2011) Peritoneal metastases show a unique complication to other peritoneal 
metastases in that they do not benefit from surgical debulking unlike colorectal 
and ovarian peritoneal metastases. (Thomassen, 2013) Hence, PDAC peritoneal 
metastasis represents a unique clinical model beyond the management of tumor 
volume and number: treatment must address both a permissive tumor 
microenvironment, and the rapid feed forward dissemination leading to a more 
rapid progression than hematogenous seeding.  
Analysis of clinical trial failures in the context of the cancer hallmark 
framework (Hanahan, 2011) supports the use of treatments that target multiple 
cancer hallmarks. For example, in Stage IV PDAC, treatment with dose-modified 
FOLFIRINOX, which targets different pathways in cell proliferation, showed a 
modest improvement in overall survival (mOS) compared to single agent 
standard of care, gemcitabine (11.1 months vs 6.8 months). (Conroy, 2011) 




underlying microenvironment, concerted mutations, and biophysical properties of 
that cancer. Despite efforts to inhibit oncogenic tyrosine kinases with anti-EGFR 
or HER-2 therapy, angiogenesis via bevacizumab, or immune suppression via 
checkpoint inhibitors, targeted therapies have failed to show a significant 
improvement in PDAC survival outcomes. (van Cutsem, 2009) (Philip, 2010) 
(Assenat, 2015) (Logsdon, 2015) These limitations underscore the need to 
identify targets specific to PDAC. 
The disconnect between preclinical and clinical results in PDAC therapies, 
especially in the setting of targeted therapy, is reflected in the limitations of 
current pre-clinical models. (Herreros-Villanueva, 2012) (Wilson, 2014) While 
there is rationale for published mouse models of spontaneous metastasis from 
primary PDAC tumors, the comorbidities of these models do not accurately 
reflect those of patients with metastatic disease; furthermore, the variability in 
metastatic tumor occurrence and latency significantly complicate the evaluation 
of treatment outcomes. The use of orthotopic or patient derived xenografts 
provides an opportunity to interrogate PDAC outside of cell culture, but fails to 
recapitulate human disease in models where there is significant tumor 
suppression and lack of stroma components. (Yachida, 2013) (Wilson, 2014) 
These limitations produce tumors with phenotypes that do not mirror clinical 
disease, explaining why therapies that show excellent preclinical promise do not 
have clinical relevance. (van Cutsem, 2009) (Philip, 2010) (Assenat, 2015)  




feed-forward dissemination-progression in PDAC metastases, stromal activation 
and immune components, with concomitant co-morbidities, (Krempley, 2017) is 
essential to provide relevant preclinical survival data that can be translated to 
clinical application. 
Metastasis is a complex process of multiple non-serial cycles of 
dissemination, seeding, angiogenesis-mediated outgrowth and progression. 
(Lambert, 2017) Insights from the clinical course of metastases in different 
cancers teach a priori requirements to advance potential metastasis therapy. 
First, the fact that metastatic tumors occur even after total surgical resection of 
the primary tumor with pathological clean margins indicates that tumor cell 
dissemination and seeding were present but were undetected at the time of 
primary tumor resection. Second, the fact that early cancer intervention is 
essential to attaining efficacy of any curative-intent intervention indicates 
advantages in prioritizing the targetable early events, such as early tumor 
seeding and angiogenic switch during micro-metastatic seeding. Third, the fact 
that mechanisms of metastasis are multifactorial, requiring complex interactions 
between tumor cells and the stromal environment, underscores the need to 
effectively target the whole tumor environment. Fourth, the fact that the current 
standard-of-care for post-operative adjuvant chemotherapy (Gemcitabine) does 
not prevent metastasis after primary PDAC resection, especially in patients with 
tumor cells in the peritoneal lavage fluid who have worse prognosis than patients 




chemotherapy-resistant, metastasis-initiating tumor cells or cancer stem-like cells 
(CSCs) should be targeted and stopped. Fifth, the fact that pancreatic peritoneal 
metastasis (PPM) has greater prevalence after PDAC resection (50%) than in 
Stage IV PDAC (20%) (Thomassen, 2013) and occurs despite post-operative 
adjuvant chemotherapy, suggests that all current chemotherapies and 
combination therapies are insufficient, hence requiring novel therapeutic 
approaches. Sixth, the fact that PD1/PD-L1 inhibitors, bevacizumab, and 
hedgehog inhibitors were not efficacious in PDAC clinical trials indicate a 
“missing puzzle piece” in the therapeutic approach to PDAC. (Van Cutsem, 2009) 
(Logsdon, 2015)  
The dual endothelin-1/signal peptideVEGF receptor (DEspR) is a candidate 
cell-surface accessible target on tumor cells, cancer stem cells (CSCs), and 
tumor microvessels. (Herrera, 2014) DEspR plays key roles in prometastatic 
CSC functions: anoikis resistance, survival in adverse conditions, tumor vasculo-
angiogenesis, and modulates pro-survival proteins Mcl1 and cIAP2 in functionally 
validated Panc1-CSCs. (Herrera, 2014) Notably, both DEspR ligands are 
expressed in PDAC: endothelin-1 (ET1) and signal peptide of VEGF (SPVEGF). 
(Herrera, 2005) The association of increased ET1 levels with metastasis and 
PDAC (Oikawa, 1994), but failure of all current ET1-A and ET1-B receptor 
inhibitors in clinical trials for cancer (Kohan, 2012) and the recent finding that the 
ET1-B receptor is a clearance receptor, (Mazzuca, 2012) support DEspR as a 




by CSCs, which a priori indicates expression of its signal peptide, SPVEGF 
DEspR’s second ligand, as both derive from the same pro-protein. Notably, as 
anti-VEGF therapies have failed in PDAC, similar to ETa/b receptor inhibitors in 
other cancers, the presence of ligands but failure of ET1-receptor antagonists 
and VEGF/receptor inhibitors validate the therapeutic hypothesis that DEspR 
may be the major ET-1 signaling receptor in PDAC tumors.  
Here I demonstrate the applicability of DEspR inhibition as a therapy in 
PDAC, with an anti-DEspR humanized monoclonal antibody. DEspR is highly 
expressed on two cancer cell lines, Panc1 and MIA PaCa2, as well as their 
derived CSC-like cells. Internalization of the antibody is specific, with shuttling to 
the nucleus from the cell membrane with the assistance of galectin-1 and 
galectin-3. Confirmation of DEspR as a unique protein expressed in PDAC, to 
refute claims as a pseudogene by the NCBI, was achieved by ADAR1 
CRISPR/Cas9 knockout in Panc1 and MIA PaCa2 and demonstrated ADAR1 
dependence in DEspR mRNA translational modifications.  Finally, using an in 
vivo model of pancreatic peritoneal carcinomatosis, anti-DEspR therapy with a 
fully humanized monoclonal antibody was shown to significantly improve survival 
outcomes, compared to the current standard of care therapy, gemcitabine. 
Altogether, data validate humanized anti-DEspR antibody as a potential novel 
therapy to prevent (as adjuvant therapy) or attenuate (as stage IV therapy) PDAC 





Section Two: DEspR Expression in PDAC Cells 
 DEspR is a single transmembrane receptor that regulates a variety of 
apoptosis-associated genes, such as APAF1, BIRC3, MCL1, and BCL10, as well 
as increasing the phosphorylation of pro-mitogenic proteins, such as STATs 
1,3,5 and FAK. (Herrera, 2016) DEspR signaling is mediated by two ligands, 
endothelin-1 (ET1) and part of the pro-peptide of VEGF, the short signaling 
peptide VEGFsp. The phosphorylation and activation of several protein kinase 
and signaling proteins was previously investigated by Herrera et al following 
binding of either ET1 or VEGFsp to DEspR-stably transfected Cos1 cells. 
(Herrera, 2016) However, this data was never complied into any pathway 
analysis; therefore, I used Ingenuity Pathway Analysis (IPA) software, to create a 
structure of potential downstream targets. For this analysis, I looked at 
phosphorylation changes that were greater than a two-fold increase, and with p 
values < 0.01 by ANOVA following either ligand binding. These phosphorylation 
changes were fit to known pathways in the IPA knowledge data base to organize 
the signaling pathways from either ligand activation (Figure 3). Both ligands lead 
to activation several pathways associated with cell proliferation, including STATs 
1,3,5, and MEK/ERK related pathways. Additionally, activation of DEspR lead to 
activation of several G-coupled protein receptor associated proteins, which is 
concordant with observations of calcium mobilization following DEspR activation, 
and speculation that DEspR is a unique, single-transmembrane G-coupled 




activating ligand of DEspR, was strongly associated with integrin mediated 
signaling, consistent with previous data showing DEspR dependent survival in 
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In order to test the applicability of DEspR targeted therapy in PDAC, the relative 
receptor expression was surveyed in commercial cell lines. Panc1 and MIA 
PaCa2 cell lines were selected based on their different KRAS mutations, the low 
sensitivity of Panc1 cells to most chemotherapeutics in vitro, and the high in vivo 
aggressiveness of MIA PaCa2 cells. (Deer, 2010) Two antibodies were prepared, 
based on recognition to the DEspR extracellular domain (Figure 4a). A murine 
7c5 recognizes the human specific Epitope 1, while a fully humanized hu-6g8 
antibodies recognizes the rat, human, and monkey sequence, Epitope 2. 
(Herrera, 2016) Expression of DEspR was elevated in both cell lines, with 40.1% 
+ 2.3% of Panc1 cells and 60.1% + 5.7% MIA PaCa2 cells being DEspR 
Positive. (Figure 4b). Both tumor cell (TC) lines were enriched to grow under 
non-adherent conditions, which induces expression of CSC markers CD133 and 
ALDH1. DEspR expression was present in both CSC enriched cell lines at 
different levels (30.4% + 6.4% and 68% + 2.8% in Panc1 and MIA PaCa2 CSCs 
respectively). (Figure 4b).  
Next, internalization of the murine 7c5 was assessed in Panc1 cell lines, 
to confirm: 1) specific uptake of the antibody by the target cell, and 2) to 
determine whether or not the antibody was retained within the target cell, or 
rapidly recycled. Fixed confocal fluorescence microscopy demonstrated greater 
internalization of an AlexaFluor 568 (AF568)-labeled 7c5 mAb than an AF568-
labeled murine isotype by 15 minutes, and significantly greater retention at 1 and 




with increasing intensity by two hours, consistent with previous imaging studies. 
(Herrera, 2016) To confirm that the DEspR-antibody complex is receptor specific, 
confocal studies of the hu-6g8 were performed in Panc1 and MIA PaCa2. Using 
an AF568 labeled hu-6g8 mAb, similar internalization and retention 
characterizations were observed, with increasing signal enhancement over time, 
and perinuclear and nuclear colocalization observed by 1 and 2 hours. (Figure 










Section Three: DEspR Inhibition Decreases Cell Stress Survival 
 
 To confirm internalization, live cell microscopy of hu-6g8-AF568 in Panc1 
cells was performed. To minimize non-specific internalization, cells were 
incubated with the fluorescently labeled antibody for 20 minutes at 4 oC, then 
washed several times, before inducing internalization with incubation of 37oC cell 
imaging media. Binding of the antibody at the cellular surface was observed, 
followed by antibody-receptor internalization, retention, and perinuclear 
localization. (Figure 5a). In both fixed confocal microscopy and live cell imaging, 
morphological signs of cellular distress and cell death were observed at 2 hours; 
morphological signs of apoptosis (cell shrinkage, blebbing, chromatin 
condensation) and necroptosis (oncosis and non-apoptotic nuclear changes) 
were observed in hu-6g8 treated, but not isotype cells (Figure 5b, c).  In Panc1 
 
 
Fig 4| Internaliztion of anti-DEspR mAbs in Panc1 and MIA PaCa2 cell lines. a. 
Representation of DEspR showing: 7c5 binding domain domain (epitope 1), hu6g8 
binding domain (epitope 2), O-gylcosylation sites (pink), internal glycosylation sites 
(green), internalization recognition site (blue) and phosphorylation sites (yellow). b. 
Comparison of DEspR surface expression showing an increase in DEspR surface 
expression from Panc1 TCs (40.1% + 2.3%) vs. to CSCs (50.4% + 6.4%), and in MIA 
PaCa2 TCs (60.1% + 5.7%) vs. to CSCs (68% + 2.8%) (100,000 cells/ replicate, n =3 
replicates). c. Representative immunofluorescence staining of Panc1 cells with an anti-
DEpsR mAb, 7c5 [red], (left) (n=282 cells) or isotype control [red] (right), (n=242 cells), 
demonstrating internalization and retention of the 7c5 antibody compared to non-specific 
isotype internalization (nuclear stain: blue). c,d Representative immunofluorescence 
staining of Panc1 cells (c) or MIA PaCa2 cells (d) with anti-DEspR mAb, 7c5 [red] (n= 50 
cells/ time point), demonstrating internalization and retention in both cell lines (nuclear 





cells, greater cell death was observed with hu-6g8 treatment vs. 7c5 treatment 
(53.8+29.0% vs. 25.2 + 17.1%, p< 0.0001, n= 108 cells for hu6g8, 280 cells for 
7c5), with no preference for apoptosis or necroptosis observed. (Figure 5d, e) 
MIA PaCa2 cells, despite having a higher DEspR expression, showed less 
morphological signs of cell death (22.3+0.9%), n = 156 cells. (Figure 5f)  
To further quantify DEspR induced cell killing, the effect of DEspR 
inhibition on cell proliferation was assessed by direct cell counting, using a 
Nexcelom Celigo multiplate reader. Kinetic studies were performed, evaluating 
apoptosis induction via activation of a caspase 3/7 cleaved green fluorophore 
(indicating active apoptosis in cell populations) and global cell death via 
internalization and nuclear signal of propidium iodide (PI). This cell counting 
method allows gating of fluorescent signals, similar to FACS analysis, for each 
cell population. Cell populations were divided into early apoptosis (green 
fluorophore signal only, indicating activation of caspase 3/7), late apoptosis 
(green and red nuclear signal, indicating cell permeability and activation of 
caspases 3/7), and necroptosis (red nuclear signal only, indicating cell death 
outside of caspase activation). Kinetic data failed to show significant difference 
from control cells, up to 72 hours, and total cell viability was not different from 
control (Figure 5g). The discrepancy between morphological changes and cell 
viability under basal conditions suggested that DEspR inhibition may not directly 
regulate cell survival, but control cell “susceptibility” to stress. This observation is 




decreased expression of pro-survival genes, like Mcl-1. (Herrera, 2014) 
Furthermore, when Panc1 cells were exposed to acidic media (pH = 6.5), an 
initial increase in surface DEspR expression was observed after 1 hour is in 
surface DEspR expression is observed after 1 hour (Appendix Figure1c). To test 
if DEspR inhibition produced a more “susceptible” phenotype, cells were 
pretreated for 16 hours with hu-6g8, then treated with gemcitabine in fresh 
media. Compared to non-pretreated cells, greater cell death was observed at 
lower gemcitabine concentrations, and a shift in the IC50 of gemcitabine was 
observed in both Panc1 (0.72 μM vs 7.26 μM) and MIA PaCa2 cells (0.21 μM vs. 
2.36 μM) (Fig 2j and 2i) but not DEspR negative HUVECs (Appendix Figure 1d, 








Fig 5| Anti-DEspR mAbs Decrease Cell Resilience. a. Representation live cell microscopy 
of hu-6g8-AF568 internalization in Panc1 cells, showing retention of antibody-receptor 
complex b. Representative immunofluorescence showing morphology of 7c5-AF568 vs. 
Isotype-AF568 treated Panc1 cells at 1 hrs and 2 hrs, with signs of apoptosis seen in 7c5 
treated but not isotype treated cells  c. Representative immunofluorescence showing 
apoptotic and necroptotic morphology of hu-6g8-AF568, which were not seen in Isotype-
AF568 treated cells at 1 hrs and 2 hrs. d. 7c5 treated cells showed signs of induced cell death 
vs. isotype at 2 hours (25.2 + 17.1% vs. 0.0 + 0.0%, p < 0.0001; n = 280 cells for 7c5 treated, 
n = 242 cells for isotype; 6 HPFs).e Hu-6g8 treated  Panc1 TCs showed signs of induced cell 
death(53.8+29.0% vs. 0.0+0.0%, p < 0.0001; hu-6g8: n=108 cells, isotype: n=104 cells, 6 
HPFs) f Hu-6g8 treated MIA PaCa2 TCs showed signs of induced cell death (22.3+0.9% vs. 






Section Four: DEspR-mAb Shuttling Colocalizes with Gal1/3 in Cell-
Dependent Manner 
Internalization of DEspR is concordant with the presence of a consensus 
Internalization Recognition Signal in the deduced amino acid sequence of DEspR 
(Figure 4a). However, DEspR has no nuclear transport signal and, thus, I 
investigated if additional proteins may facilitate nuclear shuttling. Given that 
DEspR has an intracellular N-glycosylation sequence and was identified in a 
complex with both galectin 1 (gal1) and galectin 3 (gal3) in anti-DEspR 5g12 
pulldown products, (Herrera, 2014) a time series study was performed examining 
hu-6g8-DEspR complex internalization and colocalization with gal1 and/or gal3. 
Internalization of hu-6g8-DEspR complex was tracked by immunostaining with a 
fluorescently-labeled anti-huIgG-AF546 antibody in Panc1 and MIA PaCa2 cells. 
(Figure 6a, b) Colocalization with gal1 and gal3 was tracked using corresponding 
gal1 and gal3 specific mAbs. In agreement with internalization by 15 minutes 
(Figure 4a), colocalization of the internalized hu-6g8-DEspR complex with either 
gal1 or gal3 was observed in Panc1 TCs (Figure 6c) and MIA PaCa2 TCs (Figure 
6d) to varying degrees. In both cell lines, apoptotic nuclear changes were 
 
Significance calculated with chi-square test of independence with post-hoc t-test. g-i. Non-
significant cell death was observed in hu-6g8 treatment in Panc1 TCs (g); however, 
gemcitabine potency increased in Panc1 (0.72 μM vs 7.26 μM) and MIA PaCa2 cells (0.21 






observed at 4 hours, confirming findings at 2 hours in Panc1 TCs (Figure 6a) and 
MIA PaCa2 TCs (Figure 6b).  
Quantitative analysis of colocalization of hu-6g8 bound to DEspR and gal1 and/or 
gal3 was done using Coste’s colocalization, and colocalization was assessed by 
a calculated colocalization co-efficient, with relative association strengths 
between DEspR and gal1 (kDesp-gal1) or gal3 (kDespR-gal3) (Figure 6c, 6d). Gal1 was 
highly associated with hu-6g8-DEspR complexes in all Panc1 TCs across 4 
timepoints for analysis (15 min to 4 hours) (Figure 6c) with high colocalization of 
ga1 and hu-6g8-DEspR complexes near and at the nuclear envelope (Figure 6e), 
but not farther within the nuclear space. This differed from hu-6g8-bound 
DEspR/gal3 colocalization which was detected in < 50% of Panc1 TCs (Figure 
6c), and showed significantly less nuclear colocalization (Figure 6e), that was 
limited to complexes more distal from the envelope. These findings suggest the 
gal1 is the predominant galectin associated with nuclear shuttling in Panc1 TCs. 
Notably, as these are the identical cells interrogated with anti-hu-IgG, anti-gal1 
and anti-gal3 immunostaining, it is apparent that DEspR nuclear transport uses 
both gal1 and gal3 in some cells. Selection mechanisms and differential 
advantage of either nuclear transport system remains to be elucidated. Similar 
findings were observed in MIA PaCa2 TCs with the exception that hu-6g8-DEspR 
colocalization with gal1 was diminished by 4 hours (Figure 6b), this result is 
consistent with a higher hu-6g8-DEspR fraction in the nuclear space in MIA 




with hu-6g8-DEspR near and at the nuclear envelope; however, gal3 was also 
seen to colocalize here (but not in Panc1 TCs), and was also observed to 
colocalize with DEspR farther in the nuclear space (Figure 6d). Analysis of focal 
nuclear colocalization confirms that gal1 is used predominantly for nuclear 
shuttling in Panc1 TCs (Figure 6c), but that both gal1 and gal3 nuclear shuttling 
is used in MIA PaCa2 TCs (Figure 6d). The functional outcome of the differential 






Fig 6| Anti-DEspR mAb and DEspR complex shuttle to the nucleus with Galectins-
1 and 3. a. Representation time series microscopy of hu-6g8-AF568 (red) internalization 
with either gal3-AF488 (green) or gal1-AF647 (teal) in Panc1cells, demonstrating strong 
colocalization between DEspR-hu-6g8 complex and galectin-1 and galectin-3, with high 
galectin-1 association near the nuclear membrane. b. Representation time series 
microscopy of hu-6g8-AF568 (red) internalization with either gal3-AF488 (green) or 
gal1-AF647 (teal) in MIA PaCa2 cells, showing greater association of galectin-3 with hu-
6g8-DEspR complex compared to Panc1 cells. c,d. Panc1 cells showed primary 
association of DEspR-hu-6g8 complex with galectin-1, with early association of galectin-
1 from the cytoplasmic space with antibody-bound DEspR, followed by perinuclear 
colocalization (c), while MIA PaCa2 cells show greater galectin-3 association, having a 
higher proportion of cells that are galectin-3 dependent for hu-6g8-DEspR 





Section Five: ADAR1 Mediated RNA Editing Regulates DEspR Expression 
The NCBI human DNA-sequence databases record a stop codon in 
DEspR’s tryptophan(W)-codon #14, designating DEspR a pseudogene without a 
functional protein. This observation is inconsistent with publishing work 
demonstrating DEspR transcription and protein translation: human placenta 
RNA-seq data reporting low levels of the presumed stop codon at the #14 
position, (Herrera, 2014) amplification-independent detection of DEspR RNA with 
W-14 codon rather than a stop codon, (Herrera, 2014) (Herrera, 2016) DEspR 
protein detection by anti-DEspR 5g12 mAb pulldown, and western blot detection 
of DEspR using two different DEspR-epitope mAbs, 6g8 and 5g12. (Herrera, 
2014) It is possible that this inconsistency results from misidentification of an 
adenosine within the presumed stop codon that is modified to inosine via the 
RNA editing protein ADAR1. To test this hypothesis, I evaluated the effect of 
ADAR1 regulation of DEspR protein expression.   
First, as ADAR1 binds only to double strand RNA, I note that the DEspR 
transcript spanning contested W-14 exists as double strand being antisense to 
FBXW7. Additionally, a putative hairpin loop with 3 loops to guide ADAR1 binding 
 e,f Nuclear colocalization of DEspR signal was primarily galectin-1 dependent in Panc1 
TCs, with high association from 15 minutes to 2 hr, and decreased by 4 hrs (e), while 
MIA PaCa2 cells showed higher galectin-3 association, with decreased at 4 hrs (f) 
Significance (*<0.05) compared between galectin-1 and galectin-3 dependent cells using 







for nucleotide-specific A/G editing also spans W-14. To demonstrate that ADAR1 
is expressed in PDAC cancer cells that are DEspR+, double-immunostaining of 
Panc1 and MIA PaCa2 was performed. (Figure 7a) This detected nuclear 
colocalization, with every DEspR+ tumor cell expressing ADAR1. Co-expression 
of ADAR1 in DEspR+ cells was confirmed by FACS analysis of Panc1 TCs (Figure 
7b) and MIAPaCa2 (Figure 7c). Using a CRISPR/Cas9 knockout (KO) system, 
knockout of ADAR1 was shown to lead to loss of DEspR expression in FACS 
analysis of both Panc1 (Figure 7b) and MIA PaCa2 (Figure 7c) on the 4th passage 
– indicating ADAR1-dependent DEspR protein expression via RNA-editing. 
Notably, loss of ADAR1 expression, by KO passage 3, was followed by a 
significant decrease in DEspR expression in the subsequent passage.  (Figure 7b 
and c 3rd panels). Mock-knockout of Panc1 and MIA PaCa2 cells using the mouse-
specific ADAR1 construct did not reduce ADAR1 or DEspR expression despite 
evidence of GFP-reporter gene expression (Figure 7d), thus affirming the 
specificity of human ADAR1 knockout (Figure 7b and c).  Stable ADAR1-KO and 
loss of DEspR protein was confirmed by Western blot analysis on passage 5 
ADAR1-KO Panc1 and MIA PaCa2 cells (Figure 7e and 7f, Appendix Figure 2).   
To investigate the impact of the loss of DEspR in ADAR1 knockout Panc1 
and MIA PaCa2 cells, western blots were probed with anti-Mcl1 antibody and 
showed that Mcl1 protein levels were decreased in ADAR1-KO Panc1 (Figure 7e) 
and MIA PaCa2 (Figure 7f) cells, in agreement with decreased Mcl-1 transcript 




Western blot analysis also detected decreased collagen 1 protein levels, 
consistent with the decrease observed in anti-DEspR 7c5 treated TNF-α 
stimulated Panc1-CSC plated TCs (Figure 7g). Interestingly, MIA PaCa2 cells had 
minimal baseline collagen 1 expression consistent with observations of a less 
robust extracellular matrix compared to Panc1 TCs and CSCs.  
Next, I investigated the impact of ADAR1 and DEspR protein loss on tumorsphere 
formation. To assess this, Panc1 and MIA PaCa2 WT and ADAR1-KO cells were 
plated in low adherence anoikis conditions. This showed that in contrast to control 
cells, ADAR1-KO cells exhibited significantly decreased spheroid formation 
capacity (Figure 7e), a cell culture parameter for stem cell like properties. (Singh, 








Fig 7| Effects of ADAR1 mRNA Editing on DEspR Protein Expression and 
Regulation. a. Immunofluorescence of ADAR1 and DEspR in Panc1 TCs (n=61 cells, 3 
fields at 63x magnification) and MIA PaCa2 TCs (n=38 cells, 3 fields, 63x magnification), 
showing ADAR1 expression in all DEspR+ cells. b-c. Permeabilized Panc1 TCs are 
primarily ADAR1+/DEspR+: CRISPR/Cas9-ADAR1-KO decreased ADAR1 expression by 
p3, followed by a decrease in DEspR expression by p4 (100,000 cells/replicate, n=2 





 Section Six: Anti-DEspR Therapy Shows In Vivo Efficacy Without Adverse 
Events 
 To test clinical translatability of anti-DEspR therapy in treatment of 
metastatic PDAC, I investigated the efficacy of anti-DEspR therapy in an 
established model of PPC in nude rats. I treated PPC nude rats 21 days after 
Panc1 CSC intraperitoneal injection; at this stage, multiple (> 20) peritoneal 
tumors are visibly established (~5 mm diameter) which have spread beyond the 
greater omentum to surrounding peritoneal structure. PPC without primary PDAC 
eliminates confounders from non-cancer deaths from pancreatic insufficiency. 
Survival studies compared the fully humanized mAb hu-6g8 to the current 
standard of care, gemcitabine, and saline vehicle mock-treated controls in female 
RNU rats. Initial studies compared 3 mg/kg and 15 mg/kg hu-6g8 at multiple 
intraperitoneal (IP) dosing; however, significant variability in survival was 
observed, and while treatment cohorts appeared healthier during initial rounds of 
DEspR(D): 9.4%+1.3% as well as MCL-1(M): 10.4%+1.8% and Collagen-1(C): 
9.2%+5.5% compared to WT measured by Western blot at p5(c). d-e. Permeabilized 
MIA PaCa2 TCs are also primarily ADAR1/DEspR+: CRISPR/Cas9-ADAR1-KO again 
led to decreased ADAR1 expression by p3, followed by decreased DEspR expression 
by p4 (100,000 cells/replicate, n=2 replicates)  (d) with decreased protein expression of 
ADAR1(A): 9.0%+1.3% and DEspR(D): 17.5%+6.4% as well as MCL-1(M): 
32.9%+5.6% measured by Western blot at p5(e). f. Control treated Panc1 TCs with 
murine CRISPR/Cas-9-ADAR1-KO did not show a decrease in ADAR1 or DEspR 
expression by p4, despite detection of GFP reporter in Panc1 cells at p4.  g. 
Tumorsphere colony formation was impaired in ADAR1-KO p5 Panc1 (p=0.000036) and 
MIA PaCa2 (p=0.000002) TCs compared to WT control. Analysis was performed by 
paired two-tailed t-test, repeating means, with Bonferroni-Dunn correction; 
representative images are at day 5. Legend: ADAR1 Panc1 WT  vs KO  and MIA 







treatment, rapid progression was noticed after week 2 of treatment, with higher 
treatment dosing groups more susceptible to disease (Appendix Figure 3a-c). 
Several factors were considered in initial treatment failures: 1) species 
incompatibility between the host and the humanized antibody, leading to 
autoantibody production, (Descotes, 2009) 2) higher protease concentration in 
the peritoneal space of PPC rats, leading to early antibody degradation following 
IP injections, (Alkhamesi, 2007) and 3) decreased stability of the IgG4 isotype. 
(Heads, 2012) RNU rats are known to produce auto-antibodies, (Heads, 2012) it 
was assumed that continued dosing would diminish returns, while increasing 
complications from immune-complexes from autoantibody production and 
inflammatory response. (Alkhamesi, 2007) Hu-6g8 was tested at two single 
doses, 3 or 15 mg/kg/dose, as an IV injection, compared with gemcitabine 100 
mg/kg/dose given IP, equivalent to 3x-human 1000 mg/m2 dose, and saline 
control in female RNU rats. (Figure 8a) Comparative Kaplan Meier survival curve 
analysis showed dose-response efficacy of single dose hu6g8 with significant 
differences from mock-treated controls (Figure 8a). A significant improvement in 
overall survival was seen with a single 15 mg/kg injection (189 days), while the 
lower hu6g8 dose exhibited efficacy similar to standard of care gemcitabine (92 
days in 3 mg/kg vs. 135 days with gemcitabine) (Figure 8a). A single dose study 
was repeated in male RNU rats, to determine if sex-linked differences affected 1) 
tumor growth, 2) responsiveness to anti-DEspR therapy, or 3) DEspR-dependent 




improved survival outcomes in PPC rats compared to saline control (median 
survival 154 days vs. 78 days, p = 0.0436) (Fig 8b). 
 To understand the pharmacokinetics of hu-6g8 in tumor bearing female 
RNU rats, a single intravenous injection of either 15 mg/kg or 3 mg/kg hu-6g8 
was performed 21 days after Panc1 CSC intraperitoneal injection. Sequential 
bleeds were performed, and collected plasma was analyzed for antibody content 
via western blot, as modifications to the hinge region, as well as matrix effects 
from rat plasma prevented accurate detection by commercial or prepared ELISA. 
The data were fit to both a single compartment and two compartment system; the 
rapid distribution seen at early time points is suggestive of a two-compartment 
system, where the antibody is localizing to the tumor vs other organs. A rapid t1/2α 
was observed in both dosings (0.326 hrs at 3 mg/kg and 0.484 hrs at 15 mg/kg), 
with a post-distribution half-life, t1/2β approximately 1/3 of the previously used 
murine 7c5 (49.41 hrs at 3 mg/kg and 42.8 hrs at 15 mg/kg). 
Analysis of tumor burden and comorbidity in mock-treated PPC rat at time 
of death (Figure 8c top) compared with a 15 mg/kg treated PPC rat (Figure 8c 
bottom) euthanized to match tumor duration showed greater omental tumor 
burden, hemorrhagic gut segments, and ascites in the mock-treated PPC rat. 
Additionally, biliary obstruction with jaundice from regional invasive peritoneal 
tumors with enlarged gall bladder was noted in the mock-treated rat compared to 
absence of biliary obstruction in age-matched, tumor-duration-matched 15-




induce neutropenia (Figure 8f), thrombocytopenia (Figure 8g) or anemia (Figure 
8h). Anti-DEspR mAb therapy did reduce neutrophil-lymphocyte ratios (NLR) 
(Figure 8i) concordant with reports that decreased NLR indicates better treatment 
response outcomes as observed for nab-paclitaxel in PDAC patients. (Ventriglia, 
2015) Notably, albeit single dose, no adverse events were observed in PPC nude 








Fig 8| Translatability of anti-DEspR mAb for PPC. a. single-dose 3 mg/kg (n=8) 
[p=0.005] or 15 mg/kg hu-6g8 (n=7) [p=0.002] treatment improved survival in female 
rats compared to saline (n=12); [3 mg/kg hu-6g8 and 100 mg/kg gemcitabine (n=7) had 
equivalent survival outcomes] b. Single-dose treatment of 15 mg/kg hu-6g8 (n=6) 
improved survival in male rats compared to saline (n=6) [p=0.01](g). Mantel-Cox tests 
used for survival analysis. c. Age matched post-mortem comparing (top)saline control 




Section Seven: Translatability of Anti-DEspR Therapy in Human 
PDAC 
Lastly, tumor array analysis was done using hu6g8 for immunostaining to 
determine relevance in all stages of PDAC. In contrast to normal pancreas with 
no DEspR expression, DEspR expression was detected in PDAC tumor cells, 
microvessels in Stage I-IV, and majority of invasive tumor cells in the stroma in 
Stage IV tumors (Figure 8j). DEspR was also detected in majority, but not all, 
tumor cells in hepatic, omental and peritoneal metastatic tumors (Figure 8j lower 
panels). Quantitation by blinded scoring revealed that 82% of PDAC tumor cores 
are DEspR+ with > 50% of tumor proportion scores (Figure 8k (top)), and that 
90% of 79 tumors with invasive tumor cells in the stroma were DEspR+ (8k 
bottom).       
 
Section Eight Discussion 
 Altogether, the data presented here provide key insights into anti-DEspR 
mAb therapy as a potential and much needed targeted therapy for cancer 
metastasis tested in the context of pancreatic peritoneal carcinomatosis. 
 
(bottom) single dose hu-6g8 (15 mg/kg) with hyperinflated stomach (red line); * 
denotes cecum. d,e. Pharmokinetic data of single doe 3 mg/kg (d) and 15 mg/kg (e) 
in RNU females with PPC (n=3 each cohort). f-i. Blood neutrophil levels (f), platelet 
levels (g) red blood cells (RBC), (h) and neutrophil:lymphocyte (NLR) (i) ratio of 
single dose PPC study k-m. (j) Representative immunohistochemistry of human 
pancreatic tumor tissues (n=133), k DEspR expression in human PDAC tissues, 
(top) showing DEspR-negative (n=8) vs. DEspR-positive (n=125); TPS<50% = 15, 
TPS>50% (n=115), and (bottom) DEspR expression in invasive margins, showing 




Translatability of PDAC is demonstrated in both in vivo efficacy in comparison to 
gemcitabine, and DEspR expression on human PDAC tumors. The data further 
validate the Panc1-CSC derived PPC model, as comorbidities observed, along 
with tumor burden, recapitulate the clinical picture of metastatic PDAC in 
humans. (Juhl, 1994)  
 Cumulative data provide multiple independent reasons to revise current 
NCBI-database annotation of the DEspR locus as not just an FBXW7 antisense 
RNA-1, but as a protein-coding gene. The detection of ADAR1-mediated 
regulation of DEspR protein in both Panc1 and MIA PaCa2 tumor cells identifies 
RNA-editing of the stop codon detected in human DEspR DNA-sequences, thus 
reconciling the NCBI-DNA database with the multiple independent experimental 
data demonstrating DEspR protein identity and functionality. The binding and 
efficacy of a humanized epitope-2 anti-DEspR mAb, which spans the questioned 
W-14 in DEspR, confirms translation of the full length DEspR protein. 
Internalization and colocalization with gal1 and gal3 of hu-6g8-DEspR complexes 
connects the downstream internalization recognition sequence and glycosylation 
consensus with the binding domain epitope 2, thus also indicating a DEspR 
protein not truncated at a stop codon at aa-position #14. Furthermore, the tumor-
cell-specific detection of DEspR in human patient tumor arrays, as reported 
before (Herrera, 2014) confirms DEspR expression in human cancer patient 
tissues. The fact that DEspR protein increases in cancer cells while its anti-sense 




DEspR regulation cannot be explained solely as the anti-sense of FBXW7. 
Furthermore, FBXW7 is associated with a worse prognosis at low levels in PDAC 
(Ishii, 2017) and implicates its role as a tumor suppressor, (Yeh, 2018) contrary 
to known effects of DEspR expression in PDAC. The association of ADAR1 with 
cancer, (Wang, 2017) dependency of ADAR1 in certain PDAC cell lines, 
(Gannon, 2018) and ADAR1-mediated regulation of transcript stability and gene 
expression (Wang, 2013) further supports the role of DEspR as a signaling 
receptor in pancreatic cancer. Notably, RNA-editing can be as low as 5% of 
reference sequence (Wang, 2013) hence prone to being overlooked.      
 Equally important, the detection of hu-6g8-DEspR complex internalization 
by 15 minutes with development of apoptotic changes by 2-4 hours suggests a 
robust therapeutic mechanism of action to decrease regular tumor cell and CSC 
survival. This is borne out by anti-DEspR treatment effects in the inhibition of 
tumor initiation in PPC xenograft tumor models, and the demonstrated dose-
response efficacy in increasing overall survival in PPC nude rats with established 
peritoneal carcinomatosis.  
Equally important, the development of the PPC nude rat model indicates 
the self-sufficiency of CSCs to initiate PPC which develops into the full 
phenotype PPC with biliary obstruction and jaundice, ascites, cachexia, gut 
invasion and dysfunction, as observed in human patients with resected PDAC 
and tumor cells in the peritoneal lavage fluid.  The self-sufficiency of CSCs in the 




standard of care adjuvant gemcitabine therapy to prevent PPC, as CSCs are 
known to be chemotherapy resistant.  Collagen secretion combined with Panc1-
CSC ability for vasculogenesis in vivo (Herrera, 2014) contribute to CSC self-
sufficiency in initiating peritoneal metastasis, in contrast to the paradigm 
described for hematogenous spread wherein prior preparation of the ‘soil for 
metastatic seeding’ is needed. (Fidler, 2003)  
The detected expression of DEspR in 80% of tumor cores with > 50% 
tumor proportion score in a 133 PDAC-patient tumor array, and the detection of 
DEspR in PDAC stages I-IV, and in invasive tumor cells in the stroma, supporting 
the potential for high clinical relevance of anti-DEspR mAb therapy in PDAC. 
Moreover, given that no adverse events were observed at dose regimens used, 
and that anti-DEspR decreased tumor initiation in in vivo in PPC models, anti-
DEspR hu6g8 could be an adjuvant cancer therapeutic. Most importantly, the fact 
that a single dose of anti-DEspR therapy given when PPC is established alters 
the rapid feed-forward dissemination-progression of PPC, coupled with a mode 
of action wherein hu6g8-bound DEspR is internalized, translocated to the 
nucleus and induces apoptosis, rather than recycled out or targeted to the 
lysosome, altogether indicate a robust therapeutic paradigm as a potential 







Section Nine: Methods  
Cell culture. Panc1 and MIA PaCa2 TCs were purchased through ATCC (ATCC 
CRL-1469 and ATCC CRL-1420). Cells were grown in Dulbecco's Modified Eagle 
Medium (DMEM) (Fisher Scientific, cat #: 12430-054) supplemented in 5% Fetal 
Bovine Serum (FBS) (Fisher Scientific, cat#: 10438026) and 1% Penicillin-
Streptomycin (Fisher Scientific, cat#:  15140122) in 100 mm tissue-culture 
treated polystyrene plates (Corning, cat#430167). Cells were harvested at 60% 
confluence using trypsin-EDTA (0.25%) (Fischer Scientific 25200056); 
experiments were performed from passage 3-8. Panc1 and MIA PaCa2 CSCs 
were prepared from Panc1 and MIA PaCa2 TCs respectively by selective growth 
in ultra-low attachment 100 mm plates (Corning, cat#3261) were plated on 96-
well cell culture treated plates (Corning, cat# 3603), in Mammocult media (Stem 
Cell Technologies, cat#: 05620), supplemented with Heparin Solution (Stem Cell 
Technologies cat#: 7980), and 1% Penicillin-Streptomycin (ThermoFisher, cat#:  
15140122). After 1 week, cell survival was assessed, tumorspheres were 
separated by trituration with trypsin, and cells were maintained in ultra-low 
attachment dishes in Mammocult media. HUVECs were purchased through 
ATCC (ATCC CRL-1730) and grown in F-12K Medium (ATCC, cat# 30-2004) 
supplemented with 0.1 mg/ml heparin (Sigma, cat# H3393), 5 ml endothelial 
growth supplement (Biosciences, cat# 354006), and 10% FBS.  
IPA Pathway Analysis.  Protein phosphorylation data obtained from Kinex™ 




signals which had greater than 2-fold change from control cells, and which had 
statistically significant expression changes (p < 0.01 by ANOVA). Data was 
loaded into IPA with specific phosphorylation sites included along with HUGO 
gene names. Pathway mapping was performed based on IPA knowledge 
databases without discrimination on pathway types; pathways were plotted 
based on high association (> 90%) between protein phosphorylation signals from 
the antibody array and IPA data. 
Antibody labeling. 7c5, IgG2b, hu6g8, and IgG4b antibodies were labeled using 
Alexa Fluor 568 Antibody Labeling Kit (Fisher Scientific, cat#A20184) following 
manufacturer instructions.  
Flow Cytometry: Cells were harvested at 60% confluence, using 1 ml of 5 mM 
EDTA when using normal tumor cells. For CSCs, cells were harvested after 7 
days, then disaggregated with EDTA to produce single cells. For surface 
expression of Panc1/ MIA PaCa2 TCs and CSCs: cells were labeled with 10 
µg/ml hu-6g8AF568 antibody or hIgG4-AF568 antibody 20 minutes at 4oC.  For 
ADAR1 expression. Cells were fixed and permeabilized with 4% 
paraformaldehyde (ThermoFisher, cat# J19943K2) and 0.01% Triton-X100 
(Sigma, cat# X100), followed by labeling with 10 μg/ml anti-ADAR1 (Abcam, cat# 
ab126745) and 10 μg/ml hu6g8-AF568 antibodies for 30 minutes. The anti-
ADAR1 antibody was labeled with 2 μg/ml anti-rabbit IgG-AF488 (Abcam, cat# 




Bioscience) with 561 nm laser with 610/20 (600 LP) filter for AF-568 and 488 nm 
laser with 530/30 (505 LP) filter for AF-488. 
Fixed Cell Fluorescent Microscopy. Immunofluorescence staining was 
performed as previously described. (Herrera, 2014) Panc1 and MIA PaCA2 TCs 
and were labeled with 10 µg/ml hu-6g8-AF568 (Lake Pharma), 10 µg/ml 7c5-
AF568 (Lake Pharma), 10 µg/ml mIgG2b-AF568 Isotype (ThermoFisher, cat#: 
31903), or 10 µg/ml IgG4-AF568 Isotype (Novus Biologicals, Cat# DDXCH04P) 
for antibody internalization. For ADAR1 labeling, cells were labeled with 10 μg/ml 
anti-ADAR1 (Abcam, cat# ab126745) and 10 μg/ml hu6g8-AF568 antibodies for 
30 minutes. The anti-ADAR1 antibody was labeled with 2 μg/ml anti-rabbit IgG-
AF488 (Abcam, cat# ab150077). For galectin labeling, cells were labeled with 2 
µg/ml anti-human IgG-AF546 (Invitrogen, cat#A-21089), 10 µg/ml anti-galectin-1-
AF647 (Abcam, cat# ab203327) and 10 µg/ml anti-galectin-3-AF488 (Abcam, 
cat# ab207357). Cells treated with the humanized antibody were counter stained 
with NucBlue Hoechst stain (ThermoFisher, cat #R37605); cells treated with the 
7c5 antibody were mounted with ProLong™ Diamond Antifade Mountant with 
DAPI (Fisher Scientific, cat#: P36971). Humanized cells were imaged was 
performed on a Leica SP5, with 1 AU pinhole aperture, 0.7 µm Z-stacks taken for 
comparison.  For antibody internalization, excitation was performed with 405 nm 
and 543 nm laser lines, emission was collected from 430-475 nm and 600-700 
nm to prevent overlap.  For ADAR1 studies, excitation was performed on 405 




505-550 nm, and 615-700 nm to prevent overlap.  For galectin studies, Excitation 
was performed with 405 nm, 488 nm, 543 nm, and 633 nm laser lines, and 
emission was collected from 430-470 nm, 500-540 nm, 580-620nm, and 700-750 
nm to prevent overlap. For murine antibody internalization, imaging was 
performed with a Zeiss Axiostop fluorescence microscope, as previously 
described127 and confirmed with confocal studies using the Leica SP5, with 1 AU 
pinhole aperture, 0.7 µm Z-stacks taken for comparison.  For antibody 
internalization, excitation was performed with 405 nm and 543 nm laser lines, 
emission was collected from 430-475 nm and 600-700 nm to prevent overlap.  
Quantification was performed using ImageJ with JACoP plugin-software. 
Live Cell Microscopy. Cells were imaging using 35 mm No. 1.5 Coverslip poly-
D-lysine coated plates (MatTek, cat#: P35GC-1.0-14-C). Cells were incubated 
with either 10 µg/ml hu-6g8-AF568 (Lake Pharma), or 10 µg/ml mIgG2b-AF568 
Isotype at 4oC for 20 minutes with NucBlue counterstain to allow binding. Media 
was removed, cells were washed, and imaging was started following addition of 
live cell imaging solution (ThermoFisher, cat# A14291DJ). Imaging was 
performed on a Zeiss LSM 710-Live DUO Scan, with 1 AU pinhole aperture, 0.7 
µm Z-stacks taken for comparison.   
Direct Cell Counting Cell Viability Assay. Cells were seeded at 2,000 cells in 
200 μl in 96 well Corning 3603 plates (Sigma, Cat# CLS3603), and allowed to 
grow for 2 days to restore receptor/ metabolic activity. Cells were pretreated with 




replaced with varying concentrations of gemcitabine hydrochloride (Sigma, 
G6423). After 48 hours, media was replaced with serum free media containing 
0.3 ug/ml propidium iodide (Sigma Aldrich, cat # P4864) and NucBlue stain, and 
imaging was performed using Celigo Imaging Cytometer (Nexcelom) with live/ 
total setting. For kinetic studies of apoptosis/ necroptosis with hu-6g8 treatment, 
cells were treated for a total of 72 hrs, incubated with 0.1 ug/ml propidium iodide, 
1:50 caspase 3/7 green (ThermoFisher, cat# R37111), and NucBlue stain. 
Sequential imaging was performed using Celigo Imaging Cytometer (Nexcelom) 
with target counts and gating.  
CRISPR/Cas9 ADAR1 KO. Knockout was performed following manufacturer 
instructions. Panc1 and MIA PaCa2 TCs were seeded at 3x105 cells in 6-well 
tissue culture treated plates (ThermoFisher, cat#07-200-83), and allowed to grow 
to 50% confluence. Media was then exchanged to antibiotic free, serum-free 
growth media 24 hours prior to transfection. A solution of 1.5 μg CRISPR/Cas9 
KO (h) plasmid (SantaCruz cat# sc-401611) and 1.5 μg ADAR1 HDR plasmid (h) 
(SantaCruz cat# sc-401611) was prepared in plasmid transfection media 
(SantaCruz, cat# sc-108062), and mixed with a solution of 10 μl UltraCruz 
Tranfection Reagent (SantaCruz, cat#: sc-395739) in plasmid transfection media. 
This solution was added dropwise to each well; after 6 hours, media was 
replaced. After 24 hours, complete growth media (with serum and antibiotics) 
was added. For some cells, the plate was trypsinized and re-plated to separate 




hours to remove dead cells; once cells reached 80% confluence, complete 
growth media with 5 μg/ml puromycin was added to the plate. Puromycin-
containing media was exchanged every 24 hours. Transfection efficacy was 
assessed by fluorescent microscopy, looking at GFP positive cells, and GFP, 
ADAR1, and DEspR expression was assessed at each passage. This same 
protocol was repeated for ADAR1 HDR plasmid (m) control. Plasmid and 
transfection reagent concentrations were optimized for each cell line- for Panc1 
and MIA PaCa2, both seemed to work optimally under same conditions. 
Protein lysis. Panc1 WT and KO and MIA PaCa2 WT and KO protein lysates 
were prepared by harvesting cells at 60% confluence at passage 5, followed by 
complete cell lysis with Laemmli buffer (1x in PBS) (BioRad, cat# 1610737). 
Nucleic acids were sheared by repeated sonication, protein fraction was 
collected after centrifugation; protein levels were assessed by absorbance at 280 
nm with correction for nucleic acids (NanoDrop™ One Spectrophotometer, 
ThermoFisher cat# 13-400-518).  
Western blotting. Gel electrophoresis was performed using Western blots were 
performed 4-15% Tris HCL Protein Gels (BioRad, cat# #4561086) with 10 µg 
protein lysate at 100V for 90 minutes. Protein transfer was performed using 
Immuno-Blot PVDF membrane (BioRad, cat# 1620174), transferred at 70 V for 
2.5 hrs at 4oC; completeness of transfer was confirmed using Bio-Safe™ 
Coomassie Stain (BioRad, cat# 1610786). Anti-GAPDH (Abcam, cat#: ab9485, 




loading controls. Protein levels were assessed using anti-DEspR (Lake Pharma, 
HV2-1h-[hIgG4(S228P)] + KV1-2h, lot# 7982-838882, 1:200), anti-ADAR1 
(Abcam, cat# ab126745, 1:2000), anti-Mcl-1 (Santa Cruz, cat#: sc-12756, 1:200), 
anti-collagen 1 alpha (Santa Cruz, cat#: sc-59772, 1:200), anti-human IgG HRP 
(Sigma, cat#: AP112P, 1:10000), anti-rabbit IgG HRP (Abcam, ab6721, 
1:10000), and anti-mouse IgG HRP (Abcam, cat#: ab6721). Blots were 
developed using SuperSignal West Pico Plus chemiluminescent substrate 
(Fisher Scientific, cat#: 34580), and ImageQuant LAS 4000 biomolecular imager 
(Fujifilm). 
Tumorsphere Assay. Tumorsphere assessment was modified based on 
previously described protocols. (Weiswald, 2015) Cells were grown to 60% 
confluence, then harvested with 5 mM EDTA (ThermoFisher, cat#: AM9206G) in 
PBS. Cells were plated on 96-well cell culture treated plates (Corning, cat# 
3603), in Mammocult media (Stem Cell Technologies, cat#: 05620), 
supplemented with Heparin Solution (Stem Cell Technologies cat#: 7980), and 
1% Penicillin-Streptomycin (ThermoFisher, cat#:  15140122), at 250, 500, and 
1000 cells/ plate. Cells were imaged using Nexcelom Celigo Imaging Cytometer, 
with tumorsphere colonies counted as 50 µm in size, using a 97% well mask to 
avoid fringe aberrations, and using the tumorsphere counting Celigo protocol. 
Orthotopic Panc1 PPC model. Orthotopic PPC models were prepared as 
previously described. (Herrera, 2014)   Three days following intraperitoneal 




suspended in 1 ml of M2 media (sigma, cat# M7167) were injected 
intraperitoneally into 4-5 week old nudenu/nu female or 3-4 week old nudenu/nu 
male rats (Charles River Labs), anesthetized using isoflurane maintained at 1-1.5 
L/min. For single dose treatment study, nudenu/nu rats received a single 
intravenous injection of 3 mg/kg or 15 mg/kg hu-6g8, a 100 mg/kg intraperitoneal 
injection of gemcitabine, or an intraperitoneal injection of saline, 21 days after cell 
injection. For multi-dose studies (Appendix Figure 3a-c), nudenu/nu rats received a 
single intraperitoneal or intravenous injection of 3 mg/kg or 15 mg/kg hu-6g8 or 
intraperitoneal saline, 21 days after injection. Rats were monitored daily for 
health concerns; body weights were obtained weekly; observing monitors were 
blinded to the treatment group. At the end stage, rats were assessed and 
euthanized with photo-documentation of ascites, peritoneal tumors and 
abdominal organ states, and tumor and organ collection for further analysis. For 
neutrophil, platelet, and NLR assays, blood was collected from nudenu/nu rats at 
days 28, 35, and 42 post injection in 1% EDTA (Sigma, cat# EDS). Blood was 
analyzed using HEMAVET 950 FS Auto Blood Analyzer with rat-species settings. 
Pharmacokinetic Study. Using the same orthotopic models, female nudenu/nu 
rats received a single bolus intravenous injection of either 3 mg/kg or 15 mg/kg 
hu-6g8 antibody. Rats were anesthetized, and blood was drawn at 5 minutes, 15 
minutes, 30 minutes, 1 hour, 8 hours, 24 hours, 72 hours, 1 week, and 2 weeks. 
Plasma samples were prepared as dilutions, and run on 12% Mini-Protean Gels 




PVDF membrane (BioRad, cat# 1620174), transferred at 30 V for 8 hrs at 4oC; 
completeness of transfer was confirmed using Bio-Safe™ Coomassie Stain 
(BioRad, cat# 1610786). Antibody was detected using anti-human IgG HRP 
(Sigma, cat#: AP112P, 1:10000) and blots were developed using SuperSignal 
West Pico Plus chemiluminescent substrate (Fisher Scientific, cat#: 34580), and 
ImageQuant LAS 4000 biomolecular imager (Fujifilm). 
 Immunohistochemistry. Immunofluorescence staining was performed as 
previously described. (Herrera, 2014) DEspR cell expression was detected using 
10 µg/ml hu-6g8-AF568 (Lake Pharma, HV2-1h-[hIgG4(S228P)]; collagen was 
detected using x µg/ml anti-collagen 1/3 antibody (company). Cells were 
mounted with ProLong™ Diamond Antifade Mountant with DAPI (Fisher 
Scientific, cat#: P36971). Imaging was performed with a Zeiss Axiostop 













CHAPTER FOUR: DEVELOPMENT OF A NOVEL PROTEIN CONJUGATION 
SYSTEM 
Section One: Supramolecular Assembly and Biomaterials 
Supramolecular assembly, the self-assembly of macrostructures from 
monomers into a priori designed structures, maintained by noncovalent 
interactions, is a versatile tool in biomaterials. (Fidler, 2003) (Webber, 2016) 
Designed supramolecular structures allow tunable, specific, and dynamic control 
of biomaterials, allowing the production of dynamic structures with unique, 
emergent features depending on the size and type of non-covalent interaction. 
(Lehn, 1988) (Appel, 2012) (Dong, 2015) Despite relying on non-covalent 
interactions, high affinity binding and multiple contact points throughout the 
structure can produce highly stable species, which resemble covalent networks. 
(Sijbesma, 1997) Several motifs are commonly employed in biomaterial 
applications, such as coils, (Hasenknopf, 1996) sheets, (Hartgerink, 2001) and 
spheres. (Geng, 2007) These structures can be adopted from naturally occurring 
structures, employed to biomaterial applications, or developed de novo, based on 
principles governing structural assembly. The latter is particularly challenging, as 
it requires a detailed understanding of how specific interactions govern structural 
assembly.  
A commonly employed supramolecular structure, helical or coiled coils, 
are favorable because of the extensive characterization available for de novo 




helical monomers that self-assemble into a larger helical structure with a 
suprahelical radius. (Hu, 1990) The designation of this secondary and tertiary 
structure is based on the interaction of repeating heptad peptide sequences. (Hu, 
1990) The peptide sequences vary throughout nature; however, most 
approximate the XYYYXYY motif, a repeating set of seven amino acids (heptad), 
in which the first position of the heptad and the fourth position are hydrophobic 
resiudes. (Hu, 1990) (Harbury, 1993) The heptad is typically defined as positions 
a through g (i.e. abcdefg), where the two hydrophobic positions, a and d, move 
towards the center of the helical structure. Increasing the number of hydrophobic 
residues can cause the structure to adopt a beta sheet formation, which better 
stabilizes greater hydrophobic residues. (Hu, 1990) (Harbury, 1993) 
Considerable work has been done in the characterization of coiled coils; and, 
thus, it is possible to generate coiled coils, or helical structures, based on known 
conditions to guide oligomeric state. Work by Harbury et. al in the assembly of 
parallel coiled coils based on the leucine zipper motif, show that the positions of 
the heptad determine the oligomeric state of the structure. (Harbury, 1993) 
Introduction of isoleucine at the a position and leucine at d position favors 
formation of dimers, while reversing these favors tetramers. Discrete structures 
are therefore generated based on these restrictions.  
The majority of biochemical analysis on coiled coils has been on dimers, 
with higher order oligomeric states less studied. (Apgar, 2008) This limits 




certain assumptions about the importance of residues within heptads of dimers 
do not apply to higher order oligomers. (Ciani, 2010) (Mahrenholz, 2011) This is 
a major limitation in the application of coiled coil and helical structures to 
biomaterials, as the inherent strength of dimers is significantly limited relative to 
other oligomeric states. (Rudra, 2010) (Trubestein, 2016) The majority of coiled 
coil interaction strength depends on the points of contact between the 
hydrophobic residues packing within the center (Crick’s peg and hole theory); 
(Ciani, 2010) as such higher order oligomers offer the potential of stronger 
interactions, as more residues can be buried within the center, allowing greater 
contact points between and therefore greater interaction strength of the structure. 
(Rudra, 2010) (Trubestein, 2016) 
Tetrameric coiled coils, in particular, are a useful oligomeric state when 
symmetry is necessary, and provide the benefit of improved shielding of 
hydrophobic residues that could be immunogenic. While the importance of the a 
and d position was established by Harbury et. al, the significance of other 
residues in structural stability is not as well assessed. (Harbury, 1993) For 
example, tetramers naturally “bury” at least one g/e interaction, (Harbury, 1993) 
whereas this interaction is well exposed to the water interface of tetramers. 
(Harbury, 1993)  (Apgar, 2008) (Figure 9) How buried each g/e and e/g 
interaction is within the tetramer is not well defined; however, from native 
structures it appears that at least one of these pairings could be completely 




1993) (Hu, 2018) This result suggest that the b/c and c/b interactions are more 
influential in specificity of interactions than in dimers, occupying the role of the 




Development of a unique set of peptides that self-assemble into a highly 
stable heterotetrametric is of particular interest in antibody modification or 
conjugation, where a specific modified set of peptides could be used to interact 
with a complementary sequence on the antibody heavy chain: a supramolecular 
approach. Successful development of a highly specific, highly stable interaction 
pair would allow uniform, site-specific drug loading without the need for harsh 
 
Fig 9| Interaction of Heptad Residues in Dimers vs. Tetramers.  Representative wheel 
diagram of dimers (left) and tetramers (right). To incorporate larger oligomeric states in 
supramolecular structures, more residues are buried within the core. G/E interactions can 





organic solvents or chemical contaminants, and would allow rapid, tunable drug 
loading. To be successful, this would require a set of non-self-interacting 
peptides, which form a highly stable, non-denaturing under physiological 
conditions, pH resistant, tetramer, capable of maintaining the payload through 
circulation.  
Near covalent and high affinity supramolecular structures have been 
achieved, which show excellent stability in vitro (Astruc-Diaz, 2012) (Hu, 2018) 
and in vivo, (Dai, 2015) (Sato, 2018) suggesting that this method of conjugation 
is feasible. However, to be applicable in ADC preparation, the size of the 
sequence needs to be a small as possible; based on design constrictions of 
coiled coils, the minimum number of repeating heptads that can form a coil is 
four. (Harbury, 1993) (Hu, 2018) Therefore, the sequence is designed to 
maximize interaction strength over a limited number of contact points.  To 
achieve this, a set of peptides were developed, designed to form parallel, 
tetrameric coiled coils, based on the work of Harbury et. al. (Harbury, 1993) First, 
two sets were designed with the intent of minimizing self-interaction and 
maximize heterotetramer interaction, this was achieved by having one set 
contain a number of acidic residues (glutamine), and the other basic residues 
(lysine). Next, two sets of g/e interactions were introduced, one relying on salt 
bridge formations between acidic and basic residues, while the other relied on 




this pair was varied between β-branched (leucine and valine) vs. β-unbranched 
(isoleucine) hydrophobic amino acids.  
Here, a highly stable, highly specific hetero-tetrameric structure is 
described, designed de novo based on known properties of coiled coils. By 
introducing a specific valine-valine interaction, a highly strong species if 
produced, which does not self-interact in the monomeric state, but forms a highly 
resistant tetrameric species. 
Section Two: Valine/Valine Forms a Highly Stable Heterospecies 
A set of six peptides were prepared based on design constructs to form 
parallel, tetrameric coiled coils, (Harbury, 1993) fixing the a position of the heptad 
as leucine, and the d isoleucine (Figure 10, Table I) Peptides were named based 
on the hydrophobic amino acid varied at either the G or E position, and whether 
they were acidic (glutamic acid, E) or basic (lysine, K). The following criteria was 
used in design. One set of peptides was prepared as “acid peptides”, with 
glutamic acids in the b, c, and g position; the other as “basic peptides”, with 
lysines at the b, c, and e position. Packing of oligomeric structures is unique for 
each species, with tetramers and higher oligomeric states possessing more 






These additional residues could participate in van der Waals interactions 




Fig 10| Wheel Diagram of Self-Assembled Structures.  a. Representation of 
heterotetrameric self-assembly in 2+2 arrangement, with burying of G/E interaction. b-g. 
Representative wheel diagrams of synthetic peptides L/E, V/E, I/E, L/K, V/K, and I/K 
respectively, showing which amino acids occupy each position of the heptad. Peptides are 







the coiled coil species is dependent on the sum of these hydrophobic 
interactions, along with any salt-bridge interactions. In tetramers, g and e 
positions can be buried in the core region; while in dimers, g/e interactions are 
known to facilitate in specificity of oligomeric pairings (i.e., salt bridge formation 
as designed into the acid/base peptide interaction), the exact role, and specificity 
of these positions is not well defined in tetramers. (Harbury, 1993) Here, I 
examined how different interactions between β-branched (lysine and valine) and 
un-β-branched (isoleucine) in one G/E interaction affects coiled coil strength. As 
helical structures typically possess no more than 3 hydrophobic amino acids per 
heptad, whereas β sheets may have four or more, I wanted to minimize the 
chance of non-helical structure formation and, therefore, varied the E position of 
the acidic peptides and G position of the basic peptide as either leucine, valine, 
or isoleucine. The structure of each peptide is given in the table below with wheel 












Table VI. Sequences of Peptides 
Peptide ID Peptide Type Sequence 
Peptide L/E Acidic MKLEEILSELEEILSELEEILYELEEILSEVGER 
Peptide L/K Basic MKLKKIKSLLKKIKSLLKKIKSLLKKIKSLVGER 
Peptide V/E Acidic MKLEEIVSELEEIVSELEEIVYELEEIVSEVGER 
Peptide V/K Basic MKLKKIKSVLKKIKSVLKKIKSVLKKIKSVVGER 
Peptide I/E Acidic MKLEEIISELEEIISELEEIIYELEEIISEVGER 
Peptide I/K Basic MKLKKIKSILKKIKSILKKIKSILKKIKSIVGER 
 
My goal was to allow biorthogonal functionalization of this coiled coil for drug 
delivery. To accomplish this, I included a single tyrosine residue in the F position 
on the third heptad of each acid peptide, this single tyrosine residue allowed 
conjugation with 4-phenyl-1,2,4-triazole-3,5-dione (PTAD) containing molecules 
via a specific “ene” reaction that would not interact with other residues.  
Structural analysis of each peptide was performed by circular dichroism (CD), 
using 100 μM of the individual peptides and 50 μM of each peptide to assess 
interaction. Structural analysis of each peptide, separated into acidic (a) and 
basic (b) groups is shown in Figure 11a, b. Asymmetric peptide bonds show 
strong absorption around 220 nm (npi*, a transition from non-bonding electron 
pair to an antibonding pi orbital) and 190 nm (pipi*, a transition from a pi orbital 
to an antibonding pi orbital). (Johnson, 1988) a helical structure is defined by two 




Psi) from the organized secondary structure of the helix affecting the 
contributions from these absorptions. (Kelly, 2005) (Greenfield, 2006) The coiled 
coils show a specific 222/208 ratio greater than 1.1, indicative of the discrete 
superhelical structure formed. (Johnson, 1988) 
Occupation of isoleucine in the E position of the acidic peptide, I/E, and 
leucine in the G position of the basic peptide, L/K, produced helical peptides with 
a percent helical character of 31.6% and 94.3% respectively, based on the 
following equation: 
eq. 1   100 x − [40,000 �1 − 2.5
𝑛𝑛𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟
�]/𝜃𝜃222,𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜 
Other pairs exhibit random coil structure, indicating that no discrete or 
organized secondary structure was forming. This suggests that there is no strong 
interaction occurring between these monomers to guide the formation of an 
assembled complex; therefore, they would be ideal candidates to explore for 
further testing, assuming they could for heterohelical structures.  
  Interaction of each acidic and basic peptide was next assessed to 
determine if a supramolecular structure would form. Secondary structure of each 
peptide pair was evaluated in 1:1 equimolar ratio at 100 μM total peptide. Unique 
structures were observed in only certain acid-base peptide pairs (Figure 11d, g, i, 
j), but not in all pairs, and were not observed when acid-acid pairs or base-base 
pair were mixed (Appendix Figure 4). Peptide V/K produced helical structures 
with all acidic peptides (Figure 11d, g, j) with characteristic minima at 222 and 




ratio >1.1) and near perfectly helical structure (helical character >99%). The 
lower helical character of the other peptides suggests that V/L and V/I 
interactions may be significantly less stable. Peptides I/E and L/K also formed a 
unique heterotetramer, with a coiled-coil like structure (222/208 ratio > 1.1); 
however, the helical content and characteristics are similar to L/K, and are not 
worth pursuing as a pairing for conjugation. Since the V/E-V/K peptide pairs 
formed a discrete equimolar structure, the next step was to determine if the 








Figure 11| Structural characterization of self-assembly peptides. a,b. The secondary 
structure of (a) acidic peptides L/E, V/E, and I/E and (b) basic peptides L/K, V/L, I/K (100 μM 
total protein, n =5 replicates at 10oC), showing most species have no defined secondary 
structure. c-k. Structural characterization of all acid/basic peptide pairs showing acidic 
peptides (red), basic peptides (blue), and structure of 1:1 equimolar structures (purple), at 
100 μM individual peptides and total peptides. CD signals are transformed as mean residue 
ellipticity to determine if a structure formed, or if the species remained separate. Peptide V/E-






Section Three: V/E-V/K Forms a Discrete Tetramer 
Structural analysis of peptides V/E and V/L show random, disorganized 
structures from 10-90oC in Tris buffered saline (TBS), pH=7.6; however, 
equimolar solutions of the two peptides produce a new structure, with helical 
character > 99% and a 222/208 optical ratio suggestive of a coiled coil. As this 
met part of the design criteria, the next step was to investigate if: 1) the individual 
peptides (V/E and V/K) were true monomers, 2) V/E-V/K formed a tetramer, and 
3) there were any other oligomeric species. A sedimentation velocity scan of 
each individual species, peptide V/E and V/K, as well as an equimolar species of 
peptide V/E-V/K was taken, at total concentration of 0.6 mg/mL peptide per each 
run. (Figure 12a-c). Samples were run in TBS at 40,000 rpm, and buffer density 
(1.0058) and vbar of each peptide (V/E = 0.799, V/K =0.742, V/E-V/K =0.762) 
were calculated based on sequence estimates from Sednterp, a software which 
can calculate the vbar of peptides based on their amino acid sequence. Given 
the size and low aromatic content on each species, interference optics were 
selected. Here horizontal fringes are produced with vertical displacements, ∆Y, 
as a result of the optical path difference as light passes through the sample and a 
reference cell. The vertical displacement is proportional to the refractive index 
different, ∆n, the optical path length, l, and inversely proportional to the 
wavelength of the light source, λ. (eq 2) (Richards, 1959) 






A continuous sedimentation coefficient distribution model, of the Lamm 
Equation: 
 
eq. 3   Minc(s) {∑ [𝑎𝑎�𝑟𝑟𝑖𝑖, 𝑡𝑡𝑗𝑗� − ∫ 𝑐𝑐(𝑠𝑠)L�𝑠𝑠,𝐷𝐷(𝑠𝑠), 𝑟𝑟𝑖𝑖, 𝑡𝑡𝑗𝑗�𝑑𝑑𝑠𝑠]2}𝑖𝑖,𝑗𝑗  (Shuck, 2000) 
 
was performed for V/E, V/K, and V/E-V/K. Because several assumptions are 
made in solving the Lamm equation for each species, and it is easy to make 
over-assumptions about data, I needed to introduce a factor of regularization. 
(Provencher, 1982) (Press, 1985) (Shuck, 2000) For each cell, I selected the 
maximum entropy model: 
 
eq. 4  Minc(s) {∑ [𝑎𝑎�𝑟𝑟𝑖𝑖, 𝑡𝑡𝑗𝑗� − ∫ 𝑐𝑐(𝑠𝑠)L�𝑠𝑠,𝐷𝐷(𝑠𝑠), 𝑟𝑟𝑖𝑖, 𝑡𝑡𝑗𝑗�𝑑𝑑𝑠𝑠]2 +  𝛼𝛼 ∫ 𝑐𝑐(𝑠𝑠) ln 𝑐𝑐(𝑠𝑠)𝑑𝑑𝑠𝑠}𝑖𝑖,𝑗𝑗  
(Livesey & Skilling, 1985) 
 
The second parameter included here is used to calculate the relative number of 
microstates, assuming all s-values are equally likely. I selected the set with the 
“least information” that meets fits the model the best, in order to minimize 
assumptions in calculating the sedimentation of the coefficient in each species. 
This model holds if the following assumptions are met: either 1) the 
species are non-interacting (which should fit for V/E and V/K) or if the other 
species are stable during sedimentation, indicating a higher Kd and minimal 




modified Lamm Equation, I solved for the solute diffusion constant, D, and the 
sedimentation coefficient, s, assuming that all species per cell (i.e., all species in 
cell V/E or V/K) have the same weight-average frictional ratio, in order to 
calculate the molecular weight and distribution of all species. In our calculation of 
molecular weight of each sedimentation species, I used a modification of the 
Svedberg equation by first calculating a frictional coefficient fo of a species as 
defined as a compact, ideal sphere of defined radius r, in the solvent of viscosity, 
η, 
eq. 5      fo = 6πηr 
substituted into the Svedberg equation (eq 5): 
















∗ vbar)1/3 (Shuck, 2000) 
which is resolved to give the following equation: 
eq. 8          ( 𝑀𝑀
𝑁𝑁𝑎𝑎 







to give the particle mass and partial specific volume of an ideal sphere, where M 
is the particle mass, Na is Avogadro’s number, f is the fictional coefficient, vbar is 
the partial specific volume (which reflects variations in the volume from the 
composition of each particle), and ρ is the density of the solvent. From this 




eq. 9  𝐷𝐷(𝑠𝑠) =  √2
18𝜋𝜋
𝑘𝑘𝑘𝑘𝑠𝑠−1/2(𝑛𝑛(𝑓𝑓/𝑓𝑓𝑜𝑜)𝑤𝑤)−3/2((1 − 𝑣𝑣𝑣𝑣𝑎𝑎𝑟𝑟 ∗ 𝜌𝜌)/(𝑣𝑣𝑣𝑣𝑎𝑎𝑟𝑟)1/2   
(Shuck, 2000) 
 
Peptides V/E and V/K gave single species with molecular weights at 4000 
and 4000 kDA respectively (theoretical 3904, 3997), while peptide V/K-V/E gave 
primarily a single species with molecular weight of 16,281 kDA (theoretical 







Figure 12| Sedimentation Velocity Analysis of V/E, V/K, and V/E-V/K. a-c. c(s) analysis of 
V/E (a), V/K (b) and V/E-V/K at 0.6 mg/ml total peptide, showing interference fringe traces of 
the sedimentation barrier (top of each group) with respective residuals of each fit (bottom of 
each group). V/E, V/K, and V/E-V/K each show a single species, relating to monomeric V/E 




Due to limitations in detection of higher order aggregates by sedimentation 
velocity, as well as poor detection of species less than 10,000 Daltons (10 kDA) 
by sedimentation velocity alone, (Schuster, 1994) an equilibration run was 
performed using three rotation speeds based on theoretical sedimentation, 
24,000, 30,000, and 54,000, and using three concentrations for peptide V/E, V/K, 
and equimolar V/E and V/K, 0.2 mg/mL, 0.6 mg/mL, and 1.0 mg/mL.  
Sedimentation equilibrium relies on the application of centrifugal force to 
produce a distribution of species, where the flux due to diffusion and 
sedimentation are balanced. First, each species was fit to a single species model 
to estimate MB of each species. The initial assumption, based on the 
sedimentation velocity data, is that each species is either non-interacting, such 
as V/K and V/E, or the species follows a high association model, assumed with 
V/E-V/K. The molecular weight of each species is solved by the following 
equation: 






2 )   (Bryon, 1997) 
based on the concentration of species, c, at specific radii, r, the angular velocity 
ω. The calculated molecular weight, MB, or buoyant molecular weight of each 
species in given in Table VII, along with the quality of fit as determined by the 
root mean square deviation (RMSD) of the equilibration data and fit, and global 






Table VII. Single Species Analysis of Peptides V/E, V/K, and V/E-V/K 
Species MB (MW) RMSD  GBCS 
Peptide V/E 4241 (3990) 0.005422 1.175805 
Peptide V/K 4288 (3904) 0.005684 1.1292114 
Peptide V/E-V/K 15306.316 (15788) 0.005791 1.213398 
 
Minimal discrepancy was observed between the calculated MB of each peptide 
compared to the measured Mw (peptide V/E (2.51%) and peptide V/K (0.098%). 
However, to confirm that the difference between MB and MW is from in precise 
calculate of vbar and not from species aggregation, each species was assessed 
for oligomer. The species were modeled as single species of an interacting 
system (assuming Kd = 0), and then as dimer, trimer, and tetramer aggregates, 
with mass conservation. Model parameters were set based on optimization from 
the single species analysis.  The association of peptide V/E and V/K in different 











Table VIII. Equilibration Analysis of V/E, V/K, and V/E-V/K 
 RMSD of Fit 
Species Single  Monomer/Dimer Monomer/Trimer Monomer/Tetramer 
V/E 0.005684  0.005684 0.005684 0.005442 
V/K 0.005422 0.005422 0.005682 0.005281 
V/E-V/K 0.005791 0.01106 0.01836 0.004801 
 
Peptides V/E and V/K best fit monomer/tetramer self-association models out of 
oligomeric states; however, the Ka of association between species at 0.061 and 
0.524 suggested these associations are relatively weak.  
Next, varying concentrations of V/E and V/K were fit as a 
heteroassociation model, comparing formation of constructs V/E-V/E, V/K-V/K, 
(V/E-V/K)dimer, and (V/E-V/K)tetramer between species. This comparison gave a 
Kd,V/E-V/K= 1.125 x 10-10 and Kd,(V/E-V/K)( V/E-V/K) = 1.1021 x 10-10, with Ka = 1.12 and 
Kb =0.91. (Figure 13e, f) Mass conservation of the model showed no detection of 
dimers, low concentration of only one monomer, with the majority of species 
detected as the heterotetramer. Together, these data suggest that the primary 
species of an equimolar solution of V/E and V/K produces a highly stable 










Section Four: V/E-V/K Forms A Highly Stable Tetramer 
 Having demonstrated that V/E-V/K forms a tetramer with high affinity, Kd 
approx. 1 x 10-10 M, the next step was to quantify the stability. Thermal 
denaturation provides insight into the strength and stability of peptide interaction, 
 
Figure 13| Sedimentation Analysis of V/E, V/K, and V/E-V/K. a-b. Single species analysis 
with mass conservation analysis of Peptide V/E (a) and V/K (b) with fit (lines) for each 
equilibrium of the species in solution at varying rotor speed; residuals of each fit are shown 
beneath, reflecting the accuracy of the model fit. c-d. Monomer/tetramer model  with mass 
conservation analysis of Peptide V/E (c) and V/K (d) with fit (lines) for each equilibrium of the 
species in solution at varying rotor speed; residuals of each fit are shown beneath, reflecting 
the accuracy of the model fit e. Single species analysis of Peptide V/E-V/K with mass 
conservation with fit (lines) for each rotor speed for each equilibrium of the species in solution 
at varying rotor speed; residuals of each fit are shown beneath, reflecting the accuracy of the 
model fit. f. Heterotetramer model fit with mass conservation analysis of Peptide V/E with fit 
(lines) for each rotor speed, confirming the formation of a single tetrameric species with high 




(Brandts, 1970) (Privalov, 1979) determines the reversibility of the structure, 
(Bhatnagar, 2007) and the risk of aggregation. (Wang, 2005) Previous structural 
studies demonstrate the peptide V/E-V/K do not form discrete higher order 
aggregates, so this seems unlikely; however, thermal denaturation and annealing 
would determine if this occurred. To be applicable as a biomedical tool, the 
tetramer V/E-V/K cannot form aggregates; this would be demonstrated as 
reversible re-folding of the species following thermal denaturation. Denaturation 
of helical structures is assessed by changes in the CD signal at 222 nm, 
representing shifts in the npi* absorption and provides a representation of the 
helical content of the species. As the signal decreases, it reflects the loss of 
helical character. To assess thermal denaturation, 100 μM total peptide, in 1:1 
molar ratio, of V/E-V/K was heated from 10oC to 90oC. (Figure 14a) Denaturation 
was minimal at 18.2% + 0.8% unfolding at 90 oC across three runs; furthermore, 
the denaturation process was readily reversible over three temperature study 
cycles. (14b, c). Thermal runs up to 90 oC were found to have minimal impact on 
overall stability, the species could be cyclically heated and cooled without any 
change on overall stability, indicating 1) high structural stability, 2) complete 
reversibility of denaturation and stability of structure, and 3) no aggregate 
formation, as the structure did not change over time. (Figure 14b, c).   
 Significant structural data could not be obtained from thermal data, since 
no transitional change was seen in the structure of the peptide (Figure 14c). 




with guanidinium chloride (GuCl). GuCl is a strong chaotropic denaturant, which 
gives an assessment of the dependency of ionic interactions, as well as the 
stability of the hydrophobic core. (Smith, 1996) GuCl was selected as the 
denaturant over other agents (e.g., urea, propylene glycol, sodium dodecyl 
sulfate) because of its high denaturant strength and applicability in CD. To 
measure stability of the species, a thermal run was performed at each 
concentration of GuCl, from 0 M to saturation at 6M. Initial runs were performed 
as separate species, then re-run as a titration study of one species, where the 
sample was heated, and allowed to cool before addition of more denaturant. 
(Figure 14d). Peptide V/E-V/K was resistant to chemical and thermal 
denaturation, up to the maximum solubility of GuCl, 6M, and 90 oC, with only 
53.5% of the complex unfolded. (Figure 14e). Furthermore, any thermal 
denaturation observed was reversible, even with GuCl, suggesting this species 
forms a highly stable structure that does not dissociate and aggregate. (Figure 
14c).  
Normal denaturation studies calculate the ∆Gfoldingo via linear regression of 
∆Gfolding, denaturant during the transition state of denaturation. ∆Gfolding, denaturant 
during the transition stage is calculated from the free energy equation: 
eq. 11      ∆Gf =-RTln(Kf) 
where the association constant of folding from a monomer to tetramer, assuming 
the monomers are near identical is calculated as: 




where Pt is the protein concentration of the tetramer, and  αf is the folded fraction 
at each denaturant concentration, calculated as: 
eq. 13    αf = ([θ]i − [θ]U) ∕ ([θ]N − [θ]U)  
where [θ]i  is the mean residue ellipticity at 90oC for each denaturant, [θ]U is the 
mean residue ellipticity (MRE) of the individual monomers (θ=0), and [θ]N is the 
MRE of the native peptide. However, for peptide V/E-V/K, treatment with up to 
6M GuCl only induced unfolding of 25.9% of the complex, producing insufficient 
data in the transition stage. To calculate the influence of chemical and thermal 
denaturation, a modified version of the Gibbs-Helmholtz equation is applied: 




𝑚𝑚[𝐺𝐺𝐺𝐺𝐻𝐻𝐶𝐶𝑇𝑇] (Levin, 2019) 
Calculation of ∆𝐺𝐺 requires clear definition of both pre- and post-transition states, 
in order to accurately calculate the above equation. Since the post-transition 
state is not observed, even at maximum GuCl concentrations, the influence of 
temperature and GuCl could not be delineated, nor could ∆Gfo be calculated. 
Instead, ∆Gf90 at 90oC was calculated, by plotting the linear regression of ∆Gf =-
RTln(Kf) for each denaturant in the post-transition state (2M, 4M, 6M) at 90oC. 
∆Gf90 was calculated as -27.957 kcal/ mol (-6.989 cal/mol monomer) with an m-
value of 0.6278 kcal/mol2. (Figure 14e) 
Next, the stability of the V/E-V/K tetramer was assessed as a function of 
decreasing pH. Since several salt bridge residues guide specificity of the V/E-V/K 




species, it is possible that changes in pH destabilize the structure. Furthermore, 
stability of this structure in low pH environments is essential to prevent premature 
release of drug.  First, the effect of low pH on structural stability was assessed by 
CD at 10 oC, to directly investigate the effect of pH. Decreased stability, or 
denaturation, from the change in pH is measured by the change in MRE at 222 
nm, same as thermal of chemical denaturant.  Two pH conditions, pH =5 and 3, 
were assessed to reflect supraphysiological conditions. A pH less than 3 was not 
examined, to prevent complications from amide hydrolysis. A decrease in pH 
showed a mild decrease in optical signal associated with mild denaturation 
(pH=5; fD= 0.073, pH=3; fD = 0.103) (Figure 14f). Next, a thermal denaturation 
study was performed at pH 3, to assess if structural changes significantly 
destabilized V/K-V/E. Loss of stability would be reflected in loss of denaturation 
reversibility, aggregate formation, and or shifting of helical structure. The species 
was reheated and cooled twice, showing complete reversibility of denaturation. 








Figure 14| Protein Stability Analysis of Peptide V/E-V/L 
a. Circular dichroism of Peptide V/E-V/K from 10-90oC, showing effects of thermal 
denaturation with increasing temperature (dark blue to light blue). b. Repeat thermal 
studies of Peptide V/E-V/K measuring changes in Θ222 with increasing temperature. c. 
Contour plots showing complete reversibility of thermal denaturation of peptide V/E-V/K 
through two thermal cycles. d. Circular dichroism of Peptide V/E-V/K from 10-90oC 
showing changes in Θ222 in the presence of guanidinium chloride. e. Free energy plots of 
mixed thermal-chemical denaturation of peptide V/E-V/K at 90oC with varying concentration 






 Given the stability of V/E-V/K to temperature and GuCl, it was next 
important to test the strength and influence of salt bridges on the tetrameric 
structure.  Salt concentrations exert an effect on both the salt-bridge interactions 
of the protein and interaction of water molecules between the peptide, (Perkyns, 
1996) which can both stabilize the peptide, salting-in the species, and destabilize 
the peptide, salting out. (Arakawa, 1984) Information on the overall strength of 
non-covalent interactions, as well as the stability of the hydrophobic core was 
obtained from the temperature and GuCl studies, but it was important to assess 
where changes in local salt concentrations, or interaction between other charged 
species could destabilize the structure. If the structure of the species was 
dependent on the salt-bridge interactions, then this could be destabilized by 
charge-charge interactions. 
 Dialysis of the species in de-ionized (DI) water for 3 days removed any 
trace salts from production and purification of the antibody. Secondary structure 
of the species was characterized by CD, examining the structure of V/E-V/K in DI 
water with salt titration. (Figure 15a, b). In the absence of salt, no discrete 
species was observed, rather the species adopted a non-specific aggregation, 
with a minimum shifted from 208 and 222 nm to 230 nm (Figure 15a, ). The 
f. Circular dichroism of Peptide V/E-V/K showing changes in secondary structure from pH 
7.6 to pH 5 and 3.  Circular dichroism of Peptide V/E-V/K from 10-90oC showing changes in 
Θ222, comparing thermal unfolding of V/E-V/K at pH 7.6 to two consecutive runs at pH 3. h. 
Contour plots showing complete reversibility of thermal denaturation of peptide V/E-V/K 




shift in minimum and presence of opaque solution suggests that in the absence 
of salt, the peptides V/E and V/K form a disordered aggregate to stabilize 
hydrophobic interactions. (Joshi, 2015) The observed CD is consistent with 
aggregate formation, suggesting complete loss of structure. (Joshi, 2015) This 
process; however, is completely reversible- as salt is added back to the solution, 
there is a shift from 230 nm towards 222 nm, and reformation of dual minimum 
(Figure 15a). Near physiological salt concentrations, the species adopts full 
structural formation. (Figure 15a).  
 As salt concentration is increased, up to the detection limit of the cuvette 
(1 M), no change was observed in the structure or stability of the species. (Figure 
15b). This result demonstrates that the salt bridges are necessary to direct 
formation of the coil, and improve the solubility of the individual species, but are 
either not required to maintain structure formation, or for the g/e salt-bridge 
interaction, less accessible once the structure has formed.  
 
Section Five: V/E-V/K Allows Chemical Conjugation of Drug Payload 
Without Affecting Stability 
 
In order to test the applicability of peptide V/E-V/K to form a stable, non-
covalent linkage for conjugation, it was necessary to determine if the tetrameric 
structure could form with a drug linker attached. Peptide V/E was designed such 




assumed that this position is not involved in structural stability, and exists 
orthogonal to the coil; therefore, conjugation at this site should not impact 
structure stability. However, because the drug linker contains a highly 
hydrophobic peptide, it was important to assess whether or not there would be 
any effect on the tetramer. 
First, the V/E-drug-V/K was assessed for structural differences by circular 
dichroism. To prepare V/E-drug, a custom dipeptide-PABC-DM1 drug linker was 
prepared with a tyrosine reactive 4-phenyl-urazole handle (synthesis listed in 
Chapter 5). This linker was reduced to form an activated 4-phenyl-1,2,4-triazole-
dione, with 1,3-dibromo-5,5-dimethylhydantoin (DBDMH), which forms a specific, 
orthogonal “ene” reaction with the tyrosine residue. The purified V/E-peptide was 
interacted with V/K in equimolar concentration. (Figure 15c). Mean residue 
ellipticity of the structure showed 100% helical character, but a greater minimum 
at 208, with shifting at signals below 220. Given the signal contribution from this 
is affected by pipi* transitions, and the drug linker contains numerous phenylic 
groups, as well as several non-helical amide linkages which would affect this 
region, it is not surprising to see a significant change in this region. In addition to 
the shift at 208, the signal at 222 nm is higher than an unconjugated system, but 
can be explaining if the two drug linkers are taken into consideration. Indeed, the 
shifts observed in the 200-210 nm region is observed in CD spectra of aromatic 




To confirm that the changes resulted from drug linker conjugation, and not 
a change in the stability of the species, the thermal stability of the interrogated. 
Subsequent thermal studies were repeated on V/E-drug-V/K, showing similar 
trends in thermal stability (18.6% unfolded species at 90oC), and complete 
reversibility of unfolding. (Figure 15d). 
 
 
Figure 15| V/E-V/K Allows Tyrosine Modification Under Physiological Conditions 
a. Circular dichroism of Peptide V/E-V/K showing salt dependence of structure formation 
( 0 mM,  20 mM,  40 mM,  60 mM,  80 mM,  100 mM,  125 mM NaCl), with 
structure reforming between 100-125 mM NaCl. b. Circular dichroism of Peptide V/E-V/K 
showing salt stability of structure formation ( 125 mM,  200 mM,  400 mM,   600 
mM,  800 mM,  1 M NaCl), with no change in structure observed up to 1M NaCl. c. 
Circular dichroism of Peptide V/E-drug-V/K showing secondary structure of the species, 
reflecting addition of drug linker contributing a signal shift around 200-220 nm. d. Thermal 
stability of Peptide V/E-drug-V/K showing helical character at 222 nm from 10oC to 90oC; 




Section Six: Discussion 
Expanding on previous work to show helical tetrameric selectivity 
(Fairman, 1996) (Fletcher, 2012) (Crooks, 2016), I evaluated the selectivity of a 
G/E’ buried hydrophobic interaction, hoping to 1) increase tetrameric strength, 2) 
prevent tetrameric salt denaturation, and 3) maintain high selectivity. Varying this 
G/E interaction shows that valine-valine interaction is optimal for this pairing, 
while leucine and isoleucine disrupt coil formation at the E and G position 
respectively. Similarly, leucine in the G and isoleucine in the E leads to helical 
structure formation, which significantly limits the stability of heterospecies 
formation. Taken together, these data suggest that in order for the A and D 
position of the heterohelix to adopt a close packing structure, the residues in the 
buried G/E position must be small. Valine, with the smaller isopropyl group, 
provides less instability at this position than leucine or isoleucine, although a 
pairing can occur if valine in the G position packs with isoleucine or leucine in the 
E position. Therefore, size, not the branching of the hydrophobic group, plays the 
most significant factor if packing occurs with three hydrophobic residues per 
heptad.  
In addition to determining the impact of varying hydrophobic residues at 
the buried G/E interaction position, the relative importance of the salt bridges in 
stabilizing and providing specificity for this structure can be examined. Despite 
the energetic favorability of “shielding” the hydrophobic residues from the water 




V/K. These species did not show signs of aggregation by circular dichroism, nor 
did they show sedimentation of higher order structures by sedimentation velocity 
or equilibrium scans. Combined with the circular dichroism data for isoleucine 
and leucine, this result suggests that because the valine-valine interaction does 
not significantly disrupt close packing of the helical tetramer, but rather helps to 
increase stability, that the close G’/E salt bridge interactions, and B/C interactions 
continue to serve as repulsive forces preventing V/E-V/E interaction and V/K-V/K 
interaction. This is supported by sedimentation equilibrium data, which predicts a 
very weak self-association between species, but fits best to a repulsive model 
between the structures. This repulsion is seen in stark contrast to the high 
association and stability of the tetramer of V/E-V/K, evidenced by the sub-
nanomolar Kd, resistance to thermal and GuCl denaturation, and minimal 
detection of monomeric species, which could represent contamination or 
imprecision in measuring samples. Indeed, the rapid, strong association between 
V/E-V/K, which is not evidenced in monomeric homomeric self-assembly, 
suggests that coulombic repulsion between acid-acid residues and basic-basic 
residues. This finding further suggests that in a model where I fixed the a and d” 
position to form parallel coiled coil tetramers, the occupation of the G/E’ and G’/E 
position is important for determining both strengths, and maintaining the proper 
configuration of the A/D interaction.  
Although only V/E-V/K was fully interrogated, it is of note that no other 




there is not a significant effect from valine altering the “register” of the heptad. 
Likewise, because of the size of valine, salt bridges seem to properly form; the 
relative strength contribution from a buried salt bridge (around 4 kcal/mol) 
compared to 1.1 + kcal/mol for the CH2 groups buried in the folding, indicates 
that in addition to the repulsion from the B/C interactions, the non-hydrophobic 
G/E interaction helps maintain specificity. (Joh, 2009) Likewise, since valine 
increases the number of buried CH2 groups vs. alanine, while not destabilizing 
formation of the tetramer, it suggests that this is the optimal interaction at this 
sequence.  
Interaction strength and stability of V/K-V/E, therefore, is highly dependent 
on the number of buried CH2 groups in the hydrophobic core, composed of the 
interaction between leucine, isoleucine, and valine. The stability of the 
hydrophobic core is evidenced by resistance to denaturation; saturation of the 
solution with GuCl should disrupt the packing of the hydrophobic core; however, 
the high stability of this packing, evidenced by the sum of -CH2 packing without 
disruption of oligomeric state, provides a significant energy barrier to overcome. 
Furthermore, the core packing contributes to the majority of the stability, as 
lowering the pH, which should destabilize the salt-bridge G/E interaction, did not 
significantly denature the coil. While unfolding was observed when the pH was 
dropped to pH = 3, the result was a weaker effect than 6 M GuCl with thermal 
denaturation. However, in the absence of salt, no structure was formed. This 




important for maintaining the specificity of the species, contributing a portion to 
the overall stability, but primarily in stabilizing the monomers in water to allow 
tetramer formation, as monomers could not interact in the absence of salts, and 
guiding specificity.  
Overall, the applicability of this technique to biomaterial protein 
modification is well demonstrated. In addition to the high stability of interaction, 
high affinity binding, and sequence specificity, one of the peptide pairs, V/E, can 
be functionalized with a drug linker, without disrupting the ability of both peptides 
to form a helical structure. The exact nature of the species is difficult to resolve 
based on the secondary structure alone, as the drug linker contains multiple 
aromatic residues, with a molecular weight equal to approximately ¼ of the 
monomer; therefore, contributions to the tetramer is non-significant. However, 
since the species does show equivalent resistance to thermal denaturation, it is 
likely that the changes from 200-210 nm are from signals generated from the 
linker, which is consistent with other biomaterial-drug conjugations. (Chang, 
2012) Furthermore, no aggregate species are observed for the tetramer, it 
continues to form in 1:1 molar ratio, and demonstrates equivalent biomolecular 
characteristics. 
Therefore, this conceptual approach to de novo structure development 
meets the desired criteria set forth: two sequence specific peptides that are 
capable of: 1) forming a single oligomeric state, a tetramer, 2) highly specific for 




and supraphysiological ranges, and 6) capable of carrying a drug loaded linker. 
The successful characterization of this species supports the initial model, as 
defines an optimal sequence interaction under this design.  
 
Section Seven: Methods 
Synthesis of Peptide Sequences: Peptide sequences were prepared by 
Abclonal using solid phase synthesis; peptides were synthesized from Fmoc-
protected amino acids on a resin support. Formed peptides were cleaved and 
purified by RP HPLC with 5% NH3 H2O, 8% Acetonitrile, 87% Water 
(Chromatograms and HPLC-LCMS verification in Appendix Figure 5) 
Circular Dichroism Experiments: Peptides were prepared as 100 μM 
monomeric solutions in Tris-buffered saline (TBS) pH 7.6; a 1 mm QS 100 
(Hellma) cuvette was used to collect samples. Samples were run on a CS/2 
Chirascan (Applied Photophysics) CD spectrometer; blanks were run in 5 
replicates, samples were equilibrated at 10oC and run as 5 replicates. Circular 
dichroism was measured in mDeg, and background corrected samples were 
converted to mean residue molar ellipticity (MRE, ϴ) using the following formula:  
eq. 15    ϴ = m°*M/(10*L*C) 
where mo is the signal in millidegrees, L is path length of the cell, and C is the 
concentration in g/L. 




Thermal Studies: Peptides combinations were run as total 100 μM of monomers 
on a temperature ramp from 10oC to 90oC (maximum of the instrument), at 1oC/ 
min, with scans collected every 5oC. Samples were background corrected. For 
repeat studies, the instrument was allowed to cool to starting temperature; after 
cooling, a single CD run was performed to confirm no artifacts were present from 
heating, then thermal study was repeated.  
Denaturation Studies: Peptides combinations were run as total 100 μM of 
monomers with increasing GuCl (Sigma, cat#: 50933). Samples were 
equilibrated for 10 minutes prior to each thermal scan.  
pH studies: Peptides were dissolved in pH adjusted TBS at 100 μM of 
monomers, and run as 5 replicates against background (5 replicates). 
Salt studies: Peptides were dialyzed against DI water for 72 hours (6 dialysis 
volumes of 2 L to 4 mg total peptide). Samples were run at maximum 
concentration of tetramer (30 μM monomer), with increasing NaCl (Sigma, 
S7653) concentration. Samples were equilibrated for 5 minutes before each 
scan, and run as 5 replicates against background.  
Analytical ultracentrifugation: Sedimentation equilibrium (SV) and 
sedimentation velocity (SE) experiments were performed using six-centerpieces 
with interference optics, on a  , respectively, in a Beckman XL-I. Samples for SV 
experiments were run at 40,000 rpm at 20oC using 0.6 mg/ml total peptide in 
TBS; SE experiments were run at 24,000, 30,000, and 45,000 rpm at 20oC using 




(Schuck, 2000) with a continuous c(s) distribution model. SE data was analyzed 
using Sedphat (Vistica, 2004) (Balbo, 2005) (Dam, 2005) (Dam 2005) (Schuck, 
2005) (Houtman, 2007) with single-species non-interacting fits, monomer-dimer, 
monomer-trimer, and monomer-tetramer fits, and heterotetramer fits.  
Temperature-corrected partial specific volumes (V/E= 0.7462 mL g−1; V/K = 
0.7999 mL g−1; V/E-V/K = 0.7620 mL g−1), solution density (1.00586 g mL−1), 



































CHAPTER FIVE: DEVELOPMENT OF A NOVEL ADC FOR PDAC 
Section One: Application of Supramolecular Assembly to ADC 
Development 
 Pancreatic ductal adenocarcinoma, PDAC, represents a significant 
challenge in the field of cancer development. With a dismal 5-year survival of 
8.5% (2% in stage IV), (SEER, 2018) PDAC reflects a highly aggressive disease 
that is resistant to most treatment options. (Loewenstein, 1978) Treatment failure 
in PDAC correlates to limitations in drug delivery, poor specificity of drug targets, 
and redundancy of oncogenic pathways. (Oberstein, 2013) Targeted therapies 
also show limited benefit. (Moor, 2007) (Schultheis, 2017) Past clinical trials in 
PDAC demonstrated limited efficacy in systemic chemotherapy (Makielski, 2015) 
(Lee, 2017) and in targeting singular pathways, (Assenat, 2015) (Ko, 2016) thus 
highlighting the need for effective, targeted, combination therapy. (Makielski, 
2015) (Lee, 2017) 
Antibody drug conjugates, ADCs, are an attractive potential 
pharmacological solution to the limitation of current PDAC treatment options. 
ADCs provide targeted, combination chemotherapy through the recognition of 
tumor-specific antigens and through the effective conjugation and “weaponizing” 
of antibodies, thereby increasing the therapeutic efficacy of the antibody and 
therapeutic window of the payload.  By targeting tumor specific antigens, ADCs 




theoretically avoid off-target toxicity. Efficacy in ADCs is correlated to the 
specificity of the tumor antigen, necessitating better understanding of PDAC cell 
biology, as well as conjugation efficacy and stability of the toxic payload. The 
theoretical therapeutic window of ADCs surpasses most other treatment 
modalities, and therefore provides a promising treatment option for patients with 
advanced stage and metastatic disease. 
 The application and success of ADCs requires effective, complete 
targeting of all virulent tumor cells. It is unlikely that a single specific target is 
responsible or sufficient to arrest cancer progression, and equally unlikely that a 
single ADC, even applying a highly specific receptor and effective payload, is 
sufficient to abrogate the malignant process. Rather, the application of several, 
non-redundant, synergistic targets is necessary to achieve sufficient coverage of 
all cells involved in the malignant process. This underlying theory, “Pattern 
Recognition Tumor Targetting”, (Glazier, 2006) can be capitalized through the 
development of several highly specific ADCs that are given in concert. Each ADC 
offers the potential to effectively target two non-redundant pathways, i.e. antibody 
mediated and drug mediated; therefore, two to three ADCs, targeting four to six 
specific patterns, may be sufficient to effectively treat cancer. (Glazier, 2006) If a 
set of ADCs is designed such that target specific to tumor cells, this set could be 
given in concert, with significantly less toxicity compared to systemic combination 
therapy currently employed, and provide sufficient theoretical coverage of tumor 




 Limitation in the applicability and practicality of ADCs arises from both the 
lack of effective tumor targets and poor methods of conjugation. (Lambert, 2017) 
Non-ideal drug loading, premature drug release, destabilization of the antibody, 
and non-uniform drug loading significantly impact the efficacy and toxicity of 
ADCs in vivo. (Lambert, 2017) Developments of ADCs in PDAC are showing 
some promise; (Almhanna, 2016) (Gallery,2018)  however, they employ older, 
less sophisticated methods of conjugation, which rely on non-specific cysteine 
conjugation, which destabilize the antibody, lack uniformity, and are susceptible 
to premature release from retro-Michael addition. (Lambert, 2017) Rather than 
employing or focusing on novel methods of conjugation, which could improve 
overall efficacy, a significant focus is paid to the development and verification of 
novel receptors, relying on better target recognition. While useful, the focus 
solely on novel targets ignores serious limitations in non-specific cysteine 
conjugation, as well as ignoring the significant progresses made in site-specific 
conjugation. (Kirsche, 1995) (Thompson, 2011) 
 In order to develop a more effective ADC, which maximize an antibody’s 
potential for drug delivery, a combined approach is undertaken: a novel tumor 
receptor is identified and combined with a novel method of site-specific 
conjugation. Using this rational drug design approach, I selected DEspR as the 
target. In order to produce an ADC with site-specific, tunable, and uniform 
conjugation, I employed the principles of supramolecular assembly. A peptide-




C-terminus. A set of 31-mer peptides was designed to form a specific, uniform 
coil-coil structure only in the presence of its partner. This allows the docking 
sequence to be appended to the C-terminus of the antibody, and remain inert 
until its partner, the receiving sequences, is present in solution. The receiving 
sequence is selectively functionalized, relying on a site-specific tyrosine 
conjugation method, to allow tuneability conjugation to meet target demand. The 
drug linker to the receiving sequence is designed such that any drug, as long as 
it possesses an alkyl alcohol, thiol, or amine, can be conjugated to the drug-
carrying peptide. This drug loaded receiving sequence is purified, removing any 
harmful trace chemicals, a prior before facile conjugation to its partner on the 
antibody to form the ADC. 
 By developing a highly stable, unique coupling pair, a supramolecular 
assembly approach acts like a covalently linked species, without the need for 
direct covalent conjugation. The stability and specificity of this interaction ensures 
that the conjugation occurs rapidly, under mild conditions, and produces a 
uniform species, as 1) the unconjugated monomers were significantly less 
energetically favorable than the tetrameric species, and 2) the unconjugated 
monomers were highly specific for their respective pair. The simplicity of this 
system provides the opportunity to generate functionally active, diverse ADC 
species that minimally impact the antibody and provide maximal ADC efficacy.  
 Here the individual components of the ADC, with rationale linker design, 




design, an ADC was developed which had equivalent binding and internalization 
characteristics to the antibody, but was target specific and highly effective in 
PDAC cancer subtypes. This approach underscores potential site-specific 
methods for conjugation which can significantly improve ADC efficacy and be 
applied to the development of new, more effective species.  
 
Section Two: Synthesis of a Tyrosine Specific Linker 
 The current standard in ADC linkers is the dipeptide linker with a self-
immolative spacer, based on Seattle Genetic’s brentuximab Vedotin. (Pro, 2012) 
The benefit of this linker design is the combination of high plasma stability paired 
with the favorable release characterizations following internalization, and release 
of non-charged drug, which allows effective killing of bystander receptor negative 
cells. (Drake, 2017) Currently, the only FDA approved ADC for solid tumors is 
ado-trastuzumab emtansine, a DM1 conjugated ADC approved for treatment 
refractory breast cancer. (Amiri-Kordestani, 2014) Based on the linker efficacy 
and application of DM1 in a solid tumor, the goal was to design a dipeptide drug 
linker carrying DM1 with a self-immolative spacer. Since the conjugation method 
employed requires the drug linker to react specifically with tyrosine, two 
significant modifications to the dipeptide linker are required, as discussed below. 
First, rather than using a maleimide at the N-terminus of the linker, a 
tyrosine reactive functional group is used. For this, a 4-phenyl-3H-1,2,4-




dienophiles, which undergo Diels-Alder reactions. (Cookson, 1962) PTADs are 
formed from the reduction of the urazole nitrogen bond of 4-phenylurazole 
derivatives, generating a highly reactive species. PTADs show excellent 
selectivity to tyrosine groups, forming a stable adduct at the ortho position in an 
“ene” reaction, which is resistant to acid or base catalyzed hydrolysis. (Ban, 
2013) Commonly employed bioconjugation techniques to connect PTAD groups 
to other chemical structures rely on alkyne-azide cycloaddition copper click 
chemistry, forming a triazole linkage. (Ban, 2013)  A concern was raised that 
forming the triazole group could affect cathepsin B recognition and cleavage of 
the sequence, compared to the less bulky amide linkage employed in the 
brentuximab vedotin linker. Ideally, the linkage between the PTAD group and the 
dipeptide sequence would be an amide bond, mimicking the linkage employed in 
other dipeptide linkers; however, effective coupling by this method has not been 
successfully employed. (De Bruycker, 2016) To achieve this, a new PTAD 
derivative needed to be synthesized, which allow amide bond formation with the 
N-terminal amine of the dipeptide.  
Second, the brentuximab vedotin linker employs a carbonate linkage 
between the PABC spacer and the drug, identical to the dipeptide-PABC-
doxorubicin linker it is based on. (Dubowhick, 1998) By using DM1 instead of 
MMAE, an S-thiocarbonate linkage is formed instead. This provides some 
advantages, as based on differences in bonding orbital overlap between the O-C 




elimination, improving drug release following internalization. (Roling, 2015) 
Again, this requires a new synthetic approach. Expanding upon this, the goal is 
to design a synthetic route and mechanism to allow mixed carbonate, S-
thiocarbonate, and carbamate linkers to allow diverse linker functionality. 
Achieving this enables the production of diverse chemical linkers to prepare 
multiple ADCs with different payloads. Based on this design criteria, the linker 
was rationally designed as outlined in Figure 16. 
As stated previously, limited success has been made in forming an amide 
linkage between PTAD or 4-phenylurazoles (the oxidized form of PTADs) and 
other chemical structures. (Mallakpour, 2004) The limiting factor of this reaction 
is the production of an unwanted side-product, which is the mono- or di-acylation 
of the urazole by an acid or activated acid intermediate.462 The cyclic amides of 
the urazole are more acidic than normal amides, having an equivalent pKa to 
 
 
Figure 16| Drug Linker. Overall structure of the drug linker showing tyrosine reactive 4-
phenyl-urazole group (reduced to PTAD) (blue), dipeptide sequence (L-valine-L-citrulline) 




most carboxylic acid (urazole pKa≈ 4). (De Bruycker, 2016) The equivalent acidic 
character of the amide and carboxylic acid hydrogen is sufficient to lead to 
acylation via deprotonation of urazole hydrogen, followed by nucleophilic acyl 
substitution at the carboxylic acid carbonyl. This limitation has prevented 
successful amide bond formation of carboxylic acid 4-phenylurazole derivates, 
because of self-acylation, producing difficult to separate byproducts which cannot 
form activated PTADs. (De Bruycker, 2016) The only reported synthesis of an 
amide bond from a 4-phenylurazole functionalized carboxylic acid is the reaction 
of ammonia with an acetic acid derivative of 4-phenyl urazole. (Stueber, 2001) 
Conjugation was successful when an amine functionalized 4-
phenylurazole reacted to an activated carboxylic acid, (Reidel, 1995) or acyl 
chloride (Movassagh, 2010); however more neutral conditions were required, as 
stronger bases lead to acylation 
byproducts. Unfortunately, based on the 
desired release mechanics of this linker, 
an amide bond could not be formed in 
this manner, nor did I want to form a 
mixed carbamate linkage or urea linkage. 
In order to avoid using azide-alkyne click 
chemistry, and to form a linker with a more accessible dipeptide linkage, a new 4-
phenylurazole derivative was synthesized.  
 
 




To produce a more reactive acid, which should favor amide bond 
formation over acylation, a phenoxyacetic acid, rather than a phenylacetic acid 
was selected (Stueber, 2001) (Figure 17). Inductive effect from the mixed ether 
on the acid carboxyl will likely increase the acidity of the terminal acid, providing 
one log order greater acidity compared to the urazole hydrogens, based on 
structural predictions (ChemDraw). To accomplish this, a six-step synthesis, 
beginning with paracetamol, was accomplished (Scheme 1). Synthesis afforded 
the 4-phenoxyacetic acid urazole in high overall yield (60%), with excellent purity. 
(Structural Characterization in Appendix Figure 6). This 4-phenyl urazole 
underwent high yield (> 80%) amide coupling with the dipeptide linker under 
neutral coupling conditions with 2-ethyoxy-1-ethoxycarbonyl-1,2-dihydroquinoline 
(EEDQ), forming the desired product and the carbamate byproduct as the only 










Scheme 1| Synthesis of 2-(4-(3,5-dioxo-1,2,4-triazolidin-4-yl)phenoxy)acetic acid. 
Synthesis is performed in six steps from paracetamol. Synthesis was accomplished with a 





             
         





Synthesis of the S-thiocarbonate linkage could be prepared by activation 
of the thiol to form an activated S-thiocarbonate with 4-nitrophenyl chloroformate, 
followed by conjugation with the dipeptide-PABC spacer using triethylamine, or 
by a one-pot reaction with triphosgene. (Deer, 2010) The former is applicable in 
the development of mixed carbonate linkers, where difference in nucleophilicity 
between both alcohol groups require two separate steps. By activating one 
alcohol to form an activated carbonate, the final linker is isolated in low yields 
(10-20%). The latter method is ideal for the formation of carbamates and S-
thiocarbonates, relying on the greater nucleophilicity of the thiol or amine, and 
leads to faster, more conserved, and higher yields reactions. When forming S-
thiocarbonates, the reaction proceeds by formation of the dithiocarbonate, via 
fast addition of the thiol first, followed by nucleophilic acyl substitution by the 
benzyl alcohol.  
Synthesis was accomplished by preparing the dipeptide Fmoc-L-valine-L-
citrulline-PABC linker as previously described. (Stueber, 2001) Direct conjugation 
of DM1 to the linker was performed by triphosgene coupling, following 
deprotection, and neutral amide formation with EEDQ (Scheme 2).  The linker 
was successfully synthesized and characterized by NMR studies. (Appendix 











Scheme 2| Drug Linker Synthesis. Synthesis of drug linker was accomplished in 6 steps. 
Preparation of the drug linker was accomplished by two-step synthesis of the dipeptide L-
valine-L-citrulline linker, followed by EEDQ coupling of PABOH. S-thiocarbonate linkage 
was performed via a one-step triphosgene coupling. After deprotection, amide coupling 




Section Three: Preparation of ADC 
 
 To generate the anti-DEspR ADC, a murine antibody targeting epitope 1 
of the DEspR extracellular domain, 7c5, was selected. This antibody was 
selected because using a fully-humanized antibody would produce a significant 
host response, leading to auto-antibody production and sequestration by the 
reticuloendothelial system, based on results from multi-dose treatments with the 
hu-6g8 antibody (Appendix Figure 3a-c). In the setting of an ADC, this is 
significantly problematic, as host-antibody response from a humanized antibody 
in rats will significantly elevate toxicity not related to the ADC and not reflective of 
clinical application. The 7c5 antibody, having shown efficacy in multidose 
treatments, and produced in higher yield than a murine antibody binding to 
epitope 2, was therefore selected.  
Modification of the V/E peptide was prepared by site specific “ene” 
coupling of the activated PTAD group to the ortho position of the tyrosine with 
either the drug linker, or a short tyrosine reactive fluorophore. Activation of both 
the drug linker and fluorophore was prepared by reaction with 1,3-diromo-5,5-
dimethylhydantoin to form a bright red solution, indicating successful reduction. 
The linker was reacted with peptide V/E in 10-fold excess to allow conjugation. 
The conjugated peptide was purified by serial dialysis, and the drug-conjugated 
V/E, V/E-DM1, and fluorophore-conjugated V/E, V/E-AF488, were analyzed by 




 Preparation of the antibody was accomplished by site-specific modification 
of a dual C-terminal label, recognizing sortase A and streptavidin. The small 
appended sequence included on C-terminus, LPETGGWSHPQFEK, is 
recognized by Sortase A, allowing ligation of the LPTEG sequence and a 
pentaglycine peptide, removing the GWSHPQFEK recognized streptactin 
sequence. (Chen, 2016) Use of a modified pentamuntant sortase allowed 
effective conversion of 60-68% of starting antibody following rProtein A recovery 
of the antibody and removal of unreacted antibody via double purification with 
Streptactin-binding columns. The purified antibody was reacted with V/E-DM1 or 
V/E-AF488 in slight molar excess of the V/E peptide for 20 minutes at 4oC, 
followed by rProtein A column purification and dialysis of unreacted peptide. 
(Figure 18 deaf) Verification of the purified antibodies was obtained by HPLC 
(Figure 18 d,e,f). UV-Vis analysis showed near complete conversion of the 
modified antibody into the complete ADC (A280 1.74, A252 = 1.05, ADR: 2.00), or 
antibody fluorophore conjugate, AFC (A280 = 1.08, A494 = 0.69, AFR = 1.98), 
consistent with HPLC data. 
Conjugation showed near complete conversion (within the range of 











Figure 18| HPLC Analysis of 7c5-ADC and 7c5-AFC. a. Representation of antibody 
conjugation, with C-terminal V/K (blue) and conjugated V/E (purple) forming a stable 
tetramer in the C-terminus. b. HPLC traces of V/E () and V/E-DM1 () at 280 nm 
absorbance, showing separation of drug loaded peptide. c. HPLC traces of V/E () and V/E-
488 (), showing separation of the fluorophore loaded peptide. d,e HPLC traces showing  
7c5 () and 7c5-ADC () at 250 nm (d) and 280 (e) Absorbance. f. HPLC traces of 7c5-









Section Four: Conjugation Method Does Not Affect Binding 
Subsection 4.1: Direct Binding to Antigenic Sequence 
 
 A major limitation in the development of ADCs is undesired conjugation at 
or near the antigen binding region disrupting or altering binding of the antibody, 
and thus decreasing binding affinity or increasing off-target binding. (Beerli, 2015) 
Use of a site-specific, C-terminal method of conjugation was selected to avoid 
any potential interference with binding. Approaches in C-terminal conjugation 
have shown minimal impact on binding, suggesting that modification at this site is 
ideal for ADC generation. (Beerli, 2015) (Chen, 2016) To compare any changes 
to the antigen binding region caused by conjugation, the ADC, 7c5-ADC and 
AFC, 7c5-AFC, were compared to the native antibody, 7c5, and the antibody with 
the coiled coils attached, 7c5-cc. Binding to the antigen sequence recognized by 
the 7c5 antibody (Figure 19a), was compared for all species (Figure 19b). 
Binding of 7c5-ADC and 7c5-AFC was equivalent to the native antibody (Kd,7c5-
ADC: 8.81 μg/mL Kd,7c5-AFC: 8.51 μg/mL vs Kd,7c5: 8.68 μg/mL)  
Subsection 4.2: Binding to PDAC and Normal Cells 
 Next, direct cell binding was assessed. To compare the effect of 
conjugation, and prevent confounders from double labeling, the AFC was 
compared to a commercially labeled 7c5 (conjugation to lysine via activated NHS 
ester AF-488) (7c5-AF488). Binding was assessed in four PDAC cell lines, 
Panc1, MIA PaCa2, Capan-1, and BxPC-3, selected for specific KRAS 




assessed at 60% confluence. (Byun, 2019) (Figure 19c-e). Binding of the AFC 
was equivalent to the 7c5-AF488 antibody across the three cancer cell lines 
(Panc1: 43.2% + 2.2% vs. 40.4% + 4.3%, MIA PaCa2: 60.0% + 3.5% vs. 59.4% 
+ 7.9%, BxPC3: 61.9% + 3.2% vs. 60.9% + 4.3%) and higher in Capan1 cell lines 
(40.6% + 0.5% vs. 31.0% + 1.0%). Next, four human noncancer cell lines were 
assessed: H6c7 (pancreatic acinar cells), HUVEC (endothelial cells), KV-2 
(kidney cells), and BJ (fibroblasts). (Figure 14g-j). Binding of the AFC was 
equivalent to the 7c5-AF488 antibody in two cell lines (HUVEC: 0.0% + 0.0% vs. 
0.0% + 0.0% and KV-2: 0.0% + 0.0% vs. 0.0% + 0.0%), and less in two normal 








Figure 19| Comparison of Binding of 7c5-ADC, 7c5-AFC, and 7c5 Antibody. a. 
Representation of DEspR extracellular domain, showing 7c5 binding domain (Epitope 
1). b. Binding of 7c5 , 7c5-cc , 7c5-AFC , and 7c5-ADC  to the antigen 




 Subsection 4.3: Internalization in PDAC and Normal Cell Lines 
 Binding of the AFC to the antigenic sequence of epitope 1 was equivalent 
to the 7c5 antibody, and binding of the AFC was equivalent in three PDAC 
cancer cell lines, higher in one PDAC cell line, and either equivalent or lower in 
normal cell lines. This profile suggested good preservation of binding; therefore, 
further investigation of the ADC was warranted. It was important to assess that 
the ADC, or AFC, was internalized and that following internalization, underwent 
lysosomal degradation to release the free drug. To avoid potential cofounders the 
AFC was used in internalization studies. Internalization of the AFC was 
compared in four PDAC cell lines, Panc1, MIA PaCa2, Capan-1, and BxPC-3, 
and two non-cancerous cell lines, H6c7 and mIMCD. H6c7 was selected as the 
normal acinar cells were DEspR positive, and it was important to assess if the 
AFC would be internalized. mIMCD cells, which are murine collecting duct cells, 
were assessed because these cells: 1) express low DEspR expression (< 10%) 
recognized by hu-6g8 but not 7c5, and 2) are not recognized by 7c5, and 
internalization would indicate either non-specific internalization, alteration of the 
binding site, or dissociation of V/E-AF488. 
μg/ml, Kd,7c5-ADC = 8.81 μg/ml. c-f. FACs binding showing binding of AFC (top, green) vs. 7c5-
AF488 (bottom, green) compared to isotype control (black, dashed) in PDAC cell lines: c. 
Panc1 (43.2% + 2.2% vs. 40.4% + 4.3%), d. MIA PaCa2 (60.0% + 3.5% vs. 59.4% + 7.9%), 
e. Capan-1 (40.6% + 0.5% vs. 31.0% + 1.0%) f. BxPC-3 (61.9% + 3.2% vs. 60.9% + 4.3%). 
g-j. FACs binding showing binding of AFC (top, green) vs. 7c5-AF488 (bottom, green) 
compared to isotype control (black, dashed) in human control cell lines: g. H6c7 (24.6% + 
0.6% vs. 52.3% + 1.4%), h. HUVECS (0.0% + 0.0% vs. 0.0% + 0.0%), h. KV-2 (0.0% + 0.0% 




 Internalization of the AFC was significant in all PDAC cell lines (Figure 
20a-h), showing uptake of the AFC by 15 minutes, and colocalization with the 
lysosome by 15 minutes, with a significant increase in colocalization with the 
lysosome at 4 hours, suggesting lysosomal trafficking of the AFC. This confirms 
use of a dipeptide drug linker, which would be degraded following colocalization 
with the lysosome. Binding of the AFC was observed in H6c7 cells, but 
internalization was not observed (Figure 20i, j). Nor was signal detected in 
mIMCD cell lines (Figure 20k, l). Lack of internalization in the receptor positive 
H6c7 cell line is strange, receptor positive cells show internalization of the AFC.  
This may suggest a difference in receptor trafficking and internalization 
compared to cancer cells, or may represent a lower total number of receptors, 



















Figure 20| Internalization of 7c5-AFC. Comparison of 7c5-AFC () internalization 
and colocalization with lysosome () in Panc1 cells at 15 minutes (a) and 4 hours (b), 
MIA PaCa2 cells at 15 minutes (c) and 4 hours (d), BxPC-3 cells at 15 minutes (e) 
and 4 hours (f), Capan-1 cells at 15 minutes g) and 4 hours (h), H6c7 cells at 15 
minutes i) and 4 hours (j), and mIMCD cells at 15 minutes k) and 4 hours (l). Nuclear 





Section Five: 7c5-ADC Is Highly Effective In PDAC Tissue 
Subsection 5.1: Cytotoxicity of 7c5-ADC in PDAC cell lines 
 The 7c5-AFC and 7c5-ADC demonstrated equivalent binding to the 
antigenic peptide compared to the native 7c5 antibody, and the 7c5-AFC showed 
near equivalent binding to several PDAC cell lines, and equivalent or lower 
binding to normal cell lines compared to the 7c5-AF488 antibody. Furthermore, 
significant internalization of the 7c5-AFC was observed in PDAC cell lines, but 
not normal cell lines, suggesting that the 7c5-AFC should be effective at targeting 
PDAC cells. To assess efficacy, the cytotoxicity of 7c5, 7c5-cc, 7c5-ADC, and 
free mertansine were compared in Panc1, MIA PaCa2, Capan-1, and BxPC-3 
cell lines after 72 hours of treatment with either agent. (Figure 21). Cytotoxicity at 
72 hours was selected to keep measurements consistent across all cell lines, 
despite differences in doubling times.  The 7c5-cc, representing the coiled coil 
structure appended to 7c5, did not show an increase in cytotoxicity compared to 
7c5 in Panc1, MIA PaCa2, BxPC-3, and Capan-1 (Figure 20 a, b, e, f). The 7c5-
ADC showed a significant improvement in maximal cytotoxicity compared to the 










Table IX. Comparison of Efficacy of 7c5-ADC to 7c5 in PDAC Cell Lines 
 IC50 
Cell Lines 7c5-ADC 7c5-ADC 
Panc1 38.6% + 5.9% 8.819 + 2.063 μg/ml 
MIA PaCa2 0.9% + 0.3% 3.343 + 0.424 μg/ml 
BxPC-3 11.8% + 2.2% 7.646 + 0.770 μg/ml 
Capan-1 30.5% + 9.4% 13.88 + 2.97 μg/ml 
 
 
Cytotoxicity of 7c5-ADC was significantly higher than expected if no bystander 
killing effect occurred. Based on receptor expression in PDAC cell lines (Panc1: 
43.2% + 2.2%, MIA PaCa2: 60.0% + 3.5%, BxPC-3: 61.9% + 3.2%, and Capan-
1: 40.6% + 0.5%), viability at 72 hours of 7c5-ADC in PDAC cell lines would be 
expected to be 56.8%, 40.0%, 38.1%, and 59.4% in Panc1, MIA PaCa2, BxPC-3, 
and Capan-1 respectively. Assuming 1) all receptor positive cells are dead at 72 
hrs, and 2) receptor expression is non-dynamic over the course of therapy, 
bystander efficacy can be approximated by calculating the number of receptor 
negative cells dead based on the difference between theoretical receptor 
negative cell viability at 72 hrs and observed cell viability: 
 










where 𝑓𝑓𝐷𝐷𝐷𝐷𝑜𝑜𝑝𝑝𝐷𝐷𝑛𝑛𝑜𝑜𝐷𝐷0  is the number of DEspR negative cells and 𝑓𝑓𝐷𝐷𝐷𝐷𝑜𝑜𝑝𝑝𝐷𝐷𝑛𝑛𝑜𝑜𝐷𝐷72  is cell 
viability at 72 hours. While non-ideal, this approximation is relevant in several 
models470 and gives a representation of the efficacy of bystander activation. 
Since bystander efficacy is complicated by the distance between cells (adjacent 
populations of receptor negative vs. receptor positive will benefit more than 
distant populations), and rate of efflux, kout, vs. influx, kin, it must be thought of an 
aggregate effect of ADC internalization, linker degradation, diffusional constants 
of the drug, and hydrophobicity of the target drug. (Thurber & Weissler, 2011) A 
representation of the efficacy of a drug to improve bystander killing is the 
Damköhler number, Da (Pruijn, 2008): 





which provides an understand of drug diffusion based on the drug diffusion rate, 
kin,p, radius of the tumor, R2Krogh, the void cell fraction, 𝜀𝜀𝑝𝑝, and the payload 
diffusion coefficient, Dp. For DM1, Dp is 9.8 μm2/s. Mertansine slow local 
diffusion, Da = 3.22, and poor exchange with the extracellular environment. 
(Pabst, 2017)  For ADC in vivo development, this is ideal; however, for in vitro 
treatment of a cell line with heterogenous expression, bystander killing will be 
impacted by the clustering of receptor positive/ receptor negative cells, cell 
density, and by extracellular matrix. For PDAC cell lines, bystander killing effect 




MIA PaCa2, 69.0% for BxPC-3, and 48.7% for Capan-1. These results correlated 
well with relative collagen production and cell division of cell lines. 
 Cytotoxicity of the 7c5-ADC was also compared to free mertansine in 
Panc1, MIA PaCa2, Capan-1, and BxPC-3 cell lines to determine if cytotoxicity 
was specifically from ADC internalization and lysosomal degradation, or by 
premature linker release.  Cytotoxicity between the ADC and mertansine was 
significantly different, with the ADC showing less potency and a higher 
concentration needed to kill equivalent cells, consistent with bystander killing 
from ADC internalization and degradation. (Thurber, 2011) (Figure 20, c, d, g, h). 
A comparison of the 7c5-ADC to free mertansine is given in table X.  
 
Table X. Comparison of Efficacy of 7c5-ADC to Mertansine in PDAC Cell 
Lines 
 IC50 
Cell Lines 7c5-ADC DM1 
Panc1 117.1 + 27.4 nM 1.98 + 0.1 nM 
MIA PaCa2 18.68 + 1.83 nM 0.31 + 0.02 nM 
BxPC-3 101.6 + 9.7 nM 18.8 + 2.3 nM 









Figure 21| Comparison of Cytotoxicity of 7c5-ADC, 7c5, and Mertansine in PDAC 
Cells. a-h. 7c5 (), 7c5-cc (), 7c5-ADC (), mertansine (). Comparison of 
cytotoxicity of 7c5, 7c5-cc, and 7c5-ADC in Panc1 TCs, showing increased cytotoxicity 
of ADC at comparable antibody concentrations (a), but different potency and efficacy to 
free mertansine at equivalent concentration (b). Similar results were seen in MIA PaCa2 
showing greater efficacy of ADC (c) but different from free mertansine at equivalent drug 
concentration of ADC to free drug (d), and in BxPC-3 (e,f), and Capan-1 (g,h).  
 
 





























































































































Subsection 5.2: Inhibition Tumorsphere Formation by 7c5-ADC 
Next, the effect of the 7c5-ADC to impact tumor-sphere was assessed. The 
native antibody, 7c5, decreases viability of cancer cells under non-adherent 
conditions, (Herrera, 2016) therefore, the 7c5-ADC was compared to determine if 
the ADC improves efficacy. Cells were seeded at 1000 cells CSCs per well and 
treated with a single dose of the 7c5 antibody or 7c5-ADC and monitored after 5 
days for tumorsphere formation. Treatment with the 7c5-ADC showed a 
significant reduction in CSC survival, indicated by tumorsphere formation, 
compared to 7c5 with a single treatment, after 5 days of treatment in Panc1 and 








Figure 22| ADC Efficacy in Decreasing CSCs Proliferation. a. Decrease in tumorsphere 
(TS) colony by single treatment with 7c5  or  7c5-ADC  in Panc1 CSCs. b. Decrease in 
tumorsphere (TS) colony by single treatment with 7c5  or  7c5-ADC  in MIA PaCa2 CSCs. 
c,d. Representative Panc1 TS colonies after 5 days with (c) 30 μg/ml 7c5-ADC or (d) 30 
μg/ml 7c5.  





Subsection 5.3: Cytotoxicity of 7c5-ADC in non-cancer cell lines 
Next, the cytotoxicity of 7c5-ADC was compared to the native antibody, 
7c5-cc, and mertansine. Five non-cancer cell lines were selected: H6c7, a 
normal pancreatic acinar cell line, HUVECs, which are DEspR negative when not 
activated, and represent endothelial cells that could be targeted by therapy, KV-
2, normal kidney cells which could be effected by premature drug release and 
excretion, mIMCD-3 cells, which are DEspR positive, murine cells not recognized 
by 7c5, and BJ fibroblasts, which represent non-cancerous stromal cells. (Figure 
17). No cytotoxicity of 7c5, 7c5-cc, and 7c5-ADC were observed in HUVEC, 
mIMCD, KV-2 cells, or BJ Fibroblasts, up to 30 μg/mL (Bmax of 7c5) (Figure 23 a, 
b, c, g). Similarly, efficacy of mertansine was significantly different than 7c5-AFC 
for all cell types observed (Figure 23 d, e, f, i, j), and compared in table XI. 
Cytotoxicity for 7c5, 7c5-cc, and 7c5-ADC was observed in normal pancreatic 
cells (Figure 23h), with cytotoxicity in 7c5-ADC and 7c5 being near equivalent 
(68.2% + 3.1% vs. 67.1 + 11.0% cell viability). Based on confocal microscopy, 
minimal internalization of 7c5-AFC was observed, even at 4 hrs, suggesting that 
this effect is primarily from binding of the antibody to the receptor and inhibition of 
DEspR cell signaling than release of DM1, as 7c5-AFC was not observed in the 
lysosome. Still, this suggests a considering off-target binding and a potential 






Table XI. Comparison of Cytotoxicity of 7c5-ADC to Mertansine in Normal 
Cell Lines 
 IC50 
Cell Lines 7c5-ADC DM1 
HUVEC - 2.7 + 0.5 nM 
mIMCD - 3.0 + 0.6 nM 
BJ - 182.3 + 14.0 nM 
H6c7 16878 + 41822 nM 2.4 + 1.09 nM 




















Figure 22| Comparison of Cytotoxicity of 7c5-ADC, 7c5, and Mertansine in Normal 
Cells. 7c5 (), 7c5-cc (), 7c5-ADC (), mertansine (). a,b 7c5-ADC, 7c5, and 7c5-cc 
were non-toxic in HUVEC cells (a); while mertansine was highly toxic in HUVEC cells, 
equivalent drug loading on the ADC did not cause cell death (b).  c,d.   7c5-ADC, 7c5, and 
 



























































































































































            
               
               
                
             






Section Six: Discussion 
 Antibody drug conjugates provide an attractive pharmacological tool to 
improve the efficacy of biologic therapy. Through stable, non-invasive linkage, 
ADCs can be generated which allow targeted combination therapy through the 
delivery of a single agent. However, the development of ADCs is significantly 
limited by current methods of drug conjugation. Here, a novel method of site-
specific conjugation allowed the production of a stable, effective ADC for the 
treatment of PDAC.  
 The use of a highly specific, stable pair of peptides to functionalize an 
antibody provides the opportunity for uniform, tunable drug loading. The drug 
peptide V/E allows selective, specific functionalization through the unique 
dipeptide linker. Conjugation through the 2-(4-(3,5-dioxo-1,2,4-triazolidin-4-
yl)phenoxy)acetic acid produces a more stable peptide conjugation than 
maleimide labeling, circumventing the concern of retro-Michael addition. This 
linker is amenable to drug conjugation of any species with a free alkyl thiol or 
amine via a simple one-step conjugation, or a free alkyl alcohol via a two-step, 
7c5-cc were non-toxic in mIMCD cells (c); while mertansine was highly toxic in mIMCD 
cells, equivalent drug loading on the ADC did not produce cell death. (d). e,f 7c5-ADC, 
7c5, and 7c5-cc were non-toxic in BJ fibroblasts cells (e); while mertansine was toxic in 
BJ fibroblasts cells, equivalent drug loading on the ADC did not cause cell death (f).  g,h 
7c5-ADC, 7c5, and 7c5-cc were equivalently toxic in H6c7 cells, with the 7c5-ADC not 
inducing further cell death (i); while the 7c5-ADC had a significantly different toxicity 
profile compared to free mertansine at equivalent drug levels (h).  i,j 7c5-ADC, 7c5, and 
7c5-cc were non-toxic in KV-2 cells (i); while mertansine was toxic in KV-2 cells, 





lower yield conjugation. This diversity allows the production of a wide variety of 
potential drug linker with very similar release properties. 
 The key advantage of this conjugation method is the production of ADCs 
through an admixture of different drug linkers. If two V/E-drug peptides are 
prepared, with different drug linkers, then a series of ADCs can be prepared, 
which contain an ADR of 2:0, 1:1, and 0:2 of drug linker 1 and drug linker 2. 
Through this application, two different ADCs, with the potential to target two 
different oncogenic pathways, such as microtubule inhibition or DNA alkylation. 
This can be achieved far easier than other methods with more uniform loading. 
 Furthermore, synthesis of ADCs through this method minimally impacts 
antigen binding or cell recognition. Both the prepared ADC and AFC, as well as 
the coiled coil 7c5-cc, exhibit equivalent binding to the antigen sequence as the 
native 7c5. For the majority of cells, 7c5-AFC bound equivalently to 7c5-AF488. 
Differences in binding between some cells can be explained by 1) greater 
variability in fluorochrome loading between 7c5-AFC (2.0) to 7c5-AF488 (2.8), 
and 2) non-specific fluorochrome loading in 7c5-AF488 compared to specific 
fluorochrome loading in 7c5-AFC (2.0), 3) greater variability of binding in cells 
with high collagen production (Capan-1, BJ fibroblasts, and H6c7). 
Drug conjugation significantly improves efficacy without a significant 
increase in cytotoxicity. The cells treated with the 7c5-ADC demonstrated a 
significant difference in cell viability compared to the 7c5 antibody alone after 72 




internalization and retention, the difference in cell viability is reflective of this 
process versus the antibody alone. As the assay begins at 20% confluence for 
each cell line, DEspR expression is expected to be variable, and effects on cell 
viability from the antibody alone is not expected to be significant over 72 hours, 
when presumably most of the receptor positive cells have been affected within 
the first 16 hours. Cytotoxicity is greater in cell populations with high DEspR 
expression (MIA PaCa2 and BxPC-3), and shows greater efficacy in cells with 
higher proliferation (i.e. MIA PaCa2 vs. Panc1). Furthermore, cells with a higher 
production of extracellular matrix and collagen deposition (Panc1 and Capan-1) 
show less cell death at 72 hrs compared to cells with no collagen production 
(MIA PaCa2) or minimal collagen production (BxPC-3). Taken together, this 
suggests that cell death is mediated by receptor-specific internalization and 
bystander killing via release of free drug by lysosomal degradation of the linker 
as designed.  
The lack of cytotoxicity in receptor-negative or receptor-low cell lines 
HUVEC, mIMCD, KV-2, and BJ fibroblasts after 72 hrs further supports the 
mechanism of cell death. Premature release of mertansine or loss of coiled coil 
integrity will decrease cell viability, especially at higher concentrations of 7c5-
ADC. However, this was not observed. This finding demonstrates that 
conjugation is stable, and that ADC cell toxicity is specific to internalization and 





Section Seven: Methods 
General. 1H NMR, 13C NMR, and 19F NMR spectra were recorded on an Aligent 
500 MHz VNMRS spectrometer in the stated solvents using tetramethylsilane as 
the internal standard. Chemical shifts were reported as parts per million (ppm) on 
the δ scale from the instrument standard. All materials were obtained from 
Sigma-Aldrich, and unless otherwise stated, were used without further 
purification. All solvents were purchased as ACS reagent grade or anhydrous if 
indicated. All reactions were carried out under a nitrogen atmosphere, unless 
otherwise indicated.  
Preparation of 2-(4-(3,5-dioxo-1,2,4-triazolidin-4-yl)phenoxy)acetic acid. 
Synthesis of 2-(4-acetamidophenoxy) acetic acid. In a 250 ml round bottom 
flask fitted with a Teflon stir bar, 10 g of paracetamol was added to 50 ml H2O. 11 
g of 50% sodium hydroxide and 6.8 g of chloroacetic acid were added to the 
reaction flask. The reaction was boiled for 1 hr. An additional 5.5 g of 50% 
sodium hydroxide and 3.4 g of chloroacetic acid were added, and the reaction 
was boiled for an additional 4 hrs. The reaction was then cooled to room 
temperature, and acidified to pH =2 with dilute hydrochloric acid. Once the 
reaction reached room temperature, an oil layer appeared, which crystallized 
instantly upon rubbing. The reaction was filtered, then reprecipitated in slightly 
basic water. 9 g of fine white crystals were generated. 
Synthesis of 2-(4-aminophenoxy) acetic acid hydrochloride. In a 50 ml round 




acid was dissolved in 21 ml concentrated hydrochloric acid. The reaction was 
boiled for 2.5 hrs, then cooled to room temperature and filtered. The resulting 
white filtrate was washed thrice with water to generated sharp white crystals. 
Synthesis of 2-(4-aminophenoxy) acetic acid. 5 g of the hydrochloride salt 
was dissolved in 20 ml H2O in a 50 ml beaker. Potassium chloride (0.5 eq) was 
added slowly to the reaction; the mixture was stirred for 1 hr, then filtered and 
washed with water to give a white powder. 
Synthesis of 2-(4-(2-(ethoxycarbonyl)hydrazine-1-
carboxamido)phenoxy)acetic acid. In a 250 ml, 2 neck round bottom flask, 
charged with a Teflon stir bar, ethyl carbazate (ss), and 1,1’-carbonyldiimide (ss) 
were added, followed by anhydrous THF. The reaction was stirred for 2 hrs at 
room temperature. To the reaction was added 2-(4-aminophenoxy) acetic acid 
(aa) and triethylamine (as). The reaction was stirred for 16 hrs overnight. The 
crude reaction mixture was filtered; the filtrate was extracted with 30 ml ethyl 
acetate, and washed twice with 10% HCl (20 ml), and brine (20 ml). The aqueous 
layers were combined, and washed once with ethyl acetate. Organic layers were 
combined, dried with MgSO4, and concentrated in vacuo.  
Synthesis of 2-(4-(3,5-dioxo-1,2,4-triazolidin-4-yl)phenoxy)acetic acid. In a 
100 ml round bottom flask, charged with a Teflon stir bar, 2-(4-(2-
(ethoxycarbonyl)hydrazine-1-carboxamido)phenoxy)acetic acid, was dissolved in 




material was detectable by TLC. The reaction was acidified to pH=2 with dilute 
HCl, filtered, and washed with ethyl acetate and water.  
Preparation of Dipeptide Linker: 
Fmoc-Val-OSu .Fmoc-Val (5.060 g, 14.91 mmol) and HOSu (1.72 g, 1 equiv) in 
THF (50 mL) at 0 °C were treated with DCC (3.080 g, 1 equiv). The mixture was 
stirred at room temperature for 16 h, and then, the solid DCU byproduct was 
filtered off and washed with THF. The solvent was removed on the rotovap, and 
the resulting glassy solid was used without purification in the next step 
Fmoc-Val-Cit. Fmoc-Val-OSu 58 (14.91 mmol) in DME (40 mL) was added to a 
solution of Cit (2.743 g, 1.05 equiv) and NaHCO3 (1.315 g, 1.05 equiv) in water 
(40 mL). THF (20 mL) was added to aid solubility, and the mixture was stirred at 
room temperature for 16 h. Aqueous citric acid  (15%,  75  mL)  was  added,  and  
the mixture was extracted with 10% 2-propanol/ethyl acetate (2x100 mL). The 
solid product began to precipitate but remained in  the  organic  layer.  The 
suspension was washed with water (2x150 mL), and the solvents were 
evaporated. The resulting white solid was dried in vacuo for 5 h and then treated 
with ether (80 mL). After brief sonication and trituration, the white solid product 
was collected by filtration  
Fmoc-Val-Cit-PABOH (62). Fmoc-Val-Cit 60 (1.0443g, 2.103 mmol) and 
PABOH (518.0 mg, 2 equiv) in 2:1 CH2Cl2/CH3OH (35 mL) were treated with 
EEDQ (1.0402g, 2 equiv). The mixture was stirred in the dark at room 




the white solid residue was triturated with ether (75 mL). The resulting 
suspension was sonicated for 5 min and then left to stand for 30 min. The solid 
was collected by filtration, washed with ether, and dried in vacuo. 
Fmoc-Val-Cit-PABC-DM1 Fmoc-Val-Cit-PABOH (12 mg, 0.02 mmol), DM1 (18 
mg, 0.02 mmol) in NMP (1 mL) at -15oC was treated with pyridine (20 μl, 0.08 
mmol), followed by addition of triphosgene. (5.9 mg, 0.02 mmol). The reaction 
was allowed to slowly reach room temperature for 4 hrs. The reaction was 
quenched with water, and after 20 minutes, extracted with DCM. Aqueous layer 
was extracted 3 times with DCM, and organic layer was washed twice with brine. 
Organic layer was dried, concentrated, and purified with silica chromatography 
(1:9 MeOH: DCM). 
Val-Cit-PABC-DM1 Fmoc-Val-Cit-PABC-DM1 (20 mg, 0.014 mmol) was treated 
with diethylamine (10 μl). The mixture was left to stand at room temperature for 
16 h, and then, the solvents were removed on the rotovap at 40 °C. The thick, 
oily residue was treated with CH2Cl2(15 mL), and the mixture was sonicated at 
room temperature. The resulting solid was collected by filtration, washed with 
CH2-Cl2, and dried in vacuo. 
PU-Val-Cit-PABC-DM1 Val-Cit-PABC-DM1 (10 mg, 0.01 mmol) and 2-(4-(3,5-
dioxo-1,2,4-triazolidin-4-yl)phenoxy)acetic acid (2.5 mg, 0.05 mmol) were 
dissolved in NMP (1 ml). EEDQ (5.0 mg, 0.01 mmol) was added to the reaction 
mixture. The mixture was left to stand at room temperature for 16 h, and then, 




treated with CH2Cl2(15 mL), and the mixture was sonicated at room 
temperature. The resulting solid was collected by filtration, washed with CH2-Cl2, 
and dried in vacuo. The mixture was stirred in the dark at room temperature for 
1.5 d. The solvents were removed on the rotovap at  40  °C,  and  the  brownish  
residue  purified by silica chromatography. (1:9 MeOH: DCM). 
 
Cell culture. Panc1, MIA PaCa2, Capan-1, BxPC-3, HUVEC, KV-2, BJ 
Fibroblasts, mIMCD, and H6c7 TCs were purchases through ATCC. Panc1, MIA 
PaCa2, KV-2, and mIMCD cells were grown in Dulbecco's Modified Eagle 
Medium (DMEM) (Fisher Scientific, cat #: 12430-054) supplemented in 5% Fetal 
Bovine Serum (FBS) (Fisher Scientific, cat#: 10438026) and 1% Penicillin-
Streptomycin (PenStrep) (Fisher Scientific, cat#:  15140122), Capan-1 cells were 
grown in Iscove’s Modified Dulbecco’s Medium (ATCC cat#: 30-2005) with 20% 
FBS and 1% PenStrep, BJ Fibroblasts and BxPC-3 cells were grown in RPMI-
1640 medium (ATCC cat# 30-2001) in 10% FBS and 1% PenStrep, HUVEC cells 
were grown in Endothelial Cell Growth Medium (Sigma cat# 211-500), and H6c7 
cells were grown in Keratinocyte SFM with supplements (Invitrogen cat# 
17005042) with 1% PenStrep; all cells were grown in 100 mm tissue-culture 
treated polystyrene plates (Corning, cat#430167). Cells were harvested at 60% 
confluence using trypsin-EDTA (0.25%) (Fischer Scientific 25200056); 




Antibody labeling. 7c5 and IgG2b antibodies were labeled using Alexa Fluor 
488 Antibody Labeling Kit (Fisher Scientific, cat#A20184) following manufacturer 
instructions.  
Flow Cytometry: Cells were harvested at 60% confluence, using 1 ml of 5 mM 
EDTA. Cells were labeled with 30 µg/ml 7c5-AFC, 7c5 antibody or IgG2b-488 
antibody 20 minutes at 4oC.  Detection was performed using an LSRII Flow 
Cytometer (BD Bioscience) with a 488 nm laser with 530/30 (505 LP) filter for 
AF-488. 
Fixed Cell Fluorescent Microscopy. Immunofluorescence staining was 
performed as previously described.127 Cells and were labeled with 30 µg/ml 7c5-
AFC for antibody internalization. Cells were counter stained with NucBlue 
Hoechst stain (ThermoFisher, cat #R37605); cells treated with the 7c5 antibody 
were mounted with ProLong™ Diamond Antifade Mountant with DAPI (Fisher 
Scientific, cat#: P36971). Excitation was performed on 405 nm, 488 nm, and 543 
nm laser lines, emission was collected from 430-475 nm, 505-550 nm, and 615-
700 nm to prevent overlap.   
MTT Assay. Cells were seeded between 2,000-3,000 cells/ well in 200 ul media, 
depending on their doubling times. Once cells reached 20% confluence, varying 
concentration of 7c5-ADC, 7c5-cc, 7c5, or mertansine were added. After 72 
hours Media was removed and 0.5 mmol MTT was added in serum free medium. 




at 590 nm was measured. Cells did not exceed 80% confluence for assay, 
allowing direct measurement of cell viability before confluence was ever reached.  
 
Tumorsphere Assay Panc1 and MIA PaCa2 non-adherent cells were prepared 
from Panc1 and MIA PaCa2 TCs respectively by selective growth in ultra-low 
attachment 100 mm plates (Corning, cat#3261) in Mammocult media (Stem Cell 
Technologies, cat#: 05620), with 5% MethoCult (Stem Cell technologies, cat# 
H4434), supplemented with Heparin Solution (Stem Cell Technologies cat#: 
7980), and 1% Penicillin-Streptomycin (ThermoFisher, cat#:  15140122). After 
one-week, live cells were counted and 1000 live cells were plated on 96-well 
ultralow adherent plates (Corning, cat# 3603), in Mammocult supplemented 
media. After 24 hours, treatment was added in 5 ul, and the suspension was 
triturated to allow adequate mixing. At days 0, 1, 3, and 5 cells were imaged 
using Nexcelom Celigo Imaging Cytometer, with tumorsphere colonies counted 
as 50 µm in size, using a 97% well mask to avoid fringe aberrations, and using 











CHAPTER SIX: FUTURE WORK 
 The work presented here provides a framework for developing tunable, 
functionalizable ADCs through the use of supramolecular assembly. Outlined 
here, the method proposed allows simple, efficient C-terminal conjugation of 
antibodies to weaponize the antibody with a toxic payload. In order to test the 
feasibility of this method, a sortase-conjugation method was employed. In order 
to verify that this method is applicable for large scale development, the 
successful production and modification of an antibody with this sequence must 
be attempted. This is currently underway, through recombinant modification of a 
plasmid containing GPR87, a receptor highly expressed in several cancer cell 
lines. Successful functionalization of this antibody will provide evidence that this 
technique is: 1) generalizable to other antibody systems, and 2) can be achieved 
by recombinant modification of the antibody to express the necessary C-terminal 
sequence. 
 The current ADC demonstrates excellent in vitro cytotoxicity and safety 
profiles. Further work in the characterization of this ADC includes stability 
experiments of the ADC in human and rat serum, as well as PBS for storage, 
which are currently underway. As successful stability of the ADC depends on 
maintenance of the tetrameric structure as well as conjugation of mertansine to 
the linker prior to internalization. This will be accomplished in two models: the 
first will evaluate free mertansine release in all three conditions. The second will 




peptide from other similar size peptides in plasma. Successful completion of 
these tests will confirm applicability of the ADC in vitro. 
 In vivo experiments are currently being prepared, which will assess: 1) 
safety, 2) pharmacokinetic and pharmacodynamic studies, and 3) efficacy. The 
study will be completed in a nudernu/rnu model of PPC, as previously reported.127 
This will be accomplished first by a PK/PD-mixed dose escalation study, where 
concentrations from 0.1 – 3.0 mg/kg of the ADC will be evaluated as a single 
bolus dose; female nudernu/rnu  rats will have three weeks to establish a tumor, 
sufficient for palpation, and then have serial blood draws performed, as stated in 
Chapter 3. Following the last blood draw collected at 2 weeks, the rats will be 
sacked and tissue will be collected allowing PK characterization for 2 weeks, as 
well as maximum tolerated dose characterization in this range, and collection of 
2-week tissue at distribution. Organs collected will include: brain, lung, heart, 
liver, spleen, kidney, tumor (if present), ovaries, and intestine. Collected tissue 
will be homogenized and ADC will be detected by ELISA detection of murine 
antibody and presence of free mertansine. Success of this study will be followed 
by a repeat in 3 rats to examine drug distribution 24 hours after injection to 
complete PD data. Finally, a four-group cohort (n= 8 per group) will be completed 
comparing the ADC, the 7c5 antibody at equivalent concentration, gemcitabine at 
100 mg/kg intraperitoneal (clinical control), and saline. Treatment will be 
completed twice a week at the appropriate dose for four weeks, with the major 





Table XII. Proposed Blood Chemistries for Tolerability 
 
Organ Site Tests 
  
Liver Alk Phos. ALT AST T. Bilirubin Albumin 
Hematological WBC RBC MCV Hemoglobin Platelets 
Renal Creatinine BUN    
 
 
 Work beyond this ADC will continue in the application using the 7c5 anti-
DEspR antibody, and will explore additional receptor targets, as well as other 
payloads. In order to develop orthogonal systems, the proposed method will be 
used to functionalize an anti-GPR87 antibody as well as an anti-PDL1 antibody. 
A small library of different chemotherapeutic linkers will be prepared, allowing 
production and testing of several ADCs, as well as mixed ADCs, to determine 
optimal payload loading per antibody.  
 The ultimate goal will be the applicability of the method outlined here to 
generate ADCs. Successful weaponization of each ADC in vitro and in vivo will 
allow the extension to multi-drug dosing between orthogonal ADCs to verify 
pattern recognition and tumor engagement in the metastatic environment. This 
will provide valuable application in pharmaceutical development of ADCs and 










Appendix Figure 1| Cell Viability in Panc1 Cells with hu-6g8 Treatment, DEspR 
Receptor Response to Stress and Cell Viability. a. Cell death (propidium iodide positive 
cells) in Panc1 cells following hu-6g8 treatment, measured by Nexcelom Celigo “red’ 
channel. b. Apoptosis in Panc1 cells (activation of caspase 3/7 stain) following hu-6g8 
treatment, measured by Nexcelom Celigo “green” channel. c. Change in DEspR surface 
expression in Panc1 cells at baseline (mean intensity: 1411 + 6535), and 1 hr (mean 
intensity: 4777 + 136000), 2 hrs (mean intensity: 1203 + 7703), and 4 hrs (mean intensity: 
1980 + 7785). d. Cell viability in HUVEC cells with gemcitabine treatment with () or without 
() hu-6g8 pretreatment (left) (IC50,Gemcitabine  = 175 nM, IC50,Gemcitabine+hu-6g8 = 95.0 nM) or 
mertansine treatment with () or without ()  hu-6g8 pretreatment (right) (IC50,Mertansine  = 













Appendix Figure 2| Western Blots of ADAR1 KO a. ADAR1 protein expression levels in 
Panc1 and MP2 WT and ADAR1 KO, with β-actin control (bottom) (dual stain). b. DEspR 
protein expression levels in Panc1 and MP2 WT and ADAR1 KO. c. Mcl1 protein expression 
levels in Panc1 and MP2 WT and ADAR1 KO. d. Collagen protein expression levels in Panc1 
and MP2 WT and ADAR1 KO. e. GAPDH protein expression levels in Panc1 and MP2 WT 











Appendix Figure 3| RNU Survival Studies with hu-6g8 Antibody a. Multiple dose (2x dose i.p. 
for 4 weeks) study comparing 3 mg/kg hu-6g8 to saline (median survival hu-6g8 vs. saline: 64 
days vs. 65 days, p = 0.3693 [Mantel-Cox]). b. Multiple dose (2x dose i.p. for 4 weeks) study 
comparing 15 mg/kg hu-6g8, 3 mg/kg hu-6g8 to saline (median survival 15 mg/kg vs. 3 mg/kg hu-
6g8 vs. saline: 91.5 days vs. 66.5 days vs. 67 days, p = 0.0692 [Mantel-Cox]). c. Single dose iv 
study comparing 3 mg/kg hu-6g8, gemcitabine (26 mg/kg), and dual gemcitabine + 3 mg/kg hu-
6g8 to saline (median survival 3 mg/kg hu-6g8, gemcitabine, gemcitabine + hu-6g8, vs. saline: 45 











Appendix Figure 4| Structural Analysis Between Non-Interacting Species. CD spectrum 
showing 100 μM total protein of individual species L/E, V/E, I/E interactions (a,c,e) and L/K, V/K, 











Appendix Figure 5| Structural Confirmation of L/E and L/K. HPLC chromatogram and 











Appendix Figure 5| Structural Confirmation of V/E and V/K. HPLC chromatogram 











Appendix Figure 5| Structural Confirmation of I/E and I/K. HPLC chromatogram and mass 
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